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General introduction  
Now-a-days cancer is one of the leading causes of death worldwide. In the Netherlands 
alone already 43.214 deaths from cancer were registered for the year 2014 [1]. Cancer 
is a generic term for many types of diseases, which all involve several common 
characteristics and is used for both benign and malignant tumors. A cell mass that is 
rapidly dividing and could potentially invade its surrounding tissues is often referred to 
as a cancer. The abnormal growth of this cell population starts by sequential 
accumulation of different DNA mutations inherited by cell division. Under normal 
physiological conditions tissues have the capability to replace mutated cells. However, 
when the normal cellular functions are compromised a benign tumor mass could arise. 
Cells from a benign tumor are able to evade apoptosis; however, they don’t have the 
capability to invade other tissues yet. When a cell population acquires additional 
mutations, the rise of a malignant tumor may occur. Tumors display several 
characteristics which enable the tumorigenic and/or metastatic potential of the cell 
population and include sustained proliferative signaling, evading growth suppressors, 
avoiding destruction by the immune system, enabling replicative immortality, tumor 
promoting inflammation, invasion and metastatic potential, inducing angiogenesis, 
genomic instability and genomic mutations, resisting cell death and deregulated cellular 
energetics. Often these characteristics are referred to as the ‘Hallmarks of cancer’, 
which have been comprehensively described by Hanahan and Weinberg [2, 3]. 
Treatment of malignancies is of great importance in order to increase survival and 
quality of life of cancer patients. Now-a-days many cancer treatment options are 
available in the clinic although the majority of the patients are currently still treated by 
surgery, chemotherapy or radiotherapy, or a combination of those. The choice of 
therapy is dependent on several factors such as the patient’s condition, the tumor’s 
histopathology, stage and location. Different cancer types often do benefit from 
additional hormone therapy [4, 5] or even immunotherapy [6]. Heterogeneity amongst 
patients, but also amongst tumors and their microenvironment influence treatment 
outcome. Also, heterogeneities in nutrient supply, proliferation, pH levels and oxygen 
supply or consumption influence the treatment response. Knowledge of a tumor’s 
status and the predictive power of treatment response could therefore improve 
treatment efficacy and reduce treatment costs [7]. 
The role of the tumor microenvironment in tumor survival 
The tumor and its microenvironment (TME) is a very complex but important system, 
from which our understanding is gradually increasing. The TME consists out of blood 
vessels, signaling molecules, the extracellular matrix and many cell types such as 
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fibroblasts, dendritic cells, lymphocytes and macrophages [8]. The TME is a 
heterogeneous, dynamic mechanism of various cells, all having a different gene 
expression profile, metabolism and oxygen supply. The lack of nutrient and oxygen 
supply interacts with two main characteristics of a malignancy, its bioenergetics and 
angiogenesis. Hypoxia can occur through different mechanisms. Diffusion-limited 
hypoxia arises in cells with an oxygen consumption higher than its supply or beyond the 
oxygen diffusion distance. This phenomenon is commonly referred to as chronic 
hypoxia [9]. Perfusion-limited or acute hypoxia arises around vessels which are 
temporarily closed, frequently caused by the malformation of the blood vessels in a 
tumor [9]. In order to survive, malignant cells often switch to a more glycolytic 
phenotype, independent whether or not oxygen is present, a phenomenon better 
known as the Warburg effect [10] (Fig. 1), resulting in acidification of the extracellular 
environment. The enhanced glycolysis produces massive amounts of lactate in the 
cytoplasm, contributing together with production of CO2 to an acidic intracellular pH. In 
order to survive, cancer cells correct this intracellular acidification by the increased 
expression and activity of certain pH regulating membrane transporters regulating 
lactate efflux (monocarboxylate transporters (MCT4)) and Na-driven proton extrusion 
(sodium proton exchangers (NHE) and anion exchangers AE1 and AE2) [11]. 
 
 
Figure 1. Overview of the influence of hypoxia in the metabolism of proliferative and differentiated tissues and
tumorigenic tissues.  
Adapted from [10]. 
 
Another group of important enzymes for maintaining the intracellular pH are the 
carbonic anhydrases (CAs). CAIX, a transmembrane protein with its active site 
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extracellularly, is one of the CAs often found to be upregulated in cancer leading to 
worse locoregional control, disease progression, and even leads to a higher risk to 
develop metastasis in patients [12]. CAIX catalyzes the conversion of carbon dioxide 
(CO2) and H2O into bicarbonate and a proton (H+) [13]. CO2 is an acid produced as a by-
product at the tricarboxylic acid (TCA) cycle and when pyruvate is converted into acetyl-
CoA. CO2 can also be produced as the result of the reduction of bicarbonate by 
intracellular CAs such as CAII. CO2 diffuses across the cell membrane and forms the 
substrate for rehydratation by either CAIX or CAXII to produce bicarbonate (Fig. 2). To 
sustain an alkaline intracellular pH, cells enable transport of bicarbonate via bicarbonate 
transporters or anion exchangers into the cell. This complex system results in 
acidification of the extracellular environment and is a mechanism often observed in 
tumors to promote survival [11]. 
CAIX expression is closely regulated by hypoxia as it contains a hypoxia response 
element in its promotor region and therefore is a direct downstream target of hypoxia 
inducible factor 1 alpha (HIF-1α) activity [14] (Fig. 2.) Under normal oxygen tension (Fig. 
2A), HIF-1α is hydroxylated at its proline residues by prolyl hydroxylases (PHDs), which 
targets HIF-1α for proteasomal degradation through binding with the Von Hippel-Lindau 
complex (VHL) leading to ubiquitylation via E3 ubiquitin-protein ligases. However, under 
conditions of hypoxia (Fig. 2A), causing downregulation of PHDs activity, or by 
mutations in the tumor suppressor gene VHL (mainly reported in renal cell carcinomas), 
HIF-1α is stabilized and interaction with HIF-1β (also known as aryl hydrocarbon 
receptor nuclear translocator ARNT) and translocation to the nucleus occurs. Together 
with cofactors such as CBP/p300 and the DNA polymerase II complex, the HIF-1 
complex can bind to hypoxia response elements (HREs). HIF-1α regulates specific 
regulatory sequences in the promotor region of target genes in order to let them be 
controlled by changes in oxygen concentrations (Fig. 2B). Where angiogenesis is for 
instance influenced by VEGF expression, metabolism is influenced by GLUT1 expression, 
and regulation of the extracellular pH by CAIX; all of them target genes of HIF-1α [9, 15]. 
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Figure 2. Overview of the influence of normoxia and hypoxia on the HIF pathway and its effects on its
downstream targets.  
A. HIF-1α pathway under normoxic and hypoxic conditions B. The influence of HIF-1α under hypoxic 
conditions on CAIX. ARNT (Aryl hydrocarbon receptor nuclear translocator), CAII (carbonic anhydrase II), CAIX 
(carbonic anhydrase IX), GLUT1 (glucose transporter 1), HIF-1α (Hypoxia Inducible Factor 1 α), MCTs
(monocarboxylate transporters), NHE (Na+/H+ exchangers) AE (anion exchangers) NBC (sodium–bicarbonate 
co-transporter), VEGF (vascular endothelial growth factor). Adapted from [16, 17]. 
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Mitochondria, ROS production and its role in the tumor 
microenvironment 
Mitochondria are organelles of 0.5 ~ 3 μm in size located in the cytoplasm of the cell. 
They can fuse with each other (fusion) and be separated again (fission) and thereby 
influence their function, their formed network and their own genetic material 
(mitochondrial DNA; mtDNA). Mitochondria are well known for their role in the 
production of ATP and are therefore often referred to as the power plant of a cell. 
Furthermore, they also have their own toxic waste production better known as reactive 
oxygen species (ROS). ROS plays an important role in maintaining the cellular redox 
status, but also contributes to enzymatic activity and intracellular signaling [18-20]. 
Mitochondria consist of a double-layered membrane, creating two compartments, the 
internal matrix and intermembrane space. Although both outer and inner membrane 
contains transport proteins, only the inner membrane harbors subunits of the electron 
transport chain. The matrix contains enzymes that metabolize pyruvate or fatty acids in 
order to produce acetyl CoA as well as enzymes that oxidize acetyl CoA further in the 
Kreb’s cycle [21].  Every cell itself can contain multiple copies of mitochondria and every 
mitochondrion contains multiple copies of mtDNA, depending on the energy demand of 
the respective cell. 
Under normal physiological circumstances, mitochondria use most of the oxygen 
present in the tissue to produce ATP. However when oxygen tension is low either a 
metabolic switch to glycolysis occurs [22] or cell death due to insufficient ATP 
production [23]. Mitochondria are known for their maternally inherited DNA encoding 
for 13 of the approximately 90 structural subunits of the oxidative phosphorylation 
chain (OXPHOS) [24, 25] and variations in the mtDNA can contribute to an altered 
energy supply in (tumor) cells [26, 27]. It also has been reported that severe 
mitochondrial dysfunction impairs tumor formation. However, mild mitochondrial 
dysfunction can result in tumor formation [28]. This suggests that the role of mtDNA 
variations and its subsequently dysfunctional OXPHOS system in tumorigenicity is a 
complex balance. 
The OXPHOS system is one of the major contributors to the production of ROS (Fig. 3), 
with complex I (CI) and complex III (CIII) acting as the major ROS producing sites [29-31]. 
CI (and CII) releases the produced ROS directly into the mitochondrial matrix, whereas 
CIII can release ROS either in the mitochondrial matrix or in the intermembrane space 
[32]. mtDNA variations can lead to dysfunction of OXPHOS resulting in an increased ROS 
production [33]. Also, other endogenous mechanisms (e.g. endoplasmic reticulum, 
peroxisomes and enzyme systems such as NADPH oxidases, nitric oxide synthase etc. 
[34]) or exogenous inducers (like xenobiotics and radiation [34, 35]) are contributing to 
cellular ROS production. In order to maintain the balance between ROS production, 
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which is also used as a signaling molecule in cells, and its harmful consequences when 
ROS is produced in excess, cells harbor specific defense mechanisms. The cellular 
antioxidant mechanism protects cells from the harmful ROS effects, such as damage 
towards lipids, proteins and nucleic acids and the induction of double stranded DNA 
breaks [36]. Superoxide produced in the mitochondria is transformed into hydrogen 
peroxide (H2O2) by superoxide dismutases either in the mitochondria themselves by the 
manganese superoxide dismutase (MnSOD/SOD2) or in the nucleus, lysosomes or 
cytosol by the copper-zinc superoxide dismutase (CuZnSOD/SOD1). Catalases, located at 
the peroxisomes, are responsible for the subsequent conversion from H2O2 towards 
oxygen (O2) and water (H2O). In tumors, the efficacy of these defense mechanisms is 
usually sub-optimal due to deregulated or even exhausted antioxidant systems leading 
to an increased metastatic potential. For example, it has been shown that mitochondrial 
superoxide plays a role in cellular migration, invasion and clonogenic potential [37]. 
The thioredoxin system (Fig. 3) consisting out of thioredoxin peroxidases 
(peroxiredoxins), thioredoxin reductases and its main substrate thioredoxin (Trx), is of 
great importance in catalyzing the reaction of H2O2 into H2O under the influence of 
NADPH. Mitochondria even have their own specific thioredoxin (Trx2), thioredoxin 
reductase (TrxR2) and peroxiredoxin (Prx3)[38]. Where thioredoxin is involved in redox 
regulation and can act as an antioxidant, thioredoxin peroxidases are involved in the 
regulation and reduction of peroxides [38, 39]. Also, glutathione peroxidases are able to 
catalyze the reduction of H2O2 using the substrate glutathione, a very important 
antioxidant [38]. Glutathione is a low molecular weight non-protein thiol, which is very 
abundant in the cell and especially in the mitochondria. It is mostly present in its 
reduced form (GSH) but can be oxidized into GSSG. To maintain the cellular redox 
homeostasis, GSSG can be reduced by glutathione reductases and serves therefore as 
an antioxidant defense mechanism. Studies have shown that an interplay between the 
thioredoxin and the glutathione system exists [40, 41]. Also, these systems could be 
potentially interesting to target in a prodrug-based approach. Other potential targets 
could be glutathione S-transferases (GSTs), a group of enzymes that use glutathione as a 
co-factor and catalyze the conjugation of glutathione to a wide range of endogenous 
and exogenous electrophilic compounds. Mitochondrial (GST Kappa), cytosolic (GST 
Alpha, mu, Pi, Sigma, Theta, Omega and Zeta) and microsomal (MAPEG family), as well 
as multiple classes of GSTs have been reported [42]. Overexpression is often reported in 
tumors and can contribute to a drug resistant phenotype as GSTs serve Phase II 
detoxification enzymes and are involved in the regulation of oxidative stress [43]. 
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Figure 3. Schematic representation of the mitochondrial antioxidant system.  
I-V, OXPHOS complex I-V; ANT, adenine nucleotide translocases; CAT, catalase; GSH, reduced glutathione;
GSSG, oxidized glutathione; GPx, glutathione peroxidase; GR, glutathione reductase; 4-hydroxynonenal, HNE; 
IMM, inner membrane space; LOH, lipid alcohol; MGST1, microsomal glutathione transferase; NNT;
nicotinamide nucleotide transhydrogenase; OMM, outer membrane space; SOD, superoxide dismutase; TPx,
thioredoxin peroxidase; TR, thioredoxin reductase; TRxred/TRxox; reduced and oxidized thioredoxin; VDAC, 
voltage-dependent anion-selective channel. Adapted from [44-47]. 
 
For instance, one of the MAPEG GSTs members MGST1 is highly abundant in the outer 
membrane of the mitochondria and in the membrane of the endoplasmic reticulum, 
expressed in most tissues with the highest abundance in liver tissue. MGST1 
overexpression has been reported in various tumor types ranging from acute myeloid 
leukemia, colorectal cancer to Ewing’s sarcoma [48]. MGST1 is able to act as both a 
Glutathione peroxidase and GST [48]. It can protect against induced lipid peroxidation 
and oxidative stress [49, 50] but also against doxorubicin and cisplatin exposure causing 
a drug resistance phenotype [51]. In Ewing’s sarcoma patients increased expression of 
MGST1 was found to influence prognosis via resistance against doxorubicin [52]. 
Potentially this could be counteracted by a prodrug approach were the cytotoxic agent 
is only released in a GST dependent manner [51, 53]. 
Upon insufficient oxygen supply, tumors shift their metabolism to an anaerobic glycolysis 
phenotype. It is however debatable what happens with the ROS production under these 
low oxygen conditions. It has been suggested that non-specific ROS is reduced [54]. 
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Conversely, specifically CII and CIII mediated ROS production is increased under low 
oxygen tensions [55-57]. Additionally it has been suggested that only CIII specific ROS 
contributes to HIF-1α stabilization by inhibiting PHDs [56, 58, 59]. The exact role of other 
mitochondrial ROS sources remains unknown. Mitochondrial ROS potentially could act as 
a signaling molecule contributing to tumorigenesis, tumor progression and metastasis 
formation [37, 60-63]. However, reducing ROS levels could be a double-edged sword as it 
also has been reported to stimulate tumor progression [64].  
The unfavorable treatment response in cancer patients 
Treatment resistance occurs in a substantial part of cancer patients. Resistance to 
chemotherapeutic agents is a major problem in cancer treatment and can be attributed 
1) to the genetics of the tumor, i.e. mutations in genes regulating apoptosis, cell cycle 
and DNA-repair, 2) to overexpression of drug detoxification enzymes like glutathione 
transferases and 3) to changes in membrane barriers such as influx or efflux pumps [43, 
65]. This can cause recurrence of the tumor and even can be fatal to the patient. The 
drug resistance can already exist at the moment the tumor arises or can be acquired 
during treatment. For instance drug resistance towards doxorubicin, a commonly used 
cytostatic drug for leukemia and (soft tissue) carcinomas, has been reported resulting in 
an unfavorable therapeutic outcome [66]. Additionally, low oxygen regions (hypoxia) 
heterogeneously spread in tumors can also lead to a drug resistance phenotype as a 
result of decreased drug availability or lower uptake of certain drugs due to the 
increased extracellular acidification [67, 68] and has been reported for e.g. doxorubicin, 
etoposide, cisplatin, 5-fluorouracil, gemcitabine, and docetaxel [69-74]. Furthermore, 
resistance to radiotherapy (RT) is a well-known phenomenon in cancer patients [75-77]. 
Cells with altered DNA-repair systems or hypoxic regions can contribute to this resistant 
phenotype. To be effective as therapy according to the oxygen-fixation theory, RT needs 
oxygen to “fix” the DNA damage, i.e. to convert a reactive hydroxyl radical in a 
chemically stable carboxyl group [35]. When less oxygen is available, i.e. an increased 
hypoxic fraction, the radiotherapy efficacy decreases leading to a worse prognosis in 
e.g. head and neck cancer patients [76]. The success of cancer treatment is therefore 
not only dependent on the selected therapy, but is also influenced by the tumor 
microenvironment.  
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Repurpose drug approach to decrease tumor hypoxia and improve 
treatment outcome. 
Repurposing already well-known drugs and use their therapeutic potential is a valid 
approach to improve the standard treatment of cancer patients and simultaneously 
reduce drug development costs and thereby treatment costs. One of those potential 
interesting drugs for repurposing is metformin. Metformin, a biguanide often used in 
type 2 diabetes treatment, has been linked to a reduced risk of developing cancer in this 
patient population [78]. Another fascinating feature of metformin is its potential use as 
a metabolism-changing agent. Metformin can reduce CI activity and thereby decreases 
both the ATP production and oxygen consumption of the OXPHOS system [79]. As a 
result, levels of adenosine monophosphate (AMP) increase thereby triggering an 
increase in AMP activated kinase (AMPK) levels in the cell [80]. 
Metformin can also reduce gluconeogenesis (generation of glucose from non-
carbohydrate carbonic substrates such as lipids) through interference with the 
mitochondrial glycerophosphate dehydrogenase (mGPD) enzyme [81]. Furthermore, 
also the metformin-induced increased AMPK levels and diminished glucagon signaling 
(via decreased cyclic AMP levels) contribute to a decreased gluconeogenesis [82]. In 
cancer patients, metformin probably results in decreased proliferation rates as a 
consequence of the combination of the above-described mechanisms and consequent 
reduction of glucose and increase in insulin sensitivity. In addition, metformin is able to 
decrease the hypoxic fraction in tumors, probably based on the principle that by using 
less oxygen via respiration, the oxygen can diffuse further into the tumor. Both in vitro 
and in vivo studies already showed positive effects for the combination of RT with 
metformin [83, 84]. Also in small clinical trials, it was observed that therapeutic 
response rates were indeed improved among different tumor types [85-87]. However, 
in a breast cancer patient cohort more interruptions from their radiation therapy 
schedules were observed in the metformin group due to radiation dermatitis [88] (for a 
comprehensive review see [98]). In order to increase therapeutic efficiency, recently a 
mitochondrial targeted metformin compound, mito-metformin, has been developed. 
Pre-clinical studies showed that ROS production was increased while tumor growth and 
progression was reduced in human pancreatic ductal adenocarcinoma xenografts, 
suggesting that the functionality of metformin could still be further improved [89]. 
Currently, phenformin, another more potent biguanide drug is making its comeback. 
Where phenformin was withdrawn from the North-American market in 1977 by the FDA 
due to fatal lactic acidosis in diabetic patients, it currently regained interest. Although, 
no clinical studies have been published with phenformin investigating the potential 
usage of phenformin in cancer patients, pre-clinical studies did show promising results 
on tumor growth delay and enhanced therapeutic effects in combination treatments 
[90-92]. It has been suggested that phenformin has less toxicity compared to the most 
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commonly used chemotherapeutics, making it potentially more acceptable for cancer 
treatment compared to diabetes [91]. 
Another potential candidate for a drug repurposing approach is nitroglycerin. Although 
the public knows nitroglycerin as one of the key components for dynamite it is not only 
used as an explosive. Currently, it is also a very common drug for heart diseases such as 
angina pectoris due to its nitric oxide releasing properties. Those released nitric oxides 
cause a vasodilatation effect in the affected heart tissue, and thereby increase the 
blood flow in cardiac patients. Those properties also make it an interesting drug for its 
use in cancer patients. It had been suggested that nitric oxides could influence the 
hypoxia status of the tumors by increasing the tumor perfusion as they can serve as 
vasodilators. This might result in a potentially improved cancer treatment by enhanced 
chemotherapy delivery or by influencing the radiosensitization of tumors [93, 94]. Other 
potential interesting mechanisms are increased formation of intracellular free radicals 
caused by the nitric oxide donors. 
Objective and thesis outline 
The aim of this thesis was to investigate the role of mitochondrial function, reactive 
oxygen species (ROS) and hypoxia modulation in tumors in view of the possible 
implementation in a personalized treatment approach in order to reduce the possibility 
of recurrences or adverse effects. 
A comprehensive and detailed overview on the literature involving mitochondrial 
dysfunction and mitochondrial DNA variations influencing cancer and cancer treatment 
is given in chapter 2.  Mitochondria and radiotherapy share several molecular processes 
like ROS production. Mitochondria are important for ATP production and the regulation 
of apoptosis [95], whereas ionizing radiation induces ROS formation which can lead to 
cell death [96]. It is known that exposure to ionizing radiation can up-regulate 
mitochondrial content and function [97], and ATP is required to repair radiation induced 
damages. Several molecular approaches have been used to investigate the effect of 
energetic stress and/or stress inducers (irradiation and hypoxia) in relation to 
mitochondrial function. In chapter 3 a proof-of-principle study was conducted to 
investigate the influence of mtDNA variations on RT response both in immortalized 
bronchial cells as in tumor cell lines. We used complete mtDNA depletion in our in vitro 
system as an extreme model of mtDNA-related mitochondrial dysfunction. In addition, 
the potential role of ROS and antioxidants in this response has been investigated. 
Stabilized HIF-1α contributes to a glycolytic phenotype of the tumor. However, under 
re-oxygenation, this glycolytic phenotype (Warburg phenotype) persists and is 
associated with a decreased intracellular pH. This induced Warburg phenotype could be 
General introduction and thesis outline 
19 
potentially caused by mtDNA variations, which makes it relevant to investigate the 
effect of changes in the function of Complex I. Therefore, in chapter 4 we investigate 
the effect of complex I inhibition on HIF-1α function and downstream targets under 
hypoxic conditions using the anti-diabetic drug metformin, rotenone or by genetically 
modifying mtDNA-encoded complex I genes, via the usage of cytoplasmic hybrid and 
mtDNA depletion models.  
In chapter 5 we investigated specific targeting of the biguanide phenformin (more 
potent than metformin) to tumor cells, in order to reduce the risk of phenformin-
induced lactic acidosis in normal tissue. Therefore, we exploited the tumor-specific 
expression of the hypoxia-regulated enzyme CAIX. We have designed a series of CAIX 
targeting compounds using the dual-drug approach where the CAIX active site targeting 
sulfonamide moiety is coupled to several anti-cancer drugs and evaluated these for 
their therapeutic efficacy. Specifically, the sulfonamide-phenformin was investigated for 
its inhibitory properties on mitochondrial respiration. 
Repurposing FDA approved drugs might be another approach to treat cancer since their 
side effects are known. This will reduce drug development costs and thereby treatment 
costs in order to keep cancer treatment affordable while improving cancer treatment. 
Nitroglycerin is a nitric oxide donor and used as vasodilator for angina pectoris. 
Vasodilating agents offer the opportunity to counteract tumor hypoxia by opening 
temporarily occluded vessels thereby increasing blood flow. Using a window-of-
opportunity study design, we investigated in chapter 6 the possibility of using 
nitroglycerin to reduce tumor hypoxia in NSCLC patients and furthermore, we assessed 
the underlying molecular effects such as the potential inhibitory effect on mitochondrial 
respiration as possible explanation for a decrease in tumor hypoxia. 
Another approach to increase therapeutic efficacy is described in chapter 7, in which we 
investigated specifically targeting glutathione S-transferases (GSTs), a phase II 
detoxification enzyme family. GST overexpression has been reported in many cancer 
types and plays an important role in drug resistance towards anti-cancer drugs and 
oxidative stress response. Therefore, GST targeting pro-drugs were developed. 
Doxorubicin derivatives have been developed and evaluated, for their specifically 
interaction with GSTs.  
Finally, in chapter 8 a general discussion on the implementation of influencing the 
hypoxic fractions and the role of mitochondria in respect to the metabolism of the 
tumor is included. Important findings and future perspectives are being discussed.   
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Abstract 
Several mutations in nuclear genes encoding for mitochondrial components have been 
associated with an increased cancer risk or are even causative, e.g. succinate 
dehydrogenase (SDHB, SDHC and SDHD genes) and iso-citrate dehydrogenase (IDH1 and 
IDH2 genes). Recently, studies have suggested an eminent role for mitochondrial DNA 
(mtDNA) mutations in the development of a wide variety of cancers. Various studies 
associated mtDNA abnormalities, including mutations, deletions, inversions and copy 
number alterations, with mitochondrial dysfunction. This might, explain the hampered 
cellular bioenergetics in many cancer cell types. Germline (e.g. m.10398A>G; 
m.6253T>C) and somatic mtDNA mutations as well as differences in mtDNA copy 
number seem to be associated with cancer risk. It seems that mtDNA can contribute as 
driver or as complementary gene mutation according to the multiple-hit model. This 
can enhance the mutagenic/clonogenic potential of the cell as observed for m.8993T>G 
or influences the metastatic potential in later stages of cancer progression. 
Alternatively, other mtDNA variations will be innocent passenger mutations in a tumor 
and therefore do not contribute to the tumorigenic or metastatic potential. In this 
review, we discuss how reported mtDNA variations interfere with cancer treatment and 
what implications this has on current successful pharmaceutical interventions. 
Mutations in MT-ND4 and mtDNA depletion have been reported to be involved in 
cisplatin resistance. Pharmaceutical impairment of OXPHOS by metformin can increase 
the efficiency of radiotherapy. To study mitochondrial dysfunction in cancer, different 
cellular models (like ρ0 cells or cybrids), in vivo murine models (xenografts and specific 
mtDNA mouse models in combination with a spontaneous cancer mouse model) and 
small animal models (e.g. Danio rerio) could be potentially interesting to use. For future 
research, we foresee that unraveling mtDNA variations can contribute to personalized 
therapy for specific cancer types and improve the outcome of the disease. 
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Introduction: the cancer's cell energy supply 
In normal physiology, mitochondria are very important in the cell as they produce most 
of the adenosine triphosphate (ATP) via the oxidative phosphorylation system 
(OXPHOS), which is a necessary energy supply for cellular processes. The OXPHOS 
system consists of five protein complexes (complex I–V). All complexes are partly 
encoded by the mitochondrial DNA (mtDNA), except for complex II, which is completely 
nuclear encoded [1]. The OXPHOS system also consists of electron carriers that are 
situated in the inner mitochondrial membrane (Fig. 1B) [2]. Approximately 0.15–2% of 
the electrons that enter the electron transport chain (ETC) [3] can escape the OXPHOS 
cycle, resulting in the formation of superoxide. Increased exposure to this OXPHOS-
related superoxide may not only affect the nearby located mtDNA but also the nuclear 
DNA (nDNA), proteins and lipids, resulting in impaired proteins and/or enhanced 
reactive oxygen species (ROS) production [4]. mtDNA mutations can lead to a decreased 
efficiency of the ETC and can cause more ROS production [5][6]. It has been shown both 
in vitro and in vivo that the OXPHOS system and OXPHOS-related superoxide can have a 
major influence on tumor progression [7]. As the electron transport chain is the most 
important site of ROS generation, mutations in mtDNA can cause more ROS production 
[8]. Evidence suggests when mitochondrial integrity is compromised by excessive ROS 
formation or mtDNA instability, cancer progression is enhanced. Increased ROS levels 
and oxidative damage are observed in fibroblasts of patients with mtDNA mutations [6]. 
To protect against ROS, cells have an antioxidant network from which important 
antioxidant enzyme groups are catalases, glutathione peroxidases, thioredoxins, 
peroxiredoxins, glutathione transferases and superoxide dismutases (SODs). SODs are 
capable of catalyzing the dismutation of superoxide into hydrogen peroxide and oxygen 
[9]. One of these SOD family members, manganese superoxide dismutase (MnSOD) (Fig. 
1B), is located in the matrix of mitochondria [10]. Many types of human cancer cells 
have reduced MnSOD activity compared to their originated cells [11]. Increased MnSOD 
expression was able to suppress tumor cell growth and tumor formation in MCF7, 
A172R, U118, SCC25 and DU145 cells [12]. It has been suggested that MnSOD is a tumor 
suppressor gene [13] and that mutations found in its promoter region could explain the 
reduced MnSOD activity [14]. Additionally, also antioxidants are involved in this 
network. The hydrophilic non-protein thiol, glutathione (GSH), is an important ROS 
scavenger. In a cell, GSH mainly exits in its reduced form, but is able to oxidize into 
glutathione disulfide (GSSG), with a ratio between 30:1 and 100:1. However, this ratio 
can decrease upon oxidative stress [15]. Additionally, GSSG can be converted back into 
GSH driven by glutathione reductase, the catalyzer for this reaction [16]. An inadequate 
antioxidant response, where antioxidants are not able to maintain ‘normal’ 
physiological ROS levels, will lead to a vicious circle of ROS production and create 
cellular damage [6, 17] 
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Warburg observed in 1927 that cancer cells rely less on the OXPHOS system, but rather 
on glycolysis for ATP production and therefore produce high amounts of lactate, even in 
the presence of oxygen. This phenomenon is known as the Warburg effect, or aerobic 
glycolysis [18]. Many cancer types have a tendency to be highly glycolytic and 
mitochondria in cancers cells also show altered cristae, membrane composition and 
membrane potential [4][19], resulting in an aberrant mitochondrial function influencing 
ROS production and apoptosis [4, 20]. ROS production can be increased due to aberrant 
mitochondrial function causing cells to be more prone to apoptosis by activating the 
mitochondrial permeability transition pore [21-23]. However, increased apoptosis could 
also be independent of ROS as observed in for instance the mutator mouse model [24]. 
In cancer, inhibition of factors initiating apoptosis could drive cells toward an actively 
proliferating state with ROS escalation and DNA damage. The paradox between ROS and 
apoptosis, in aging or cancer has been extensively reviewed by Wallace [22, 25]. 
Mitochondrial dysfunction can be observed in tumors, particularly in those that are 
aggressive and growing rapidly [26, 27]. Simonnet et al. compared mitochondrial 
enzymes and DNA contents in renal cell carcinoma (RCC) to normal kidney tissue. 
Mitochondrial impairment was increased from the less aggressive to the most aggressive 
RCCs and correlated with a considerably decreased content of OXPHOS complexes [27]. 
To maintain optimal ATP levels, some tumor cells are able to stimulate the glycolysis 
pathway upon pharmacological inhibition of the OXPHOS system. In contrary, after 
inhibition of glycolysis, the OXPHOS system cannot compensate for the loss of ATP 
production in these same cells [28, 29]. This is, however, not universal as other tumor 
cell lines are still capable of maintaining high ATP contents when they are deprived of 
glucose [30, 31]. The extent of changes in mitochondrial respiratory capacity seems to 
depend on the tumor type and its microenvironmental characteristics, such as hypoxia 
and hormones [32-34]. Adaptation of these processes might affect the tumor 
responsiveness to therapies, which points to a potential therapeutic target for new 
cancer therapies. 
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Figure 1. Global representation of the OXPHOS system and the link to glycolysis in a cell.  A. 
Overview of the mitochondrial DNA. The genes coding for subunits of OXPHOS complex I are ND1-ND6 and 
ND4L. Genes for cytochrome c oxidase (complex IV) are COI-COIII. The gene encoding for Cytochrome B of
complex III abbreviated with Cyt B. Additionally the subunits of Complex V (ATP synthase) are ATPase 6 and 8
abbreviated with A6 and A8 respectively. The 22 tRNAs are indicated with a single letter. The two ribosomal
RNAs encoded by the mtDNA are 12S and 16S. The displacement loop is represented as D-loop and contains 
sequences for initiation for replication and transcription including the origin of heavy-strand replication (OH). 
The light strand replication origin is indicated by OL. The position of the Light strand promoter is shown as LSP
and the position of the heavy-strand promotor as HSP.  B.  Overview of OXPHOS system.  When glucose enters
the cell it is converted to glucose-6-phosphate, after which it undergoes glycolysis. The final step of glycolysis
is the formation of pyruvate and reduced nicotinamide adenine dinucleotide (NADH). Pyruvate can be either 
transformed into lactate and nicotinamide adenine dinucleotide (NAD) by lactate dehydrogenase (LDH) or can
be transported immediately into the mitochondria. This transport is mediated by a mitochondrial pyruvate 
carrier (MPC) which transports pyruvate across the outer mitochondrial membrane (OMM), the
intermembrane space (IMS) and the inner mitochondrial membrane (IMM) into the mitochondrial matrix,
where pyruvate dehydrogenase (PDH) catalysis it is converted into acetyl coenzyme A (acetyl CoA). At the
same time, the MPC transports hydroxide out of the mitochondria. Acetyl CoA is able to enter the Krebs cycle,
where organic acid oxidation takes place and results in succinate production as part of the Krebs cycle and
NADH. Electrons from NADH can enter the electron transport chain (ETC), formed by complex I, complex II, 
complex III and complex IV (I-IV). CI is also known as NADH dehydrogenase / NADH ubiquinone
oxidoreductase, the largest of the oxidative phosphorylation (OXPHOS) complexes, and is one of the starting
points of enrolling the electrons into the ETC [5]. The ETC transports electrons through the IMM, towards 
coenzyme Q (Q), after which they are transferred to complex III (III). The electrons can also skip CI and be
transported via flavin containing enzyme complexes directly towards Q [2]. Another route for electron 
donation to the ETC is via complex II, succinate dehydrogenase/ succinate ubiquinone oxidoreductase (II), 
where succinate is reduced and electrons are transferred towards coenzyme Q and complex III (III). Via
complex III and cytochrome c (C), electrons are moved towards CIV. During electron transport, a proton
gradient is formed over the IMM by CI, CIII and CIV, which drives protons into the mitochondrial matrix via,
CV, ATP synthase, (V) with concomitant production of ATP [2, 35]. All complexes combined are called OXPHOS.
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In total, OXPHOS can produce up to 36 mol of ATP per mol of glucose[36]. Additionally, reactive oxygen 
species can be formed which can be transferred into H2O2 by manganese superoxide dismutases (MnSOD). 
H2O2 and glutathione can be transformed into H2O and oxidized under the influence of glutathione peroxidase
(GPx). Via glutathione reductase (GR) and nicotinamide (NNT) eventually NAD+ can be formed again. 
Mutations in nuclear-encoded mitochondrial genes can cause 
cancer 
Next to the conventional cancer causing mutations (e.g. TP53 encoding for p53 which is 
involved in proliferation, apoptosis and DNA repair [37-39]), some cancers (e.g. 
paraganglioma) are found to be associated with a mutation in one of the nuclear 
mitochondrial genes encoding for OXPHOS subunits or parts of the Krebs cycle. Patients 
suffering from this disease have a dysfunctional succinate dehydrogenase (SDH), better 
known as complex II, which is composed of four subunits. Whereas mutations in subunit 
A are mostly responsible for Leigh's disease (a rare neurometabolic disorder), mutations 
in subunits B, C or D mainly cause paraganglioma [40-43]. In a xenograft study studying 
a SDHC missense mutation it was found that mice formed benign tumors comparable 
with paragangliomas [43]. In 2 other studies investigating families with paragangliomas 
carrying mutations in SDHD [41] or SDHC [42] a causative role was found for these 
mutations and a tumor suppressor function for the genes was suggested [41, 42]. 
Nevertheless, a family with mutated SDHA was recently reported to have paraganglioma 
as well [44]. A proposed mechanism in patients could be that mitochondrial ROS 
increases and more oxidative damage occurs. This could result in oncogenic 
transformation as occurs for paragangliomas [43]. 
Additionally, mutations in succinate dehydrogenase have been found in breast cancer, 
gastrointestinal stromal cancer and renal carcinomas [45-47]. For other cancers like 
uterine leiomyomas and RCCs [48, 49], associations with mutations were found in other 
nuclear-encoded mitochondrial genes such as fumarate hydratase. Heterozygous 
mutations have been reported in the gene encoding for fumarate hydratase, which 
catalyzes the reversible hydration of fumarate to malate, a Krebs cycle substrate (see 
Fig. 1B) [50]. Similarly, for iso-citrate dehydrogenase, catalyzing the conversion of 
isocitrate into 2-glutarate in the Krebs cycle, mutations in the cytoplasmic (IDH1) and 
the mitochondrial (IDH2) isoforms are reported in a wide variety of human cancer types 
such as: acute myeloid leukemia [51, 52], angioimmunoblastic T-cell lymphomas [53], 
cartilaginous tumors [54], colorectal cancer [55], glioblastomas [56], glioma [57] and 
prostate cancer [58]. For a more extended review see Gaude and Frezza [59]. 
Although, evidence for a causative role of the latter mentioned mutations in 
oncogenesis is mostly indirect, the consequent changes in metabolite levels such as 
succinate have been shown to influence hypoxia inducible factor (HIF) stabilization [60]. 
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Mitochondrial DNA mutations and cancer 
Over recent years, accumulating evidence suggests that mtDNA mutations may also 
contribute to a cell's potential to become a cancer cell [61-63], ultimately leading to 
tissue invasion and metastasis. mtDNA variations, such as deletions, point mutations and 
copy number differences, are associated with a wide variety of cancer types [64-74]. 
Genetic insight into mtDNA 
mtDNA characteristics 
The mtDNA is a 16.5 kb double-stranded, circular-shaped DNA molecule that is distinct 
from nDNA in several ways: (1) mtDNA is only maternally inherited; (2) mammalian cells 
can contain thousands of mtDNA molecules, but they nevertheless represent only a 
minor percentage of the total DNA [75]. As mtDNA is polyploid, a mitochondrion 
contains five to ten copies of mtDNA, which can differ in composition from each other. 
Homoplasmy indicates that the mtDNA copies in a cell are all identical, while a mixture 
of wild-type and variant copies is referred to as heteroplasmy [76]; (3) mtDNA is almost 
completely comprised of coding sequence. It codes for 13 OXPHOS subunits, 22 tRNAs 
and 2 rRNAs; less than 10 percent of the entire mtDNA is non-coding [1] (Fig. 1A). This 
non-coding region is mainly located in the displacement (D)-loop, a 1.1 kb region 
involved in mtDNA replication and transcription. In addition, mtDNA encoded genes do 
not contain introns and have none or only a few non-coding bases between them. The 
coding sequences of some of the encoded genes are even overlapping, i.e. they share 
several mtDNA bases [1]. Consequently, changes in the mtDNA are more likely to have 
functional consequences than nDNA variations [70, 77, 78]; (4) in the mitochondrial 
genome, transcription starts from one of the two mitochondrial promoters and can take 
place on both DNA strands. Subsequently, transcription produces a polycistronic 
precursor RNA that results in individual tRNA, rRNA and mRNA molecules after 
processing; (5) mtDNA replication occurs independent of the cell cycle which is 
therefore referred to as relaxed replication. This means that the number of mtDNA 
molecules replicated per cell cycle is only restricted by the levels of available replication 
machinery factors and nucleotides [79, 80]; (6) mtDNA has a higher mutation frequency 
compared to the nDNA in mammals [81, 82]. Possible explanations are: mtDNA is 
located close to the ROS producing OXPHOS and mtDNA lacks protective histones [83, 
84]. However, there is a debate about the protective role of histones, as there is also 
evidence showing that the electrons can transfer easily from histones to DNA leading to 
damage [85] and under some conditions (exposure to Cu(II)/H2O2) histones can even 
enhance DNA damage [86]. It is also suggested that DNA-binding proteins of 
mitochondrial nucleoids can be as equally protective as histones for mtDNA under H2O2 
or X-ray exposure [87, 88]. 
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Mitochondrial DNA maintenance 
The replication of mtDNA is maintained via DNA polymerase γ (POLG1 and POLG2 
genes) [89], mitochondrial transcription factor A (TFAM) [90], Twinkle (C10orf2) [44], 
mitochondrial 12S rRNA dimethylase 1 and mitochondrial 12S rRNA dimethylase 2 
(TFB1M and TFB2M, synonyms: mtTFB or Mtf1) [50], mitochondrial single stranded DNA 
binding protein (mtSSB) [91] and mitochondrial RNA polymerase gene (POLRMT) [74]. 
Both polymerase γ and TFAM are essential for maintaining mtDNA copy number and 
integrity [92-96]. More frequent point mutations and deletions were observed when 
introducing mutations in the exonuclease domain of POLG resulting in misincorporation 
of nucleotides [97, 98]. Furthermore, compared to nDNA, mtDNA damage persists 
longer [84]. 
In murine models having a complete knockout for TFAM, loss of mtDNA and severe 
OXPHOS defects are observed leading to embryonic death [96]. Inducible knock-down 
leads to cell death of the targeted cell type [99, 100]. In 2011, Balliet and colleagues 
showed that fibroblasts lacking TFAM exhibited mitochondrial dysfunction and 
increased oxidative stress due to the loss of certain OXPHOS components and over-
production of hydrogen peroxide and lactate [101]. 
mtDNA dynamics 
Mitochondria are able to change their number and shape in different cell types under 
varying physiological conditions [102, 103]. One possible way for mitochondria to 
maintain their integrity and thus to ensure a healthy population is by exchanging 
mtDNA through constant fission and fusion processes. It can guard a cell by allowing the 
mitochondria to fuse or divide and thereby protect the cell from detrimental effects of 
(accumulating) mtDNA mutations [104]. 
Mitophagy, a degradation process of mitochondria through autophagy, controls the 
number of mitochondria in the cell and initiates the removal of dysfunctional and 
damaged mitochondria [105]. Previous studies had already shown that defective 
mitochondria displayed increased mitophagy [106, 107]. So when a mutation leads to a 
reduced mitochondrial membrane potential (depolarization of mitochondria) the 
mutation causes a phenotypical change and mitochondria loose therefore their ability 
to function normal. Consequently, the mitochondria are not able to re-fuse with the 
mitochondrial network after fission and are recycled [108]. 
When a somatic mtDNA mutation first occurs, it will be in one mtDNA molecule. The 
process of random genetic drift, i.e. the change in the frequency of a variant in a 
population due to random sampling, will at first determine the persistence and 
expansion or loss of this mutation since it will not have significant functional effects and 
thus selection advantage as a single copy. These mutations are not targeted by 
mitophagy and via fusion dominant mutations can become homoplasmic [70]. It is 
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known from haplogroup studies that mtDNA variation can have an effect on how 
efficient electron transport and ATP production are coupled in the mitochondria [109]. 
In that sense, varying percentages of mutant mtDNA can lead to bioenergetic defects 
ranging from mild mitochondrial dysfunction to severe metabolic distress and cell death 
[110] or they can lead to more optimal functioning of the OXPHOS process. In 
combination with the proposed model that cancer metabolism switches from mainly 
glycolysis to preferentially OXPHOS and back during the cancer process [111], this 
suggests that mutations reaching certain heteroplasmy levels by random genetic drift 
resulting in a detrimental (stimulating glycolysis) or beneficial effect on OXPHOS will be 
selected and clonogenic expanded in these respective metabolism waves. 
Germline mtDNA mutations associated with cancer 
Different studies have explored the association between germline mtDNA mutations 
and cancer. There are indications that different germline mutations could actually 
contribute to the development of a certain cancer type in a specific population. 
Different human populations can be distinguished by different human mtDNA 
haplogroups which are defined by unique sets of mtDNA polymorphisms, reflecting 
mutations accumulated by a discrete maternal lineage [112]. The haplogroups are 
associated with region-specific mtDNA sequence variation as a result of genetic drift 
and/or adaptive selection for an environment-favored mitochondrial function [109, 
113]. Tanaka et al. classified 30 different haplogroups in a retrospective study and 
found that the risk in the population M7b2 haplogroup was related to increased risk for 
hematopoietic cancer [114]. Furthermore, Booker et al. showed that haplogroup U was 
related to a 2.5-fold increased risk for developing renal cancer in Caucasian American 
men [115]. They also reported a two-fold increased risk for development of prostate 
cancer, a finding which was supported by Canter et al. [115, 116]. 
Bai et al. identified two different haplogroups that influence breast cancer risk in a 
Caucasian population: haplogroup K indicates an increased risk whereas haplogroup U is 
a protective haplogroup [117]. Additionally, they identified four different single 
nucleotide polymorphisms (SNPs) that influence cancer risks in certain populations. 
The m.10398A is especially of interest as it also defines the European haplogroup N 
[118]. The revised Cambridge Reference Sequence (rCRS) [119] has an A as reference 
nucleotide. In the paper of van Oven et al. a different sequence was published based on 
a phylogenetic approach. Here it was shown that the original wild-type nucleotide on 
this position should be a G and this site is prone for mutations as the G>A 
polymorphism occurs in different haplogroups [118]. Annotations in this paper are 
based on the rCRS nomenclature and HGVS guidelines. 
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The m.10398A>G and m.16519T>C variants were found to be related to an increased 
risk of breast cancer. Two other SNPs, m.13708G>A and m.3197T>C, were identified as 
protective variations [117]. Interestingly, in a population of African-American women, 
the m.10398A variant led to an increased risk of invasive breast cancer [120]. In an 
Indian population with haplogroup N, an association was found between m.10398A and 
breast and esophageal cancer [121]. However, in another study by Francis et al. within 
an Indian population no correlation was found between the m.10398A polymorphism 
and increased breast cancer risk [122]. In a study performed by Mosquera-Miguel et al. 
also no association was found for this variation in a Spanish population [123]. Recently, 
Salas et al. reanalyzed all studies and no correlation could be found regarding the 
m.10398A>G SNP [124]. 
For prostate cancer, Petros et al. have demonstrated an association for four different 
germline mutations in cytochrome oxidase subunit I (m.6253T>C, m.6340C>T, 
m.6261G>A, and m.6663A>G) in a cohort study. Additionally, in a proof of principle 
study they showed for the germline mutation m.8993T>G in ATP6 a 7-fold enhanced 
tumor volume for mutants compared to wild-type tumors. This indicates that mtDNA 
germline variations could play a role in tumor growth for prostate cancer [68]. 
For pancreatic cancer Wang et al. investigated if pancreatic cancer risk increase was 
associated with mtDNA SNPs however no correlation could be observed [125]. Navaglia 
et al. showed by sequencing the D-loop region that germline m.16519T worsened the 
prognosis in pancreatic cancer patients. However, somatic D-loop mutations seemed 
not to be involved [126]. Also, Halfdanarson et al. investigated if survival outcome in 
pancreatic cancer could be predicted based on mtDNA variations by using a SNP 
approach; but they did not find a relationship between certain SNPs and pancreatic 
survival [127]. However, Lam et al. found using genome wide sequencing an association 
with pancreatic cancer and the variant m.5460G>A encoding for a non-synonymous 
p.A331T substitution in the ND2 gene. In the same study it was found that haplogroup K 
was correlated with a reduced risk compared to haplogroup H, however this could be a 
false positive finding, since these results were inconsistent with previous data and the 
amount of haplogroup K participants was very low. Additionally, in haplogroup N the 
amount of rare singleton (variants unique to a single participant) variations in HV2 and 
12S RNA regions was increased compared to controls. The same was found for 
singletons ND4 and ND5 among patients with haplogroup L [67]. These findings indicate 
that mtDNA variations might contribute to pancreatic cancer risk, however this needs to 
be further investigated. 
The mentioned studies above took different approaches to identify mtDNA variations. 
Multiple studies only looked at certain SNPs [68, 117, 120, 122, 123, 125-127], and 
others performed complete mtDNA sequencing to pick up variants [67], which give 
more inside in the different types of variations. It should be taken into account that also 
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individual non-synonymous polymorphisms are able to influence mitochondrial function 
and that restricting analysis to haplogroup variation does not cover the load of mtDNA 
variation. Epistatic interactions (interactions between 2 or more variations) between 
the mtDNA and the nDNA are worth investigating in relation to cancer predisposition or 
development. There seems to be some evidence that germline polymorphisms and 
haplogroups are related to different cancer types. Note that studies finding germline 
mtDNA variations often face high frequencies of functional polymorphisms and high 
mutation rates can lead to the rise of the same mutation in different populations and 
therefore should be adjusted for population substructures as it is done in similar to 
Genome Wide Association studies. Otherwise, the SNPs can just mark different 
ancestral populations and not causal mechanisms [128]. 
Identifying germline mutations related to a specific cancer type in a defined population 
can be very difficult, as the same mutation can lead to a different risk in another 
population. From this perspective, somatic mtDNA mutations have an advantage as 
they are only carried in the tumor and not the patients’ normal tissue [70]. 
Somatic mtDNA mutations related to cancer 
In 1998, Polyak et al. demonstrated that somatic variations in the mtDNA were present 
in the primary tumors of colorectal cancer patients [68]. In the following years, 
numerous somatic mtDNA mutations were reported in a wide variety of tumors (e.g. 
colorectal, breast, bladder, esophageal, head and neck, ovarian, renal, leukemia, lung 
and thyroid cancer) [69-71, 129-133]. Furthermore, somatic mutations have been 
shown to influence cancer progression and metastasis [68, 73, 134, 135]. Data analysis 
by Larman et al. showed that, across 5 different cancer types, displayed somatic mtDNA 
mutations ranging, from 13% in glioblastoma to 63% frequency in rectal 
adenocarcinomas [135]. Some data suggests that the effect of the somatic mtDNA 
mutations and the degree or nature of the tumorigenesis effect depend on the 
functional and threshold effect of the mutation [136-138]. For instance, the 
m.3460G>A/MT-ND1 mutation (decrease in complex I activity) result in different 
tumorigenic potential as determined by colony forming efficiency and tumor growth of 
osteosarcoma cybrids (cytoplasmic hybrids, Fig. 2) [137] compared to the 
m.3571insC/MT-ND1 and the m.3243A>G/MT-TL1 mutation (severe structural and 
functional complex I alteration). More severe alterations in complex I (m.3571insC/MT-
ND1 and the m.3243A>G/MT-TL1 mutation) resulted in a reduced tumorigenic potential 
both in vitro and in vivo, compared with cells displaying milder complex I dysfunction 
(m.3460G>A/MT-ND1 mutation) [137]. 
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Figure 2. Cybrid model for investigating the influence of mtDNA on cancer.  
Cybrids are produced by combining nucleated cells without mtDNA (ρ0 cells) with cytoplasm from non-
nucleated cells (cytoplasts). A cytoplast is made by removing the nucleus through ultracentrifugation (7200 
RPM), leaving a cell that only contains mitochondria with mtDNA. Nucleated cells without mtDNA (ρ0 cells) are 
formed by the depletion of the mtDNA by exposing the cells to ethidium bromide (Etbr). As these cells contain
nuclear DNA, they define the nuclear background of the cybrid. Fusion of ρ0 cells with the cytoplasts leads to 
the formation of cybrids.   
Changes in mtDNA copy number and its association with cancer 
The number of mtDNA molecules could be another factor of consideration since this 
can affect proper mitochondrial function too [139]. Other reviews describe this subject 
in more depth or have been exclusively dedicated to this subject (see [140]). Here we 
give a short summary on this subject; however, this is not a complete list regarding 
observed changes of mtDNA copy number in cancer. The association between copy 
number variation and cancer is still subject of debate. Different trends have been 
reported in multiple tumor types. Both an increase and a decrease in mtDNA copy 
number have been reported to be associated with an increased risk for tumorigenesis. 
In genomic DNA extracted from blood an elevated copy number (compared to matched 
control subjects) has been observed in of patients with various cancers e.g. breast 
cancer [141], RCCs [142], non-small cell lung cancer [65]. Additionally, there are also 
studies investigating mtDNA copy number in tumor tissues. In tumor tissues compared 
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to matched control subjects an elevated copy number was found for endometrial 
cancer [143], glioblastoma [144], head and neck cancer [145] and ovarian cancer [146]. 
Also in tumor tissue compared with paired non-tumor tissue from the same patient an 
elevated copy number have been found for colorectal carcinoma [147], esophageal 
squamous cell carcinoma [148], metastatic fibrolamellar carcinomas [149], prostate 
cancer [150] and thyroid carcinoma [151]. 
Increased mtDNA copy numbers in tumors could possibly be explained by an increase of 
oxidative stress [152]. However, the precise mechanisms have not been fully 
understood. Potentially mtDNA replication could be increased to compensate for 
metabolic effects caused by mtDNA variations or oxidative stress [140]. 
In contrast, decreased mtDNA copy numbers have been reported in patients compared 
to matched tissue subjects for astrocytoma [153] and Ewings sarcoma [154], and in 
tumor versus non-tumor tissue samples from the same patient for breast cancer [151], 
lung cancer [155], primary fibrolamellar carcinoma [149], gastric cancer [156], 
hepatocellular carcinoma [149] and RCC [157]. A twin study found that a reduced 
mtDNA copy number was related to an increased risk for the development of RCC [158]. 
Furthermore, there are indications that the depletion of mtDNA in cancer cells can be 
responsible for disease progression [159]. Lowered mtDNA is correlated with metastasis 
in patients suffering from Ewing's sarcomas [154]. In addition, shorter survival time was 
related to low mtDNA copy numbers in patients suffering from astrocytoma [153]. 
Again, a reverse observation was made for head and neck tumors where increased 
mtDNA copy number was found to be associated with a decreased survival [160]. 
Low mtDNA content can be caused by p53 or POLG1 mutations, resulting in tumor 
initiation or progression [159, 161-163]. The POLG1 gene was found to be mutated in 
63% of breast tumors, and thought to be responsible for a depletion of mtDNA in these 
tumors [162]. TFAM mutations associated with a lowered TFAM protein and a 
decreased mitochondrial copy number were found in colorectal cancers with 
microsatellite instability while no TFAM mutations were observed in colorectal cancers 
with microsatellite stability. Additionally, TFAM mutated cells (TFAM frame-shift 
mutation) were able to grow larger tumors in vivo [95] and lowered mtDNA copy 
number and more oxidative mtDNA damage was observed in TFAM+/− mice [96, 164]. 
When this model was crossbred with the adenomatous polyposis coli multiple intestinal 
neoplasia (APC−/+) mouse cancer model, mtDNA instability enhanced tumorigenesis 
[164]. These findings suggest that both polymerase γ and TFAM might play an important 
role in tumorigenesis. Although, it is not investigated if POLG1 and TFAM mutations 
influence oncogenic transformation as such, a promotion of oncogenic potential after 
primary transformation has been shown especially for TFAM [95]. 
There have been several reports of higher cancer incidence with both increased and 
decreased copy numbers in the same tumor type. An example is RCC, for which both 
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increased [142] and decreased copy numbers has been described [157][158]. 
Furthermore, there seems to be no specificity for tumor type or primary site. The exact 
molecular and metabolic differences between the cancer types that relate to these 
copy number differences should be examined in more detail for a plausible rationale to 
be found. 
Previously, we discussed several types of nuclear encoded mitochondrial and mtDNA 
mutations exhibiting mitochondrial dysfunction and how they relate to cancer and 
cancer therapy (see Fig. 3). (1) Certain mutations display a causative effect for nuclear 
encoded mitochondrial and mtDNA genes in cancer. Some of the mutations in nuclear 
encoded mitochondrial genes have been reported to behave like tumor suppressor 
genes (like SDH or MnSOD) and loss of function or lowered expression increases tumor 
formation. Additionally, it has also been reported that mtDNA depletion can result in a 
tumorigenic phenotype in vitro as well as in vivo [53]. (2) The multiple-hit model could 
be an explanation for the observed alterations of mtDNA variations observed in cancer 
as most scientific findings presented only an association of mtDNA mutations in cancer. 
These mutations are not directly involved in generating the neoplastic phenotype but 
can be responsible for tumor progression or play an important role in the metastatic 
potential of the tumors. Additionally, such mutations can also influence the outcome of 
disease by promoting cancer treatment insensitivity. However, there is also a second 
mechanism for the multiple-hit model possible. In this mechanism some driver 
mutations, without direct selective value, can be randomly fixed via random-drift. In this 
manner, they only express their clonogenic or metastatic potential at a later stage and 
only in combination with other driver mutations. (3) Another option could be that 
neutral mtDNA mutations occur random and are not related to clonogenic potential or 
metastatic potential and are subject to genetic drift (= can disappear or accumulate) 
and are so called bystander (or passenger) mutations. However, it is likely that 
combination of the different models takes place in a tumor. 
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Figure 3. Representation of different scenarios possibly explaining how mitochondrial genes encoded in nDNA
or mtDNA could contribute to cancer.  
When a cell gains clonogenic potential and evolves into a primary tumor or metastasis, different alterations
occur in nuclear encoded mitochondrial genes and mtDNA. Potentially three different scenarios could
describe and explain these observations. In the causative model, mutations in mitochondrial genes encoded
either in the nDNA or mtDNA cause the development of a carcinoma and/or metastasis. The multiple-hit 
model describes a scenario where different types of mutations (in classic oncogenes or tumor suppressor
genes and in mtDNA or nDNA OXPHOS genes) together contribute to the clonogenic potential and the
development of a carcinoma or metastasis. Mutations can follow sequentially or a driver mutation needs
additional mutations after which it can express its mutagenic or metastatic potential resulting in a pathogenic
phenotype. Additionally, also low heteroplasmic mtDNA mutation levels can be increased via drift. This 
increased mutation percentage could thereby exhibit the pathogenic effect of the mutation. The third 
scenario consists of passenger mutations observed in the tumor but not contributing to an increased
clonogenic or metastatic potential. The mutations can accumulate or disappear over time (genetic-drift). All 
different models can exist in the same tumor site, tumor or tumor type. 
mtDNA and cancer treatment implications 
In cancer patients, the choice of therapy depends on multiple factors such as the 
histopathology of the tumor, the stage of the disease and the patient's condition. The 
three most commonly used treatment options, sometimes combined with one another, 
are surgery, chemotherapy and radiotherapy. 
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Chemotherapy 
mtDNA abnormalities affect the response and outcome of therapies in cancer patients. 
As described in a review by Singh et al. different studies have already shown that 
alterations in mtDNA can result in chemotherapy resistance [4]. It has been reported 
that mutations in the NADH dehydrogenase subunit 4 (MT-ND4) contributed to 
acquired chemoresistance during paclitaxel carboplatin treatment [165]. 
However, it also has been suggested that mtDNA variations can be induced by 
chemotherapy. In a case report a patient with ovarian carcinoma had a mtDNA 
mutation in the MT-ND4 gene (m.10875T>C) which occurred after chemotherapy 
treatment [165]. A second study observed that in a leukemia patient 6 months after 
chemotherapy more mtDNA variations were found compared to the samples withdrawn 
prior to treatment [8]. In the same study, leukemia patients treated with a 
fludarabine/alkylator-based chemotherapy regimen displayed an increase in mtDNA 
mutations in primary leukemic cells compared to non-treated patients [8]. Additionally, 
accumulation of mtDNA damage even persisted after ending doxorubicin treatment and 
was associated with adverse effects such as cardiotoxicity [166]. Therefore, it seems 
that de novo variations can be induced by chemotherapy. Another possibility is that due 
to selection a very low heteroplasmy mutation load could be increased in the patients 
due to its clonogenic advantageous property. Both possible mechanisms should be 
further investigated as well as the observations should be validated in larger study 
populations before any conclusions could be drawn. 
Another chemotherapeutic drug, cisplatin, is able to accumulate in the mitochondria, 
causing impairment of mtDNA and mtRNA synthesis [167]. This drug has been shown in 
vitro to induce more adduct formation in the mtDNA compared to the nuclear DNA 
[168]. In addition, cisplatin leads to caspase-dependent apoptosis by changing the 
mitochondrial membrane permeability and resulting in the release of cytochrome c into 
the cytosol, subsequently activating caspase 8 and 9 [169]. For the intestines, a 
correlation was observed between the mitochondrial density and cisplatin sensitivity. 
Cisplatin sensitivity was limited in normal ileum tissue having a low mitochondrial 
density, while the opposite was observed for the normal duodenum tissue, which has a 
high mitochondrial density. In line with these findings, in vitro cultured cells depleted 
from their mtDNA, rho-zero cells (ρ0, Fig. 2) generated from normal intestinal epithelial 
cell lines (IEC-6) showed a four- to five-fold increased resistance against cisplatin 
compared to their parental counterparts [170]. This can be explained by the fact that 
cisplatin-induced adduct formation in mtDNA measured in head and neck squamous cell 
carcinoma cell lines can be up to 500 times higher compared to nDNA [171]. However, 
it has also been suggested that mtDNA mutations lead to an increased ROS production 
and that combination with chemotherapeutics with the same effect (like cisplatin) can 
lead to exhaustion of a cell's antioxidant capacity/response and thereby eventually lead 
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to apoptosis [172-174]. Correlations of ROS production and sensitivity to 2-
methoxyestradiol, a ROS generating agent, have already been reported [175, 176] 
There seems to be some evidence that mtDNA variations could contribute to 
chemotherapy resistance and some drugs directly interact with the mtDNA. The 
observations also apply to radiotherapy, another conventional cancer therapy. 
Radiation therapy 
Ionizing radiation (IR) is a widely used cancer therapy that results in cellular damage in a 
direct or indirect cellular manner. The direct mechanism involves the transfer of energy 
from incident photons or particles to target molecules in their path. ROS are formed in 
the presence of oxygen, resulting in secondary damage [177]. Upon DNA damage, cells 
might undergo a temporary cell cycle arrest to repair the damage or die, mainly by 
mitotic catastrophe and only partly by apoptosis [178]; both processes require ATP 
[179, 180], and might involve directly or indirectly mitochondria as both are at least in 
part dependent on mitochondrial membrane permeabilization. This suggests that 
mitochondria are potentially involved in downstream irradiation effects [181, 182]. 
Studies have shown that ρ0 cells are more radioresistant than parental cells containing 
wild-type mtDNA [183][184]. Human fibroblast and pancreatic cancer ρ0 cells have 
shown higher survival rates following radiation, which could be related to decreased 
G2/M cell cycle arrest [183] or decreased apoptosis without alterations in cell cycle 
distribution [184]. Improved survival could not be linked to differences in antioxidant 
enzyme expression [183]. In contrast, other studies did not identify differences in 
survival after irradiation between human fibroblast and osteosarcoma in parental 
versus ρ0 cells, although less micronuclei (fragments found in the cytoplasm which 
originates from nuclear DNA and correlates with dose/quality of irradiation [185]) 
formation was observed in ρ0 cells after irradiation [186, 187]. 
A differential radiation response was observed between a normal B-lymphoblastoid cell 
line and the mitochondrial mutant cell lines for Leigh's syndrome (m.8993T>G mutation 
in MTATP6 ATP synthase gene) or Leber's optic atrophy (m.11778G>A mutation in 
MTND4 gene [188, 189]. In both cell lines, the apoptosis-related genes showed a 
remarkable up-regulation compared to the control cell line. However, the repair of the 
irradiation-induced double-stranded breaks was different for each of the mutant cell 
lines. Repair was significantly decreased in cells with Leigh's mutation, leading to worse 
short-term radiation survival, while for the Leber's cells, double-strand breaks could be 
repaired resulting in better short-term radiation survival although the studies were not 
performed in cell lines with the same background [188, 190]. In a recently published in 
vivo study it was shown that irradiation of a SiHa cell line with induced mitochondrial 
dysfunction (showing a decrease of oxygen consumption upon exposure to ethidium 
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bromide) lead to an increased time to reach the endpoint compared to their parental 
counterpart [191]. 
There are also indications that mtDNA variation may not only affect radiotherapy 
outcome, but that radiotherapy and chemotherapy itself also can induce mutations in 
the mtDNA. Wardell et al. observed an increased number of point mutations and 
deletions in patients treated with radiotherapy and chemotherapy [192]. Additionally, a 
decrease in mtDNA content has been reported as a result of radiotherapy in cancer 
patients [193]. However, another study found no evidence that radiotherapy for 
pediatric cancer, which resulted in scatter radiation to the ovaries, is associated with 
the mitochondrial genome mutation frequency in female cancer survivors and their 
children [194]. In conclusion, mtDNA mutations (induced by radiotherapy or germline) 
can also affect the response and therefore the outcome of radiotherapy although the 
precise role and mechanisms are not yet fully understood. 
Mitochondrial function interventions in cancer therapy 
ROS is one of the major processes implicated in cancer. It may be possible to reduce the 
ROS escalation caused by dysfunctional OXPHOS using metformin, a type II diabetes 
drug that is used to suppress gluconeogenesis and, among others, inhibits ROS 
production as well as mitochondrial complex I [195-197]. A previous study showed that 
type II diabetes patients have an increased risk of developing cancer with a poorer 
prognosis [198]. In 2005, Evans et al. observed a correlation between a reduced risk of 
developing cancer and treatment of type II diabetes patients with metformin [199], 
which was recently confirmed in a large cohort study [200]. 
Metformin activates adenosine monophosphate activated protein kinase (AMPK) and 
therefore stimulates muscles to take up glucose from the blood, a process also 
activated by exercise [199]. Furthermore, the activation of the cell metabolism 
regulator AMPK results in inhibition of mTORC1 and its downstream signaling pathway, 
thereby decreasing protein synthesis and cell proliferation crucial for tumors [201, 202]. 
The combination of metformin and radiation therapy was shown to be successful in 
vitro since cellular survival was decreased [203]. Song et al. found that metformin was 
able to increase radiosensitivity of cancer cells in vitro and enhance radiation-induced 
growth delay of fibrosarcoma tumors as well as non-small cell lung cancer [204, 205]. 
When metformin treatment was combined with 2-deoxyglucose (2-DG, a glucose 
analog), it resulted in an energetic stress cell death [206, 207]. Instead of using a 
glucose analog, glucose uptake could be inhibited by other substances (e.g. Pholertin, 
WZB117 or Fasentin) to enact a similar mechanism [208-210]. Inhibition of glucose 
uptake of the cell could also be a potential target for tumors with a dysfunctional 
OXPHOS system [211]. 
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Both chemo- and radiotherapy could be influenced by mtDNA variations. Additionally, a 
combination therapy including conventional therapies and drugs influencing 
mitochondrial function could be explored as a therapeutic option for cancer patients. 
Opportunities and pitfalls in studies using mtDNA models 
Multiple studies have identified potential associations between mtDNA variations and 
cancer [64-73]. Mutations/deletions and copy number variations in the mtDNA are able 
to affect proper OXPHOS function and consequently change predisposition for a 
disorder. mtDNA variations (de novo, inherited, caused by ROS production in tumors or 
by cancer treatments) can promote tumor development and progression. Different 
mtDNA models are available for diagnostic and research purposes. Table 1 presents a 
short representation of in vitro, in vivo and ex vivo models. 
In vitro mtDNA models 
Effects of mtDNA depletion are commonly investigated in the ρ0 cell model, mammalian 
cells depleted of mtDNA by exposure to ethidium bromide (Etbr) [212]. Consequently, 
ρ0 cells rely completely on glycolysis instead of oxidative phosphorylation for energy 
production. Removal of Etbr leads to mtDNA repopulation and therefore it should be 
used throughout the entire experiment. Etbr treatment can lead to stalled proliferation 
[213], is genotoxic to cells in vitro (http://ntp.niehs.nih.gov) and can lead to off-target 
effects on the nDNA. Therefore, this model is not suitable for in vivo studies. 
Most studies on pathophysiology have exploited fibroblasts derived from patients with 
mtDNA diseases or mutations. These models allow for high-throughput screening [77, 
78, 214] and testing of potential therapies in vitro. Unfortunately, the consequences of 
OXPHOS-related defects are sometimes less pronounced in in vitro fibroblast cultures, 
since cells are capable of switching from oxidative phosphorylation toward glycolysis 
under specific culturing conditions [215]. In addition, these cells are generally not able 
to form tumors by themselves. Therefore, fibroblasts are not suitable for investigating 
the link between cancer and mtDNA. 
A cybrid cell line is another model used to study the effect of mtDNA variations in 
cancer. These are cell lines with the nuclear DNA background of a tumor cell line [134] 
and the mtDNA of another cell line (Fig. 2). The mtDNA can come from a patient-
derived cancer cell line, a fibroblast or a lymphocyte cell line. The main advantage of 
these cybrids is the ability to investigate whether phenotypes and biochemical changes 
are related to changes in the nDNA or mtDNA. Furthermore, cybrid models enable the 
investigation of in vitro and in vivo effects of different mtDNA mutations in cancer cell 
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lines and tumors with the same nuclear background [216]. A possible disadvantage is 
the dependency on naturally occurring patient mtDNA variations. 
Mitochondrial animal models 
Patients with variations in their mtDNA are often unique, so grouping them is very 
difficult. Therefore, data obtained from patient studies should be carefully interpreted 
with respect to large inter-individual variation. The use of murine models is in this 
respect advantageous, as experimental settings can be better controlled than in patient 
studies. For instance, cell lines with the same nuclear genetic background harboring one 
mtDNA variation can be used as xenograft models. Additionally, to easier investigate the 
molecular mechanisms, specific mitochondrial murine models, such as the POLG 
mutator mouse, can be used either combined with mouse models which spontaneously 
develop cancer. 
Currently, different mouse models are available to unravel the pathways involved in 
mtDNA mutations and cancer (Table 1). The most studied mouse model created for 
translational research in this particular field is the POLG knock-in mouse. These mice 
lack the proofreading function of pol γ and therefore show an accumulation of 
mutations and deletions in their mtDNA [217].  
In homozygous mice, but not in heterozygous mice, a premature aging phenotype 
resulting in effects such as heart enlargement and hearing impairment has been 
observed. However, no cancer development has been reported [217, 218]. Another 
mouse model carries a mutation in the complex I subunit NADH dehydrogenase 
ubiquinone Fe-S protein 4 (NDUFS4). These mice displayed a phenotype similar to that 
in human patients carrying a NDUFS4 mutation, and a full knockout was lethal at 
approximately seven weeks of age [219, 220]. A heterozygote mutant of the NDUFS4 
mice was viable and still showed the biochemical changes observed in patients suffering 
from Leigh's syndrome [221]. 
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A third model, the thymidine phosphorylase (Tp) and uridine phosphorylase (Upp) 
double knockout mouse model (Tp−/−Upp-1−/−) has been developed for studying 
mitochondrial neurogastrointestinal encephalomyopathy (MNGIE). Murine UPP-1, 
unlike human UPP-1, cleaves thymidine as well as uridine; therefore, the full capacity to 
cleave mouse thymidine is abolished in this mouse model [222-224]. In addition, 
deficiencies of complex I and IV could be observed in the brain of very old Tp−/−Upp-1−/− 
mice [224]. This thymidine-induced dNTP imbalance has been recently demonstrated to 
be overcome by the metabolic switch into the salvage pathway in acute lymphoblastic 
leukemia cells, therefore avoiding the lethal replication stress and the subsequent 
tumor progression. Accordingly, strategies focused on inhibition of this switch have 
been suggested as metabolic intervention in acute lymphoblastic leukemia [225]. Tp is 
found to be overexpressed in different tumors (e.g. non-small-cell lung cancer and 
colorectal cancer) and seems to play an important role in angiogenesis, invasion and 
metastasis of tumors [226, 227]. A study by Moghaddam et al. found that Tp has 
angiogenic properties and, in a MCF7 breast cancer xenograft model, Tp overexpression 
led to faster tumor growth [228]. In contrast, low Tp expression correlates to the 
favorable prognosis of gastric cancer treated with chemotherapy [229, 230] and 
promoter methylation has been proposed as a mechanism of its expression down 
regulation in different cancer cells [231, 232]. 
Mice can be given a trigger (e.g. a toxin such as nitrosaminoketone) or have a nuclear 
gene background such as the K-rasLA mouse model to develop cancer [233, 234]. This in 
combination with a murine model with a pathological mtDNA background could lead to 
the creation of a model containing both the mtDNA phenotype and the cancer 
phenotype to investigate the contribution of both parameters to the phenotype of the 
tumor. 
As every mouse strain has specific differences and it is labor intensive to make genetic 
mouse models for every human phenotype, another option is to use small animal 
models specially created for studying the mitochondrial DNA mutation pathology. 
Animal models, such as Danio rerio (zebra fish) [235], Drosophila melanogaster (fruit fly) 
[236] and Caenorhabditis elegans (round worm) [237], develop rather quickly and the 
model can be manipulated by directly adding compounds to the food, medium or 
water, or irradiating their culture dish. Because the evolutionary distance to humans is 
larger than for mice, some of these organisms do not contain all the organs affected in 
humans [238]. 
OXPHOS inhibitors in cellular models for therapeutic interventions 
Several studies demonstrated that inhibition of glycolysis could be a possible treatment 
option for cancers with compromised mitochondrial function (see review Pelicano et al. 
[211]). As these cancers rely more on aerobic glycolysis (Warburg effect), driving the 
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tumors to use OXPHOS instead would lead to sever energetic stress. Cells with mtDNA 
mutations or with a lack of oxygen (hypoxia) are not able to use alternative energy sources 
such as fatty acids and amino acids to produce metabolic intermediates which can be 
used in the Krebs cycle for ATP production through OXPHOS. In these cells inhibition of 
glycolysis could induce cell death [239, 240]. For instance, in an in vitro system using 
human leukemia cells (HL-60) and human lymphoma cells (Raji), cells with a respiration 
defect were less sensitive to cytostatic drugs like 1-β-d-arabinofuranosylcytosine (ara-C), 
doxorubicin (Adriamycin), taxol and vincristine [29]. However, lonidamine, 3-
bromopyruvate and 2-deoxyglucose are known inhibitors of glycolysis that showed 
promising results [29, 206, 207, 241]. In addition, partial inhibition of OXPHOS can be 
achieved by inhibition of the different complexes of the OXPHOS system. The pesticide 
rotenone is known for its ability to inhibit complex I [220]. It can be used in an 
experimental set-up at low concentrations, but it is not likely to obtain U.S. Food and Drug 
Administration (FDA) approval for usage in humans due to toxic effects (e.g. irritation of 
the respiratory tract and apoptosis of erythrocytes) [242, 243]. Metformin, an FDA 
approved drug prescribed to patients with type II diabetes [201], is another inhibitor of 
complex I [195]. However, as discussed above metformin is also used as an anti-cancer 
drug by inhibiting the mTOR signaling through activation of AMPK. A more potent drug for 
complex I inhibition is phenformin [244] a drug related to metformin from the biguanide 
class that is able to inhibit the development and growth of MCF7 and MDAMV231 tumors 
in a xenograft mouse model [245]. Additionally, it also affects the mTOR signaling pathway 
[246]. In xenograft melanomas and in genetically modified mice for melanomas 
(BRAFV600E) combined therapy of phenformin and PLX4720 showed a significant growth 
reduction whereas treatment with only phenformin or PLX470 resulted in growth 
inhibition but no tumor regression [246]. However, FDA has redrawn phenformin from the 
North-American market in 1977, due to its association with fatal lactic acidosis in diabetic 
patients. 
Future prospects 
There is still a lot of debate about the precise relationship between mtDNA variants, 
OXPHOS abnormalities and cancer. Are these mtDNA variations driving disease, involved 
in disease progression or implicated in treatment response and adaptation to 
treatment? Or are they merely passenger observations? 
Detecting mtDNA mutations 
Various platforms can be used to identify mtDNA mutations in tumor material or other 
specimens. Using mutation specific restriction digestion or restriction fragment length 
polymorphism (RFLP) analysis, screening for common mtDNA mutations becomes 
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possible [247]. Denaturing high performance liquid chromatography can be used to 
determine heteroplasmy mtDNA mutations [248]. Pyrosequencing allows accurate 
quantification of the heteroplasmy levels of a variation [249]. For detection of mtDNA 
deletions long-range PCR [250, 251] or quantitative real-time PCR based methods [252] 
and southern blotting [253] could be used. Though, currently there is more desire for 
high-throughput methods of which some of these are listed below. 
Random Mutation Capture (RMC) assay is based on single molecule amplification which 
facilitates the user in measuring relative values of the spontaneous mutation frequency 
and mtDNA deletions [254]. Another method is digital deletion detection (3D assay) and 
is based on the RMC method; with 3D it is also possible to identify rare deletion events 
[255]. Currently, next generation sequencing (NGS) of mtDNA is the standard for 
determination of homo- and heteroplasmic variations. Heteroplasmy depends on tissue 
type; therefore somatic mutations in tumor tissue are mainly heteroplasmic since 
tumors exist out of different cell types. NGS has an enhanced sensitivity for detecting 
low levels of heteroplasmy and has as well an increased coverage [256]. The previously 
used platform, 
MitoChip, is commonly used for the identification of homoplasmic mutations. Although 
the detection range is limited, also some heteroplastic variants can be found [257, 258]. 
mtDNA variants detected with MitoChip usually have to be confirmed using 
conventional Sanger sequencing. 
Identification of potential drug targets 
mtDNA research is not only pursuing the identification of variations of mtDNA that are 
involved in cancer and its treatment, but also the identification of potential drug 
targets. The ideal treatment would be to repair the appropriate defective mtDNA 
sequence, although this would be almost impossible for cancer-related somatic mtDNA 
mutations. Different strategies to achieve this goal have been suggested for severe 
germline mtDNA mutations. For example, blocking the replication of mutated mtDNA by 
peptide nucleic acid might result in repopulated cells with unaffected wild-type DNA 
[259]. However, as interventions specifically for mtDNA are difficult to implement, 
mitochondria and mtDNA can be targeted at multiple downstream steps of 
physiological processes. Drugs can interact with mitochondrial permeability, membrane 
potential, energy supply, antioxidants, ROS production and apoptosis. For instance, 
influencing the function of B-cell lymphoma 2 (Bcl-2), an anti-apoptotic protein, might 
be used as a target. Bcl-2 is often overexpressed in solid tumors and contributes to 
resistance to conventional therapies [260]. Possible targets in the cell are the 
mitochondrial outer membrane proteins (e.g. monocarboxylate transporter 1 (MCT1) 
and mitochondrial pyruvate carriers (MPCs)) or inner membrane proteins (complex I, 
complex II, complex III, complex IV and complex V), the ETC and the Krebs cycle. 
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Alternatively, variations in mtDNA can be exploited to tailor patients’ therapy. It is 
unlikely that all patients with different variations causing OXPHOS deficiency will benefit 
from the same treatment. To illustrate, for tumors with heteroplasmic driver mutations 
interventions that stimulate mtDNA quantity can result in high mutation levels and 
should be avoided to prevent that tumors become more therapy resistant. In this case, 
stimulating mitophagy could be a better option to eliminate the mutation. Altogether, 
personalized treatments should be carefully evaluated in respect to the pathological 
process in the tumors of the cancer patients. 
Conclusions 
Over the last decade, the role of mitochondria and, more specifically, mtDNA in cancer 
has started to be explored. Different signaling processes and ROS production have been 
implicated in the development and progression of cancer, and these processes can be 
affected by changes in the mtDNA. However, the exact molecular mechanisms are not 
yet known. The link between mtDNA and different processes (DNA damage, ROS and 
apoptosis) and how this plays a role in cancer remains especially vague and is not well 
defined. In this review, we discussed 3 different types of models (Fig. 3) of nuclear 
encoded and mitochondrial encoded DNA mutations and how they relate to cancer and 
cancer therapy. The mutations can have a causative effect, could depended on the 
multiple hit model or can be just neutral the so-called passenger mutations. Although a 
combination of these models could occur in the tumor. 
Future research should focus on establishing whether these processes are causes or 
consequences and under which circumstances, and exploring whether they are 
connected or unrelated to changes in the mtDNA. Upon progressive knowledge about 
the role of mtDNA, it will be possible to better understand cancer initiation and 
progression and to improve the prognosis and treatment of patients. 
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Abstract 
Several clinically used drugs are mitotoxic and cause mitochondrial DNA (mtDNA) 
depletion, mutations or deletions. Several studies have shown that these mtDNA 
alterations influence cancer treatment response. We hypothesized that radiation 
responsiveness will be enhanced in cellular models with decreased mtDNA content, 
attributed to altered ATP production, ROS production and antioxidant capacity. For this 
purpose, BEAS-2B (immortalized bronchial epithelium), A549 (lung adenocarcinomic 
epithelium) and 143B (osteosarcoma) cell lines were depleted from their mtDNA by 
ethidium bromide treatment generating ρ0 cell lines. mtDNA depletion resulted in 
significantly (p<0.05) decreased proliferation. Intrinsic radiosensitivity, assessed by the 
surviving fraction at 2Gy, was not influenced. However, at irradiation doses of 4Gy and 
higher, survival was increased (p<0.001) for the BEAS-2B ρ0 cells, while decreased for 
both tumor ρ0 lines (p<0.05). In agreement, increased residual DNA damage was 
observed after mtDNA depletion for A549 and 143B cells 24 hours after 4Gy irradiation. 
Since radiation therapy relies on the production of reactive oxygen species (ROS) for its 
lethal properties, we investigated whether ROS levels are causative for the alterated 
radiation response. Baseline ROS formation was similar between BEAS-2B parental and 
ρ0 cells, while reduced in A549 and 143B ρ0 cells, compared to their parental 
counterparts. ROS levels were significantly increased for all parental cell lines 24 hours 
after irradiation, while levels for the ρ0 cells remained unchanged. Excessive production 
of ROS can result into oxidative stress if the antioxidant defense systems are insufficient 
or defective. The GSH:GSSG ratio can serve as indicator of such oxidative stress. Here 
we found that the GSH:GSSG ratios were in line with the altered radiation response. 
Exposure to irradiation reduced GSH:GSSG ratios for the BEAS-2B parental and 143B ρ0, 
while for the A549 this ratio remained unchanged. Also, changed levels were observed 
for KEAP1 and for downstream targets of the Keap1-Nrf2 pathway. Our results indicate 
that mtDNA copy number depletion results in varying radiation responses depending on 
the background of the cell line, potentially involving variation in cellular ROS levels and 
antioxidant defense mechanisms. We therefore suggest that when mitotoxic drugs are 
combined with radiation, in particular at high dose per fraction, the effect of the 
mitotoxic drugs on mtDNA copy number should be explored. 
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Introduction 
Under normal physiological conditions, mitochondria are important organelles in the 
cell. One of their key functions is the production of adenosine triphosphate (ATP) via 
the oxidative phosphorylation system (OXPHOS), thereby providing the cell with its 
essential energy supply. It has been observed that tumor cells rely less on OXPHOS but 
are more dependent on aerobic glycolysis, also known as the Warburg effect [1]. New 
findings have revealed that this metabolic shift could be the result of metabolic 
reprogramming from a more OXPHOS to a more glycolytic phenotype (uncoupled 
glycolysis) regardless of oxygen presence in the tumor tissue, supporting the tumor’s 
anabolic growth and microenvironmental adaptations. This may be a possible 
explanation for an increased metastatic potential of tumor cells [2, 3]. Potential causes 
for such metabolic reprogramming could be changes in the mitochondrial genome 
(mtDNA) such as deletions, substitutions and even mtDNA copy number variations, 
leading to dysfunctional mitochondria [4]. Mitochondria play an important role in 
processes like reactive oxygen production, redox signaling and apoptosis, while these 
processes influence significantly radiotherapy (RT) response [5-8]. Furthermore, repair 
of RT-induced damage is dependent on mitochondrial energy supply which heavily 
relies upon the functionality of mitochondria [9]. mtDNA alterations, such as mutations, 
deletions or copy number variations, may therefore influence RT response. These 
variations can be potentially caused by mitotoxic agents, such as cisplatin [10] or 
doxorubicin [11]. Cisplatin is able to induce a decrease in mtDNA copy number and 
impairment of mtRNA synthesis [10]. Doxorubicin intercalates with mtDNA and thereby 
contributes to mitochondrial toxicity [11]. Different types of alterations of the mtDNA 
genome have been found to be related to cancer and treatment outcome [4]. Cells fully 
depleted from their mitochondrial genome, Rho-0 (ρ0) cells, are an extreme in vitro 
model to investigate the association between radiation outcome and dysfunctional 
mitochondria due to abnormalities in the mitochondrial genome [12, 13]. Several 
contradictory results on cellular mtDNA depletion using various (tumor) cell lines have 
been published. Different radiation responses were observed varying between a 
radioresistant phenotype to no difference in radiation response in vitro [14, 15]. 
However, an increased radiation response was observed in an in vivo model [16]. To our 
knowledge no mechanistic insights have been proposed to explain the observed 
differences in radiation response of mtDNA depleted cell lines. Therefore, carefully 
elucidating the effect of these processes in radiation response will be important. We 
hypothesized that reduced mitochondrial function after mtDNA depletion changes the 
radiation response and this is dependent on altered ATP production, ROS production 
and on the cells’ antioxidant capacity.   
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Material and Methods 
Cell culture model  
The parental 143B and mtDNA depleted 143B Rho-0 (ρ0) osteosarcoma cells were 
cultured in Gibco’s Dulbecco’s modified Eagle’s medium (DMEM, D-glucose 4.5 g/l) with 
10% fetal bovine serum (FBS; Lonza), the latter supplemented with 150 μg/ml uridine 
and 100 μg/ml bromodeoxyuridine (Sigma-Aldrich) [17]. A549 (alveolar type-II 
carcinoma cells) ρ0 cells were created by Prof. Dr. Ian Holt (Cambridge University, 
United Kingdom) and parental and ρ0 cells were kindly provided by Dr. Lodovica Vergani 
(Padova University, Italy). mtDNA depletion of BEAS-2B (immortalized bronchial 
epithelial) cells was accomplished by culturing cells in medium supplemented with 
ethidium bromide (50 ng/ml; Sigma-Aldrich). Both A549 and BEAS-2B cells were 
cultured in DMEM (D-glucose 4.5 g/l) supplemented with 25% FBS, vitamins, 1X 
essential and non-essential amino acids (Sigma-Aldrich) and 50 μg/ml uridine (Acros 
Organics). 
mtDNA copy number determination 
Confirmation of mtDNA depletion was obtained by performing quantitive PCR. DNA was 
isolated using the gentra puregene kit (Qiagen). Ratios of nDNA (B2M) and mtDNA (D-
Loop) were obtained in order to determine the mtDNA content. Primer secquences can 
be found in Supplementary Table 1. Quantitative PCR was performed on the 7900HT 
Fast Real-Time PCR System (Applied Biosystems). The PCR mixture contained 5ng/ul 
DNA, 0.3 uM forward and reverse primer and 1x master-mix (SensiMix SYBR® HiRox kit, 
Bioline Reagents). The cycling conditions were: 2′ 50°C, 10’ 95°C, 40 cycles of 15′′ at 
95°C + 1′ 60°C. 
Proliferation and clonogenic survival assay 
Proliferation was monitored during 7 days using the IncuCyte FLR after seeding 2500 
cells/well. For clonogenic survival analysis, cells were seeded on day 0 and irradiated 
using a 225kV Philips X-ray tube on day 1. Subsequently, cells were trypsinized and 
plated in triplicate for clonogenic survival. Cells were allowed to form colonies during 10 
days, fixed and stained with a 0.4% methylene blue (Sigma-Aldrich) in 70% ethanol 
solution. Colonies were defined as >50 cells [18]. 
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Metabolic profiling 
Cells were seeded at an optimized cell density of 3x104 cells/well (BEAS-2B) or 1.5x104 
cells/well (143B and A549). Metabolic profiles were generated by replacing the growth 
media by assay media 1 hour before using the Seahorse XF96 extracellular Flux analyzer 
(Seahorse Bioscience) according to manufacturer’s guidelines [19]. A mitochondrial 
stress test was established measuring the oxygen consumption rate (OCR) after 
subsequent injections of 1 µM oligomycin, optimized FCCP concentrations 0.3 µM 
(A549), 0.5 µM (143B) or 0.6 µM (BEAS-2B) and 1 µM mixture of rotenone and 
antimycin A (Sigma-Aldrich). The glycolysis stress test was performed by measuring 
extracellular acidification (ECAR) after sequential addition of 10 mM glucose, optimized 
oligomycin concentration 1.0 µM (all cell lines) and 0.1 M 2-deoxyglucose (2-DG) 
(Sigma-Aldrich). 
Molecular assays 
ATP levels were measured based on the Cell-TiterGlo Luminescent cell viability test 
(Promega) on the Glomax 96 well luminometer (Promega). Levels of extracellular L-
Lactic acid were measured as previously described [20]. Formation of reactive oxygen 
species (ROS) was detected 24 hours after ionizing radiation (4Gy). Cells were exposed 
for 1 hour to 20 µM dihydrorhodamine (Invitrogen). Levels of ROS were determined in 
the propidium iodide (Sigma-Aldrich) negative population by flow cytometry (BD FACS 
Canto II) and expressed using mean fluorescent intensity. Glutathione levels (GSH and 
GSSG) were measured in the cell lysates as described previously [21].  
γ-H2AX immunocytochemistry 
Cells were fixed with 100% methanol at −20 °C. Subsequently cells were permeabilized 
with 0.05% Tween-PBS and normal goat serum was used as blocking agent. Cells were 
stained with a primairy anti-phospho(Ser139)-H2AX antibody (1:500, Millipore) followed 
by anti-rabbit Alexa Fluor 488 (1:500, Invitrogen) as secundairy antibody. Hoechst33342 
(20 ug/ml, Sigma–Aldrich) was used as nuclear counter stain. Images were acquired 
using a Leica TCS SPE confocal microscope.  
RNA isolation and quantitative PCR analysis 
mRNA was extracted using the NucleoSpin RNA II kit (Bioke) using iScript cDNA 
Synthesis Kit (BioRad). Both methods were performed according to the manufacturers’ 
instructions. Quantitative PCR was performed on the CFX96 (Biorad). The abundance of 
the genes of interest were detected with SYBR® Green I (Eurogentec). Values for each 
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gene were normalized to 18S expression levels. Primer sequences are listed in 
Supplementary Table 1.  
Statistics 
All statistical analyses were performed with GraphPad Prism version 5.03 for Windows 
(GraphPad Software, 2009, California, USA). A non-parametric Mann–Whitney U test for 
small groups was used to determine the statistical significance of differences between 
two independent groups of variables. Clonogenic survival curves were compared using 
an extra sum F-test. For all tests, a p<0.05 was considered significant. 
Results 
To investigate if extreme changes in OXPHOS capacity affect radiosensitivity, we used ρ0 
cell lines with different genetic backgrounds. All our ρ0 cell lines showed a strong and 
significant decrease in mtDNA copy number (Fig. 1A; BEAS-2B p<0.001; A549 p<0.05; 
143B p<0.05). Additionally, proliferation was decreased as evaluated by an increased 
doubling time (on average 54%) for all ρ0 cell lines (Fig. 1A). We confirmed the drastic 
effect on OXPHOS upon mtDNA depletion as basal respiration was almost absent 
(p<0.05) in the BEAS-2B, A549 and 143B ρ0 (Fig. 1B) while the parental cells had a 
functional OXPHOS system with spare capacity (Fig. 1C). To compensate their loss of 
OXPHOS function, ρ0 cells showed an enhanced (p<0.05) glucose metabolism 
accompanied with a loss in glycolytic reserve (Fig. 1C; Fig S1). The mtDNA depletion did 
not result in reduced cellular ATP levels and no differences in lactic acid production 
were observed between ρ0 and their parental counterparts (Fig. 1D). Together our 
results indicate that mtDNA depleted cells upscaled their glucose metabolism. 
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Figure 1. Validation of mtDNA depleted cell lines  
A. qPCR assessed mtDNA copy number levels expressed in percentage normalized to each parental (left panel)
and the doubling time for all investigated cell lines (right panel). B. Basal respiration expressed as oxygen
consumption rate (OCR) in function of time (minutes). C. Stacked plot of mitochondrial (left panel) or
glycolysis (right panel) stress test after measuring OCR or extracellular acidification rate (ECAR) respectively. D.
ATP levels (left panel) and L-Lactic acid levels (right panel), both normalized to each parental. Data represent 
the mean ± SEM from at least 3 independent biological experiments. * p<0.05, *** p<0.001. 
 
In order to assess the influence of mtDNA depletion on radiation response, clonogenic 
survival assays were performed. Overall survival was increased (p<0.001) for the BEAS-
2B ρ0 cells, while decreased for A549 ρ0 (p<0.01) and 143B ρ0 (p<0.0001) cells (Fig. 2A). 
However, the intrinsic radiosensitivity assessed by the surviving fraction at 2Gy was not 
influenced (p>0.05). mtDNA depleted cells showed differences in residual DNA damage 
24 hours after 4Gy irradiation as compared to the parental cell lines in line with the 
clonogenic survival data. An increased number of residual γH2AX foci was observed for 
the 143B ρ0 and to a lesser extent for the A549 ρ0 cells. The opposite was observed for 
the BEAS-2B, where the ρ0 cells showed a lower residual signal compared to the 
parental cell line (Fig. 2B). 
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Figure 2. Radiation response in mtDNA depleted cell lines 
A. Clonogenic survival plots, fitted according to the LQ model. Results show mean ± SEM from at least 3
independent biological replicates. 0 Gy conditions are sham irradiated. B. Representative merged fluorescent 
images of γH2AX foci (green) and nuclei (blue) visualizing residual foci upon irradiation. 
 
Radiation therapy relies on the production of reactive oxygen species (ROS) for its lethal 
properties. Additionally, cellular mitochondrial function plays an important role in ROS 
production and redox signaling. Here we assessed ROS formation (Fig. 3A) at baseline 
(0Gy), which was found to be similar (p=0.878) for BEAS-2B parental and ρ0 cell lines, 
while reduced for A549 (NS) and 143B (p=0.0211) ρ0 cells. ROS levels were significantly 
increased (p<0.05) for all parental cell lines 24 hours after irradiation, while levels for the 
ρ0 cell lines remained equal. ROS formation 24 hours after irradiation was significantly 
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lower (p<0.05) for the the A459 and 143B ρ0 cell lines compared to their parentals. Since 
“oxidative stress” indicates a disbalance between ROS and antioxidants in favor for ROS, 
we investigated the antioxidant capacity of the ρ0 cell lines using the ratio of GSH:GSSG 
as a proxy to assess if ROS scavenging mechanisms were altered. GSH:GSSG ratios were 
decreased for the BEAS-2B parental and 143B ρ0 cells upon irradiation. No alterations 
were observed for both A549 cell lines (Fig. 3B). The kelch-like ECH-associated protein 1 
(Keap1) - Nuclear factor erythroid 2 (NF-E2)-related factor 2 (Nrf2) pathway is an 
important oxidative stress response regulator and down-stream targets of Nrf2 are 
found to be involved in NADPH production, glutathione metabolism and utilization [22]. 
KEAP1 mRNA levels were elevated for both tumor ρ0 cell lines at baseline and after 
irradiation compared to their parentals (Fig. 3C). mRNA expression levels of NRF2 were 
not significantly altered. Certain downstream targets of the Keap1-Nrf2 pathway such as 
the malic enzyme 1 (ME1), involved in NADPH production, displayed elevated mRNA 
levels in the tumor ρ0 cell lines (Fig. S2) while other targets such as glucose-6-phosphate 
dehydrogenase (G6PD), phosphogluconate dehydrogenase (PGD), NAD(P)H quinone 
dehydrogenase 1 (NQO1, involved in quinone detoxification) and glutathione peroxidase 
(GPX1) did not show altered mRNA expression levels for the ρ0 cells (Fig. S2). Baseline 
levels of the antioxidant superoxide dismutase 2 (SOD2) were elevated in the ρ0 cells (Fig. 
3C), being significant for A549 (p=0.0493). Irradiation increased SOD2 expression for 
both parental A549 (p<0.05) and ρ0 (NS; p=0.0519) cells. On the other hand, SOD2 
expression levels were decreased upon irradiation for 143B parental cells (p=0.0093). 
Irradiation did not alter SOD2 expression levels for the 143B ρ0 cells (p=0.5476) neither 
for both BEAS-2B cell lines. Expression levels of SOD1 were not significantly altered upon 
irradiation for the BEAS-2B, A549 and 143B cells (Fig. S2). 
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Figure 3. ROS and GSH levels at basal levels and 24 hours after 4Gy of irradiation 
A. ROS levels at baseline and 24 hours after irradiation, normalized to each parental at baseline. B. Ratio of 
GSH:GSSG levels at baseline and at 24 hours after irradiation for parental and ρ0 cell lines. Data represents the 
mean ± SEM from at least 3 independent biological repeats. mtDNA depleted cells are indicated by the
dashed bars. * p<0.05. C. mRNA expression of KEAP1 and SOD2 24 hours after irradiation, normalized to each
parental at baseline. Data represents the mean + SEM from at least 2 independent biological repeats. * 
p<0.05.  
Discussion 
Recently, mtDNA variations have been linked to a wide variety of cancers and cancer 
outcome through influencing mitochondrial pathways [4] and may explain the 
hampered cellular bioenergetics found in many cancer types. Mitochondrial dysfunction 
has been found to be related to a chemoresistant phenotype in vitro [23-26] and 
chemotherapeutic agents might be associated with a decreased mitochondrial function 
[10, 11, 27]. Furthermore, several studies investigated the effect of mtDNA depletion 
with respect to radiotherapy by using different (tumor) cell lines with contradictory 
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results, from a radioresistant phenotype or no difference in radiation response in vitro 
[14, 15, 28] to an increased radiation response in vivo [16]. 
Reactive oxygen species (ROS) are formed in the presence of oxygen and are further 
induced upon radiation resulting in DNA damage. Functional mitochondria are found to 
be essential for radiation-induced ROS production [29]. Radiation causes either cell 
death (mainly by mitotic catastrophy) or induces a sublethal DNA damage initiating a 
temporary cell cycle arrest in order to repair the damage [4]. The interplay between 
mitochondrial function and radiation response is of great importance in such a 
radiation-induced DNA damage repair [30]. As both ROS production and ATP are vital 
parameters for radiotherapy outcome and mitochondrial function is essential for 
radiation-induced DNA repair, mtDNA variations could alter the response to irradiation 
possibly via increased lactate production as a consequence of a reduced OXPHOS 
function [25, 31]. Additionally, it has been shown that Increased lactate results in a 
radioresistant phenotype [32]. However, in our study, no differences could be observed 
in cellular ATP levels for mtDNA depleted cells, in agreement with the observed 
compensation by glycolysis induction often found in cell lines with a dysfunctional 
OXPHOS system [33, 34]. Although mtDNA depletion resulted in a glycolytic phenotype, 
no elevated lactic acid production was observed. A possible explanation for this finding 
could be that most lactic acid is catabolized in order to control the intracellular pH of 
the cell [35, 36].  
We hypothesized that mtDNA depletion results in a more radiosensitive phenotype 
related to altered ROS and ATP levels and changes in the antioxidant ROS scavenging 
capacity. Our data showed, in line with literature, that a varying irradiation response 
occurred in different cell lines after mtDNA depletion. Overall, in our study the 
immortalized epithelial BEAS-2B ρ0 cell line was less radiosensitive compared to the 
parental line, while the tumor derived ρ0 cell lines (A549 and 143B) were more prone to 
a decreased survival upon radiation. However, the intrinsic radiosensitivity, correlated 
to clinical outcome after conventional fractionated radiotherapy and quantified by the 
survival fraction at 2Gy, was not significantly modified [37]. Residual γH2AX foci after 
irradiation were in agreement with the survival data, as described previously [38]. 
Irradiation is able to elevate ROS levels [7]. In the parental cell lines used in this study, 
the irradiation-induced increase in ROS levels was evident, while no increase was 
observed in ρ0 cells. Potentially, this is due to the fact that both NADH ubiquinone 
oxidoreductase (CI) and ubiquinol-cytochrome c oxidoreductase (CIII), the major ROS 
generating sites of the oxidative phosphorylation chain, might be deficient in the 
established ρ0 cells. This may explain why we found relatively lower ROS levels in the ρ0 
tumor cell lines [39-41]. In contrast to the elevated ROS levels found in cells with 
mtDNA variations [25, 42, 43], Park et al. demonstrated that ρ0 cells can also have 
normal ROS levels due to the protective up-regulation of their antioxidant system 
during the ρ0 development [25]. 
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Glutathione and SOD2 are important antioxidants that can be located in the 
mitochondrion [44]. Here we observed that the ratio between GSH and GSSG was 
decreased upon irradiation for the parental BEAS-2B and the 143B ρ0 cells, whereas no 
differences were found for the A549 cells. These data suggest that differences in 
radiation response between parental and mtDNA depleted cells could be determined by 
the antioxidant capacity of the cells. SOD2 is an antioxidant able to scavenge superoxide 
radicals in the mitochondrial matrix [45] and therefore can protect cells against radiation 
[46]. Cells with an overexpression of SOD2 are found to have a higher cell survival [46]. 
We indeed observed an increase in SOD2 levels upon irradiation for the A549 parental 
cells. On the other hand, mitochondrial SOD2 levels where unaffected in the 143B cells. 
Previously, it has been reported that ρ0 cells originating from different tissues can have 
altered glutathione antioxidant mechanisms [47, 48]. The Keap1-Nrf2 pathway is an 
important oxidative stress response regulator and downstream targets of Nrf2 are found 
to be involved in glutathione metabolism and utilization [22, 49]. KEAP1 mRNA levels 
were found to be elevated for both tumor mtDNA depleted lines, suggesting a role for 
this pathway in the antioxidant response. Some, but not all, downstream targets of the 
Keap1-Nrf2 pathway were found to be elevated indicating that Keap1-Nrf2 could play a 
role in the antioxidant capacity of ρ0, however this remains to be further elucidated. 
Furthermore, it has also been suggested that variations in culture medium can influence 
oxidative stress and oxidative stress responses, possibly explaining the observed 
differences in antioxidant mechanisms [48, 50]. A well-known example is cysteine, the 
precursor for glutathione [50]. Therefore, the use of glutathione and its effectors in 
culture medium should be carefully considered when elucidating the interactions of 
mitochondrial function and antioxidants.   
Taken together, mtDNA depletion resulted in decreased proliferation for all ρ0 cell lines, 
increased clonogenic survival for the epithelial BEAS-2B cells, but reduced clonogenic 
survival at higher irradiation doses for the tumor cell lines. Our findings indicate that 
inhibition of OXPHOS might be useful to enhance radiotherapy effects, in particular for 
patients treated with hypofractionated radiotherapy in rapidly proliferating tumors. This 
is in line with the well-known OXPHOS inhibitor metformin, an FDA approved drug for 
diabetes leading to an improvement of tumor oxygenation and better outcome 
following radiotherapy [51, 52]. Concluding, mtDNA depletion resulted in varying 
irradiation responses in different cell lines, potentially attributed to ROS and antioxidant 
capacity. 
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Supplementary Data 
 
Supplementary Figure S1. Representative images of the glycolysis stress test for BEAS-2B, A549 and 143B. 
Basal measurements followed by subsequent injections of 10 mM glucose, 1.0 µM oligomycin and 0.1 M 2-
deoxyglucose. 
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Supplementary Figure S2. Expression of antioxidant genes.  
Data represents the mean ± SEM from at least 2 independent biological repeats, normalized to each parental 
at baseline **p<0.01.  
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Table S1. Quantitative PCR primer sequences  
Target gene Forward primer Reverse primer 
D-loop CATCTGGTTCCTACTTCAGGG TGAGTGGTTAATAGGGTGATAGA 
B2M TGCTGTCTCCATGTTTGATGTATCT TCTCTGCTCCCCACCTCTAAGT 
18S AGTCCCTGCCCTTTGTACACA GATCCGAGGGCCTCACTAAAC 
KEAP1 AACGGTGCTGTCATGTACCA CCAATCTGCTCAGCGAAGTT 
NRF2 GAATACTCCCTGCAGCAAACAA CTGGCTTCTTACTTTTGGGAACA 
ME1 GGCTGGTTGATTCAAAAGGA TCTTCATGTTCATCGGCAAA 
NQO1  GCACTGATCGTACTGGCTCA CATGGCATAGAGGTCCGACT 
PGD TGAGGCATACCACCTGATGA CCATCGGTGTCTTGGAACTT 
G6PD  CCAAGCCCATCCCCTATATT CCACTTGTAGGTGCCCTCAT 
SOD1 (CuZnSOD) GCGGAGGTCTGGCCTATAAAG CTGGTTCCGAGGACTGCAA 
SOD2 (MnSOD) GCTCCGGTTTTGGGGTATCTG GCGTTGATGTGAGGTTCCAG 
GPX1 TATCGAGAATGTGGCGTCCC TCTTGGCGTTCTCCTGATGC 
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Abstract 
Background and objective: For several years evidence is accumulating that not only 
more eminent known nuclear DNA mutations but also different variations (e.g. 
deletions and mutations) in the mitochondrial DNA (mtDNA) are associated with a wide 
variety of cancers. These mtDNA variations often result in a bioenergetic dysfunction of 
mitochondria causing the tumor cell to make a metabolic switch towards glycolysis 
resulting in an unbalanced pH homeostasis. In hypoxic cells, expression of the tumor-
associated carbonic anhydrase 9 (CAIX), which is transcriptionally regulated by HIF-1α, 
is enhanced to maintain cellular pH homeostasis. Therefore, we hypothesized that cells 
with dysfunctional OXPHOS display elevated CAIX expression levels.  
Material/methods: A549 (non-small cell lung carcinoma) and 143B (osteosarcoma) 
parental and mtDNA depleted cell lines (ρ0) were used. Additionally, cytoplasmic hybrids 
(cybrids) were produced by fusing the mtDNA-deprived 143B cell line with mtDNA 
derived from patient fibroblasts with the m.3243A>G MELAS mutation and were 
metabolically characterized using the Seahorse XF96 analyzer to determine 
mitochondrial respiration and glycolysis. OXPHOS complex I (CI) inhibition was achieved 
by exposing cells to metformin (5 mM) or rotenone (1 µM) for 16 hours. CAIX, VEGF, 
HIF-1α and PHD2 mRNA expression was determined by qPCR and CAIX and HIF-1α 
protein levels were determined by Western blotting. Reactive oxygen species levels 
were determined by DHR flow cytometry. Tumor growth, time to reach 500 mm3 and 
hypoxic fraction (pimonidazole and CAIX positivity) was monitored for xenografts 
generated from the cytoplasmic hybrids. 
Results: The MELAS cybrid model showed a reduced mitochondrial respiration 
compensated by an increased glycolysis. CAIX mRNA and protein expression levels upon 
hypoxia (0.2% O2) were blocked upon pharmacological or genetic OXPHOS inhibition. 
Also, VEGF (mRNA) and HIF-1α (protein) expression levels were reduced. Levels of ROS 
were lowered for the 143B mtDNA depleted cells but remained similar for the cybrid 
model upon hypoxia exposure. PHD2 expression (mRNA) levels were not affected. 
Hypoxia levels were decreased in vivo for the MELAS compared to control cybrid 
xenografts.  
Conclusion: Our results demonstrated that OXPHOS inhibition, either genetically or 
pharmacologically, leads to a decreased HIF-1α stabilization and expression of 
downstream targets like CAIX and VEGF. Inhibition of mitochondrial function is 
therefore an interesting approach to increase therapeutic efficacy.  
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Introduction 
As the tumor microenvironment is a heterogeneous and dynamic entity, cells within a 
tumor can have different gene expression profiles, metabolism and oxygen supply. The 
lack of nutrient and oxygen supply is associated with two main characteristics of a 
malignancy, namely bioenergetics and angiogenesis [1]. The adaptation of cancer cells 
to hypoxia, the low oxygen regions within a tumor, is critical for tumor progression and 
is regulated by the hypoxia-inducible factor-1 (HIF-1) [2]. In addition to its role in 
proliferation, survival, angiogenesis and metastasis, HIF-1 is also involved in the 
regulation of tumor cell metabolism. During hypoxic stress, HIF-1 is able to reprogram 
tumor cell metabolism towards the low yield-energy production of the glycolytic 
pathway [3], which is associated with an increase in glucose uptake and lactate release 
[4]. HIF-1 reprograms metabolism not only by the up-regulation of glycolysis itself [5] 
but also by down-regulation of the mitochondrial respiration through regulating for 
instance pyruvate dehydrogenase kinase 1 expression [6, 7]. Transport of lactate, a by-
product of the glycolysis, into the microenvironment leads to extracellular acidification.  
One important family of proteins involved in tumor pH regulation are the carbonic 
anhydrases (CA). One of these CA members is the membrane bound zinc-metallo-
enzyme CAIX, which is capable of re-hydrating CO2 into bicarbonate (HCO3-) and a 
proton (H+) upon passive CO2 diffusion out of the cell. HCO3- will subsequently re-enter 
the cell in order to neutralize the intracellular pH. The remaining proton remains in the 
extracellular environment and contributes to extracellular acidification, which is related 
to worse prognosis in cancer patients [8, 9]. High CAIX expression results in a higher risk 
of locoregional failure, disease progression and metastases development in cancer 
patients [10]. In hypoxic tumors CAIX expression is found to be upregulated through 
transcriptional activation upon interaction of HIF-1α with the hypoxia response element 
(HRE) identified in its promotor region [11]. Also, the transport of lactate into the 
microenvironment leads to an increase in extracellular acidification. The role of the 
dysfunctional mitochondria in these mechanisms is of interest. It has been suggested 
that dysfunction of the oxidative phosphorylation machinery contributes to the tumoral 
metabolic reprogramming [12, 13]. Therefore, we hypothesized that mitochondrial 
dysfunction as a result of mtDNA variations would potentially lead to an increased 
expression of CAIX.  
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Material and methods 
In vitro models  
mtDNA depleted cells 
The parental and mtDNA depleted (rho-zero|ρ0)143B osteosarcoma cell lines were 
kindly provided by Dr. Valeria Tiranti (Milan, Italy). Both cell lines were cultured in 
Gibco’s Dulbecco’s modified Eagle’s medium (DMEM) with 10% fetal bovine serum 
(FBS; Sigma-Aldrich). Culture medium of the mtDNA depleted cells was supplemented 
with 150 μg/ml uridine (Acros Organics) and 100 μg/ml bromodeoxyuridine (Sigma-
Aldrich). The parental and mtDNA depleted A549 (alveolar type-II carcinoma) cell lines 
were cultured in DMEM supplemented with 25% FBS, vitamins, amino acids (Sigma-
Aldrich) and uridine (50 μg/ml; Acros Organics). mtDNA depletion was sustained by 
culturing cells in the medium supplemented with ethidium bromide (50 ng/ml; Sigma-
Aldrich). Fluorescent confocal imaging and quantitative PCR were used to confirm 
mtDNA depletion. For confocal imaging, cells were stained (45 min) with MitoTracker® 
Deep-Red FM and Picogreen (Invitrogen) in D-PBS (GIBCO) according to manufacturer 
protocol. Subsequently, cells were washed twice with D-PBS and visualized using a Leica 
AOBS confocal microscope. Overlays were generated using Image J. Ratios of nDNA 
(B2M) and mtDNA (D-Loop) were obtained by quantitative PCR in order to determine 
the mtDNA copy numbers. DNA was isolated using the gentra puregene kit (Qiagen). 
Quantitative PCR was performed on the 7900HT Fast Real-Time PCR System (Applied 
Biosystems). Gene abundances were detected using SensiMix SYBR® HiRox kit (Bioline 
Reagents). The cycling conditions were: 2′ 50°C, 10’ 95°C, 40 cycles of 15′′ at 95°C + 1′ 
60°C. Primer sequences for B2M and D-Loop can be found in supplementary Table 1.   
Cytoplasmic hybrids (cybrids) and quantification of mutant mtDNA percentage  
Cytoplasmic hybrids cell lines (cybrids) were generated as previously described [14, 15]. 
In short, cybrids were produced by fusing the mtDNA from patient fibroblasts with the 
mtDNA depleted 143B cell line. Two control cybrid cell lines were generated using 
fibroblast mtDNA from healthy volunteers (kindly provided by Dr. Hubertus Smeets, 
Maastricht, the Netherlands), while 2 mutant cybrid cell lines were created using 
fibroblasts harboring the m.3243A>G mutation encoding for mitochondrial tRNA-
Leu(UUR) (MT-TL1) and responsible for the “mitochondrial encephalomyopathy, lactic 
acidosis, and stroke-like episodes” (MELAS) syndrome [16]. All cell lines were cultured in 
DMEM supplemented with 5% dialyzed serum (Invitrogen). To determine the 
percentage of mtDNA harboring the MELAS m.3243A>G mutation, the coding mtDNA 
sequence was amplified using primer sequences found in supplementary Table 1. The 
PCR amplification consisted of an initial denaturation at 94°C (5 min), followed by 32 
cycles at 92°C (1 min), 53°C (1 min), 72°C (45 s) and a final elongation at 72°C (7 min). A 
FAM labeled forward primer was added to the first PCR product which was subjected to 
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an additional PCR cycle. Gel electrophoresis (2% agarose) confirmed size of the PCR 
products. Fragments were excised from the gel and digested (2.5 h at 37°C) using a mix 
of sterile water, digestion buffer and the restriction enzyme Hae III. Digestion products 
were purified using the QiaQuick PCR Purification kit (Qiagen) and analyzed with ABI 
3730 using a G5 filter. The primer sequences for fragment analysis can be found in 
Table S1. 
Metabolic profiling  
Metabolic profiles were generated using the Seahorse XF96 extracellular Flux analyzer 
(Agilent) according to manufacturer’s guidelines [17]. Cells were seeded at an optimized 
cell density of 30.000 cells/well. The glycolysis stress test was performed by sequential 
addition of 10 mM glucose, optimized oligomycin concentration (2.5 µM) and 0.1 M 2-
deoxyglucose (2-DG) (Sigma-Aldrich). 
OXPHOS inhibition 
500.000 cells of each cell line were seeded in 6 cm centimeter dishes. Cells were 
exposed to either normoxia (20% O2) or hypoxia (0.2% O2) for 16 hours simultaneously 
with incubation of vehicle, 5mM metformin (Sigma-Aldrich) or 1 μM rotenone (Sigma-
aldrich). After 16 hours, cells were immediately put on ice and were washed with PBS 
prior to protein or RNA isolation. 
DNA isolation, RNA isolation and quantitative PCR analysis 
mRNA was extracted using NucleoSpin RNA II kit (Bioke) and reverse transcribed using 
iScript cDNA Synthesis Kit (BioRad). All procedures were according to the 
manufacturers’ instructions. Quantitative RT-PCR was performed in the ABI 7700 
(Applied Biosystems) or 7900HT Fast Real-Time PCR. Gene abundances were detected 
with SYBR® Green (Eurogentec). mRNA expression was normalized to 18S. Primer 
sequences can be found in Table S1. 
SDS-PAGE and Western blotting 
Cells were lysed and processed as described previously [18]. Antibodies used were M75 
(1:40) (kindly provided by Silvia Pastorekova, Institute of Virology, Slovak Academy of 
Science, Bratislava, Slovak Republic) against CAIX, anti-HIF-1α (1:250, BD transduction) 
and anti-β-actin (1:200.000, MD biosciences). Proteins were visualized by the 
horseradish peroxidase method (anti-mouse 1:2000, Cell Signaling) by using ECL prime 
western blotting detection reagent (Amersham Corp) or ECL supersignal west pico 
(Thermo Fisher). 
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Proliferation assay 
2500 cells/well were seeded in a 96-wells plate and allowed to settle overnight. 
Subsequently, proliferation was monitored during 7 days in the IncuCyte FLR (Essen 
Bioscience) or until >90% confluency was observed. 
Flow cytometry. 
Formation of reactive oxygen species (ROS) was detected 16 hours after hypoxia or 
normoxia exposure. Cells were incubated with 20 μM dihydrorhodamine-123 during the 
last hour of exposure. ROS levels were determined in the propidium iodide (Sigma-
Aldrich) negative population by flow cytometry (BD FACS Canto II).  
Hypoxia tolerance 
Cells were seeded in 6 cm dishes, allowed to attach under normoxic conditions 
overnight and exposed to hypoxic conditions (0.2% O2) for 24, 48 or 72 hours. After 
hypoxic exposure, medium was replaced and cells were allowed to form colonies under 
normoxia for 7 days. Colonies were quantified after staining and fixation with 0.4% 
methylene blue in 70% ethanol. A colony was defined as > 50 cells.  
In vivo models 
All experiments were in accordance with local institutional guidelines for animal welfare 
and were approved by the Animal Ethics Committee of the University. Control and 
mutant cybrid cells (1.5*106) were resuspended in Basement Membrane Matrix 
(Matrigel™ BD Biosciences) and injected subcutaneously into the lateral flank of adult 
NMRI nu/nu mice (28–30 g). Tumor growth was monitored until reaching a volume 
of 1.2 cm3.  
Immunohistochemisty 
Frozen cybrid xenograft tumors were sectioned (5 μm) and stained for hypoxia 
(pimonidazole) and CAIX. Sections were fixed using cold acetone, rehydrated in TBS with 
0.2% Tween-20 (TBS-T) and pre-incubated with 1% normal goat serum (NGS) before 
exposing them to the primary antibodies: rabbit anti-pimonidazole (1:150, HP3-1000, 
Bio-connect) and rabbit anti-CAIX (1:1000, Novus biologicals). After washing with TBS-T, 
incubation with the secondary antibody goat anti-rat Alexa488 (1:750) and goat anti-
rabbit Alexa 594 (1:500) (Invitrogen) was performed. Sections were mounted using 
fluorescent mounting medium (DakoCytomation) and digitally scanned using an 
Olympus BX51WI fluorescence microscope with a Hamamatsu EM-CCD C9100 digital 
camera, a motorized stage (Ludl Mac 2000) and a 10x objective. Micromanager 1.4 
software was used for automated image acquisition. Image stitching was performed by 
using ImageJ software. 
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Statistics 
All statistical analyses were performed with GraphPad Prism (GraphPad Software, 
version 5.03, 2009, California, USA). A non-parametric Mann–Whitney U test for small 
groups was used to determine the statistical significance of differences between two 
independent groups of variables. A p-value < 0.05 was considered significant. 
Results 
In order to investigate if extreme changes in oxidative phosphorylation (OXPHOS) 
capacity would lead to a change in CAIX expression, we used A549 and 143B mtDNA 
depleted cancer cell lines (ρ0 cells). Both cell lines showed a substantial decrease of 
mtDNA in mitochondria (Fig. 1A) which is confirmed by the significant (p<0.05) decrease 
in mtDNA copy number (Fig. 1B). CAIX expression was decreased under hypoxic 
conditions (p<0.05) in the cells depleted from their mtDNA, on both mRNA (Fig. 1C) and 
protein levels (Fig. 1D).  
 
 
Figure 1. Generation and characterization of mtDNA depleted cell lines. 
A. Merged images of dsDNA staining (green) and mitochondria (red). Yellow areas contain both mitochondria
and dsDNA. B. Percentage mtDNA copy number. C. CAIX mRNA expression upon hypoxia and D. CAIX protein 
expression. Data represent the mean +/- SEM of at least 3 biological repeats. *p<0.05, **p<0.01. 
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Our observations were extended to a second model, in which mtDNA is not abolished 
but harbors a point mutation, the so-called cytoplasmic hybrid or cybrid model. For this 
purpose, the mtDNA depleted 143B osteosarcoma cell line was fused with the 
cytoplasts from a fibroblast cell line from a MELAS patient. The mutant cybrid polyclonal 
cell line MELAS 1 had an average mutation load of 96.80%, while the control cybrid 
clones contained 99.85 (control 1) and 99.65% (control 2) of the wild-type sequence. 
MELAS 2 cells showed a mutation load of 82.33% (Fig. 2A). To further characterize the 
cybrid models, metabolic respiration was investigated by assessing mitochondrial 
respiration and glycolytic capacity. Basal respiration of the MELAS 1 cells was 
significantly (p<0.05) reduced compared to the control lines (Fig 2B). MELAS 2 cells, 
displayed an increase is mitochondrial respiration compared to MELAS 1 cells (Fig 2B). 
Where MELAS 1 cells were completely dependent on glycolysis, since no glycolytic 
reserve capacity could be observed (Fig 2B), MELAS 2 did display a glycolytic reserve 
capacity with comparable levels to the control cell lines, suggesting that the OXPHOS 
was still functional in these cells. Baseline respiration and glycolysis was similar for both 
control cybrid lines, therefore control 1 was selected for subsequent experiments. Upon 
hypoxia CAIX mRNA and protein expression was abolished in MELAS 1 cells (Fig. 2C-D). 
For MELAS 2 mutants harboring a lower mutation percentage this effect was rescued 
(Fig. S1) and therefore these mutant cells were excluded from further experiments. 
MELAS mutation leads to a reduction in activity of Complex I - IV of the oxidative 
phosphorylation chain [16]. In order to investigate if the observed effects from the 
genetic approach could be mimicked by pharmacological inhibition, wild-type cells were 
exposed to either metformin or rotenone, both complex I (CI) inhibitors. Metformin 
exposure decreased proliferation rate in the control cybrid line, while no effect was 
observed for the MELAS 1 mutants. The doubling increased with 27% (p<0.05) for 
control cybrid line 1. Similarly, an increased doubling time was observed for 143B 
(p<0.05) and A549 (p<0.0001) parental lines upon metformin exposure (Fig. 2E). 
Pharmacological CI inhibition resulted in reduced CAIX mRNA and protein expression 
upon hypoxia exposure in the 143B parental cells (rotenone p<0.05) and the control 
cybrid line (metformin p<0.05 and rotenone p<0.05). CAIX expression was not reduced 
for the A549 cells (Fig. 2F-G).  
Additionally, VEGF mRNA expression, another HIF-1α downstream target was also 
decreased (Fig. 3A). HIF-1α protein expression upon hypoxia was reduced for the 
parental lines and the control cybrid line after exposure to metformin. HIF-1α protein 
expression was in general low for the mitochondrial dysfunction A549 ρ0 and the MELAS 
1 mutant cells (Fig. 3B), while HIF-1 α mRNA expression was not affected (Fig. 3C).  
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Figure 2. Generation and characterization of the cybrid model and influence of pharmacological CI inhibition
on CAIX expression.  
A. Procedure to generate MELAS and control cybrid cell lines (left) and percentage m.3243A>G mutated
mtDNA in these cybrid lines (right). B. Metabolic profiling of the cybrid lines, showing basal respiration (left)
and glycolysis stress test results (right). C. Normalized CAIX mRNA expression upon hypoxia. D. Representative 
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Western blot of CAIX protein expression upon normoxia (-) or hypoxia (+). E. Normalized doubling times upon 
metformin. F. CAIX protein expression upon normoxia (-) or hypoxia (+) with or without Metformin (5mM) or 
Rotenone (1uM). Data represents mean + SEM of 2 independent biological repeats. G. CAIX mRNA expression 
upon hypoxia with or without Metformin (5mM) or Rotenone (1uM). All data (B-E,G) represents the mean +/-
SEM of at least 3 independent biological repeats. * p<0.05 **p<0.01. 
 
 
Figure 3. HIF-1α expression and other downstream targets.  
A. VEGF mRNA expression under hypoxia. Data represents the mean of at least 3 independent biological repeats
+/- SEM. B. Representative Western blot of HIF-1α protein expression upon normoxia  (-) or hypoxia (+), 
followed by exposure of vehicle (-); metformin (M) and rotenone (R). Quantification of the data is shown in the
right panel. Data represents the mean of at least 2 independent biological repeats +/- SEM. C. HIF-1α mRNA 
expression under hypoxia. Data represents the mean of at least 2 independent biological repeats +/- SEM.  
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PHD2 is the main regulator of HIF-1α stabilization [19-21]. Therefore, we investigated if 
changes in PHD2 expression could explain the observed reduction in HIF-1α stabilization 
and expression of downstream targets. PHD2 mRNA expression was not changed upon 
genetic imposed mitochondrial dysfunction (Fig. 4A, C). Similarly, mRNA expression of 
PHD1 and 3 did not alter (data not shown). Another major contributor to HIF-1α 
stabilization is the presence of ROS production [22, 23]. Contradictory results have been 
reported on the influence of mtDNA variations on ROS production, which can be 
increased [16, 24] or decreased [25, 26]. Hypoxia induced ROS production 1.5 to 2 fold 
for cybrid and ρ0 cells respectively. Overall, ROS production decreased for the mtDNA 
depleted 143B cells, while no differences were observed for the cybrid cells (Fig. 4B, D). 
Additionally, pharmacological inhibition was not able to change ROS production.  
 
 
Figure  4. HIF-1α regulators.  
A, C. PHD2 mRNA expression. Data are normalized to either 143B parental (A) or ctrl 1 cybrid cell lines (C). 
Data represents the mean of at least 2 independent biological repeats +/- SEM. B, D. Normalized ROS 
production upon mtDNA depletion (B) or mtDNA mutation (D) under normoxic or hypoxic conditions with or
without OXPHOS CI inhibitors. Data represents the mean of at least 3 independent biological repeats +/- SEM. 
 
In order to investigate the functional consequences of decreased CAIX expression we 
assessed clonogenic survival upon hypoxic conditions. Survival under prolonged hypoxia 
for parental and mtDNA depleted 143B cells was not altered, while decreased for the 
cybrid models with a tendency of lower survival for the control cybrid line (Fig. 5A). In 
vivo, MELAS cybrid xenografts need longer to reach 500 mm3 compared to control 
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cybrid tumors, however no differences were found in tumor doubling time suggesting a 
delayed tumor take (Fig. 5B). Additionally, the mutation percentage for the mutant 
hybrid xenografts at sacrifice decreased compared with the injected cells (Fig. 5B). HIF-
1α protein was reduced in the mutant hybrid xenografts compared with control tumors, 
however a large variation was observed. Additionally, we observed that in the 
cytoplasmic hybrids cells harboring a MELAS mutation hypoxia, evaluated by 
pimonidazole was reduced. However, no large differences upon CAIX staining could be 
noticed (Fig. 5C).  
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Discussion 
In the present study, the effect of OXPHOS inhibition using genetic models (mtDNA 
depleted cells and mtDNA mutated cytoplasmic hybrids) or pharmacological inhibitors 
(rotenone, metformin) on CAIX expression and HIF-1α stabilization was investigated. 
We hypothesized that a decrease of mitochondrial respiration through oxidative 
phosphorylation (OXPHOS) would lead to an increase in CAIX expression upon hypoxia 
exposure. However, contradicting our hypothesis we observed that CAIX expression was 
reduced upon low oxygen tensions, with reduced HIF-1α levels in cells with 
mitochondrial dysfunction. Since the tumor microenvironment is a heterogeneous and 
dynamic mechanism, cells within a tumor can have different gene expression profiles, 
metabolism and oxygen supply [27-29]. The adaptation of cancer cells to for example 
hypoxia is critical for tumor progression and metastasis formation and is regulated by 
the hypoxia-inducible factor-1 (HIF-1)[30-33].  Under reduced oxygen conditions 
normally HIF-1α is stabilized [34, 35] . Mitochondrial ROS production seems to be 
necessary for HIF-1α stabilization [36], even when a functional OXPHOS is not present 
[37]. In addition to its role in proliferation, survival, angiogenesis and metastasis, HIF-1 
is also involved in the regulation of tumor cell metabolism [34, 38, 39]. Studies have 
described an association between HIF-1 and mitochondrial function. For instance it  has 
been shown that BAY 87-2243, a potent inhibitor of HIF-1α, reduced tumor growth, 
potentially through targeting mitochondrial CI [40, 41]. 
During hypoxic stress, the low efficiency glycolytic pathway is further upregulated, 
mainly driven by HIF-1α. Similarly, a shift towards the glucose metabolism is induced 
upon mitochondrial dysfunction (Fig. 2B). The high rate of glycolysis, which persists in 
tumor cells even under re-oxygenation, is associated with an increase in glucose uptake 
and lactate release by the cells. Transport of lactate into the microenvironment leads to 
an enhanced extracellular acidification. Lactic acidosis is a symptom that is often 
observed in patients with mitochondrial diseases like myoclonic epilepsy with ragged-
red fibers (MERFF) syndrome [44]. A cybrid model harboring a m.8344A>G mutation 
encoding for ND5 subunit of CI, corresponding to the MERFF phenotype in patients 
resulting in CI dysfunction, displayed reduced levels of carbonic anhydrase VIII (CAVIII) 
[45]. Furthermore, it has been suggested that CAVIII regulates stress responses in the 
cell and could also play a role in metabolism. CAVIII knockdown cells were found to have 
a decreases glycolytic activity and increased cell death under reduced glucose 
Figure 5. Functional consequenses of mtDNA mutations in relation to hypoxia.  
A. Hypoxia tolerance. Data represents the mean of at least 3 independent biological repeats +/- SEM. B.
Doubling time (left panel), percentage not reaching 500mm3 (middle panel) and mutation percentage before
injection and after tumor excision (right panel). C. Protein expression of HIF-1α and actin (left). 
Immunohistochemisty (right) of hypoxia assessed using pimonidazole (green) and CAIX (red).  
Chapter 4 
96 
concentrations in vitro [46]. These data suggest that mitochondrial dysfunction leading 
to decreased carbonic anhydrase expression levels could be translated to other CA 
forms. One of these isoforms is the membrane bound carbonic anhydrase IX (CAIX) 
which has been involved in maintaining a physiological intracellular pH [47]. In our 
study, we observed in a MELAS cybrid model (m.3243A>G encoding for MT-TL1) that 
indeed CAIX mRNA and protein expression was reduced under hypoxic conditions. 
Although the data on CI inhibition were not always as clear as for the genetical cellular 
models, the differences in effects could probably be explained by the differences 
between cell lines. 
Our findings show that the time for tumor take was longer for mutant hybrid 
xenografts, but growth rates were not altered once the tumor was established 
compared to control tumors. Previously it has been shown that HIF-1α is responsible for 
tumor establishment, since HIF-1α knockdown resulted in a longer time needed to 
reach 60 mm3. However, once tumors were established no difference in tumor 
growth rate was observed [48]. In agreement, HIF-1α expression levels were reduced 
for the mutant hybrid xenografts. Furthermore, most of the tumors established from 
the mutant cell line lost their m.3243A>G mutation in vivo, possibly explaining the 
tumor take as we observed. The presence of HIF-1α in cell lines with lower mutation 
percentage supports this observation.  
Another possible explanation of the absence of HIF-1α might be the involvement of the 
AMPK-mTOR pathway, which regulated energetic stress responses under normoxic 
conditions, as for instance the CI inhibitor metformin used in our experiments causes 
inhibition of mTOR [49, 50]. However additional experiments are necessary to evaluate 
if OXPHOS inhibition is inducing alterations in AMPK-mTOR signaling and results in this 
observed HIF-1α deregulation by altered mRNA translation. Alterations in general mRNA 
translation are influenced upstream by the unfolded protein response (UPR) a 
mechanism influenced by hypoxia and energetic stress [51-53]. Not only general UPR 
responses but also the mitochondrial UPR response could possibly be an interesting 
mechanism. One of the regulators influencing this mitochondrial UPR is NAD-dependent 
deacetylase sirtuin-3 (SIRT3) [54]. SIRT3 is located in the mitochondria and is involved in 
various cellular mechanisms such as nutrient stress [55], fatty acid oxidation [56], AMPK 
activation [57], antioxidant mechanisms [58] and in the activation of a hypoxia-induced 
mitochondrial form of autophagy (mitophagy) [59]. Additionally HIF-1α stabilization 
under hypoxic conditions is suppressed under the influence of SIRT3 [60, 61] however, 
other SIRT enzymes can influence the functionality of HIF-1α [62, 63]. Therefore, we 
suggest that SIRT3 expression causes the destabilization of HIF-1α and mitophagy 
and/or autophagy whereas upregulation of autophagy was observed in the CA8 mutant 
cell lines under normoxic conditions [45], although these relationships have to be 
further investigated.  
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Supplementary data  
 
Supplementary Figure S1. CAIX Expression for control and MELAS cybrid lines upon exposure to hypoxia. 
 
Supplementary Table 1: The primer sequences for quantitative real-time PCR and fragment analysis. 
Target gene Forward primer Reverse primer 
D-loop 5’-CAT CTG GTT CCTA CTT CAG GG-3’ 5’-TGA GTG GTT AAT AGG GTG ATA GA-3’ 
B2M 5’-TGC TGT CTC CAT GTT TGA TGT ATC T-3’ 5’- TCT CTG CTC CCC ACC TCT AAG T-3’ 
MELAS 5'-CAA CTT AGT ATT ATA CCC ACA C-3' 5'-TTT CGT TCG GTA AGC ATT AG-3' 
MELAS-FAM FAM-5'-CAA CTT AGT ATT ATA CCC ACA C-3'  
CAIX 5'-CAT CCT AGC CCT GGT TTT TGG-3' 5'-GCT CAC ACC CCC TTT GGT T-3' 
VEGF 5'-GAC TCC GGC GGA AGC AT-3' 5'-TCC GGG CTC GGT GAT TTA-3' 
HIF-1α 5´-ATC GCG GGG ACC GAT T-3´ 5´-CGA CGT TCA GAA CTT ATC TTT TTC TT-3´ 
PHD2 5’- GCA CGA CAC CGG GAA GTT-3’ 5’-ÇCA GTT CCC GTT ACA GT-3’ 
18S 5'-AGT CCC TGC CCT TTG TAC ACA-3' 5'-GAT CCG AGG GCC TCA CTA AAC-3' 
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Chapter 5 
New approach of delivering cytotoxic drugs 
towards CAIX expressing cells: 
A concept of dual-target drugs 
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Highlights 
• New dual-target drugs combining cytotoxic agents with CAIX inhibitors were designed. 
• Dual-targeting drugs may allow for specific drug delivery to hypoxic tumor areas. 
• Increased binding affinity to CAIX was found for most of the dual-targeting drugs. 
• Higher efficacy of dual-target ATR inhibitor was found in CAIX overexpressing cells. 
• Design of alternative CAIX-targeting drugs may increase their therapeutic window. 
Abstract 
Carbonic anhydrase IX (CAIX) is a hypoxia-regulated and tumor-specific protein that 
maintains the pH balance of cells. Targeting CAIX might be a valuable approach for 
specific delivery of cytotoxic drugs, thereby reducing normal tissue side-effects. A series 
of dual-target compounds were designed and synthesized incorporating a sulfonamide, 
sulfamide, or sulfamate moiety combined with several different anti-cancer drugs, 
including the chemotherapeutic agents chlorambucil, tirapazamine, and temozolomide, 
two Ataxia Telangiectasia and Rad3-related protein inhibitors (ATRi), and the anti-
diabetic biguanide agent phenformin. An ATRi derivative (12) was the only compound to 
show a preferred efficacy in CAIX overexpressing cells versus cells without CAIX 
expression when combined with radiation. Its efficacy might however not solely depend 
on binding to CAIX, since all described compounds generally display low activity as 
carbonic anhydrase inhibitors. The hypothesis that dual-target compounds specifically 
target CAIX expressing tumor cells was therefore not confirmed. Even though dual-
target compounds remain an interesting approach, alternative options should also be 
investigated as novel treatment strategies. 
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Introduction 
Solid tumors are characterized by a hypoxic microenvironment caused by their immature 
and inadequate vascular supply of oxygen and nutrients. These hostile hypoxic conditions 
result in a phenotype that is associated with a worse prognosis [1] and resistance to 
standard treatment options such as radiotherapy, chemotherapy, and surgery [2-4]. 
Several different approaches are currently being investigated to target these hypoxic 
areas to make tumors more sensitive to standard treatment modalities [5-7]. 
Carbonic anhydrase IX (CAIX) can be a valuable therapeutic target since it plays an 
important role in maintaining the intracellular pH homeostasis [8, 9]. Furthermore its 
expression is predominantly tumor specific [5, 8, 10] and directly regulated via the 
hypoxia-inducible factor (HIF) pathway [11]. Even though alternative pathways are also 
able to modulate CAIX expression [12-14], its significant prognostic value in many 
different tumor types [15] has promoted investigations in its use as an imaging agent 
for diagnostic and prognostic purposes [5, 16-19]. Together these characteristics of 
CAIX support investigations into the therapeutic targeting of CAIX to improve efficacy of 
standard treatments. The function of CAIX is evolutionary conserved and catalyzes the 
hydration of carbon dioxide to bicarbonate at the cell membrane. The bicarbonate is 
transported back intracellular from the extracellular space, whereas the free proton is 
extruded in the extracellular space. CAIX thereby maintains the balance between an 
acidic extracellular and alkaline intracellular pH of tumor cells, the latter of which would 
otherwise acidify due to the increased acid production resulting from their glycolytic 
metabolism [8, 9]. Many different inhibitors are currently being developed to 
specifically target the tumor-associated CAIX isoform and have shown promise in 
reducing tumor cell survival, migration, invasion, and reduce tumor xenograft growth 
and metastases formation [20-23]. Furthermore, the combination therapy of CAIX 
inhibitors (CAIXi) with standard treatment options was previously found to increase the 
efficacy of radiotherapy [24] and of weakly basic chemotherapeutic agents such as 
doxorubicin [25]. 
The predominant expression of CAIX on hypoxic tumor cells can also be exploited to 
direct cytotoxic agents specifically to those CAIX expressing cancer cells thereby 
possibly minimizing normal tissue toxicity. This can be achieved by conjugating anti-
cancer drugs with CAIX inhibiting molecules that bind to the Zn2+ active site of CAIX and 
hence inhibit its enzymatic function [8, 26, 27], i.e. a so-called dual-targeting approach. 
Our group showed previously that such a dual-target approach with a sulfamide CAIXi 
moiety coupled to the radiosensitizing compound nitroimidazole to be a more effective 
radiosensitizer than an indanesulfonamide CAIXi [28]. Alternative novel dual-target 
compounds have been developed to investigate this strategy of dual-targeting further in 
the context of anti-cancer agents to target CAIX. Here we have designed five different 
classes of dual-target compounds conjugated to CAIXi (sulfonamide, sulfamide, or 
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sulfamate), which included the chemotherapeutic anti-cancer agents chlorambucil, 
tirapazamine, and temozolomide, two ataxia telangiectasia and Rad3-related protein 
inhibitors (ATRi), and the biguanide agent phenformin, previously used in diabetes 
treatment. We hypothesize that these new dual-target compounds will have the ability 
to specifically target CAIX expressing cells and modulate their efficacy in a CAIX-
dependent manner. 
Results and discussion 
Chemistry 
Chlorambucil was converted to its acid chloride [29] 1 by using oxalyl chloride. This 
chlorambucil acid chloride reacted with different benzene sulfonamides under basic 
condition to obtain good yields of chlorambucil derivatives 2a, 2b and 2c. Chlorambucil 
carbamate derivatives were obtained by converting compound 1 into a methyl ester 
[30] using methanol. This ester was reduced to alcohol [31], i.e. compound 3, after 
treating with lithium aluminium hydride. Compound 3 was treated with triphosgene to 
obtain its respective chloroformate [32], i.e. compound 4 (Scheme 2). The reaction of 
chlorambucil chloroformate (4) with different benzene sulfonamides resulted in 
compounds 5a, 5b and 5c (Scheme 3). 
 
 
Scheme 1. Reagents and conditions: (i) (COCl)2, DMF, DCM, 0 °C–rt; (ii) DIPEA, THF, 0 °C–rt. 
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Scheme 2. Reagents and conditions: (i) MeOH, DCM; (ii) LAH, THF; (iii) Triphosgene, Na2CO3, Toluene, DMF. 
 
 
Scheme 3. Reagents and conditions: (i) DIPEA, THF, 0 °C–rt. 
Tirapazamine derivatives 8 and 11 were synthesized from 6 and 9 with the previously 
described procedure [33]. In short, 6 and 9 reacted with 4-(2-aminoethyl) benzene 
sulfonamide under reflux conditions and was followed by oxidation of the mono-oxides 
(Scheme 4). 
 
 
 
Scheme 4. Reagents and conditions: (i) RNH2 (3 equiv.), DME, reflux; (ii) TFAA, H2O2, DCM, rt. 
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The ATRi derivatives 12 and 13 were synthesized from commercially available VE-821 
and VE-822 (MedChemTronica) using a classical synthetic strategy described previously 
[25] (Scheme 5). 
 
 
Scheme 5. Reagents and conditions: (i) ClSO2NCO, tBuOH, NEt3, DCM, 0 °C to rt; (ii) 20% TFA-DCM. 
 
Commercially purchased temozolomide (SelleckChem) was converted into its respective 
acid by treating with concentrated sulfuric acid and sodium nitrate at 0 °C–15 °C 
(Scheme 6) [34]. Reacting the temozolomic acid with different benzenesulfonamides, 
aminoxysulfonamide [35] and 5-amino-1, 3,4-thiadiazole-2-sulfonamide hydrochloride 
under known amide bond formation conditions [34] resulted in compounds 15a, 15b, 
15c and 15d (Scheme 7). 
 
 
Scheme 6. Reagents and conditions: (i) Con. H2SO4, NaNO2, 0 °C to 15 °C 
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Scheme 7. Reagents and conditions: (i) BOP, NEt3, DCM, rt. 
 
The compound 18 was obtained by a slight modification based on the method reported 
by Kelarev et al. [36]. The commercially available compounds 4-(2-aminoethyl) 
benzenesulfonamide 16 and cyanoguanidine 17 were coupled in n-butanol using a 
stoichiometric amount of hydrochloric acid (Scheme 8). 
 
 
Scheme 8. Reagents and conditions: (i) 6.0 M HCl aq, nBuOH, reflux. 
Binding affinity human CAs 
Increased binding affinity to human carbonic anhydrases (CAs) as compared with their 
respective parental compound are observed (Table 1) for most of the compounds, 
except for the CAIXi conjugated ATRi (12 and 13), which do not bind to any of the four 
tested human CA isoforms included (Ki > 50000 nM). The Ki values of the other dual-
targeting compounds are higher than of the previously reported CAIXi [20] with 15a 
showing relatively good Ki for the CAII and CAIX isoforms, but not for CAXII. Only the 
phenformin derivative 18 was found to be selective for the transmembrane CAIX and 
CAXII isoforms. To investigate whether the biological efficacy of the functionalized 
compounds is dependent on CAIX expression, canine kidney epithelial (MDCK) cells 
without CAIX (CAIX−), i.e. both human and canine [37], or MDCK cells transfected with 
human CAIX [37], i.e. overexpressing CAIX (CAIX+), were used. Western blotting 
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confirmed differential expression of CAIX in these cells both under normoxic and 
hypoxic conditions (Supplementary Fig. S1). 
 
Table 1: Binding affinity (Ki) to human CAI, CAII, CAIX, and CAXII of the parental compounds (bold) and their 
CAIXi conjugated derivatives. 
 Ki (nM)a  Selectivity Ratiosb 
Compound hCA I hCA II hCA IX hCA XII Ki hCA II / Ki hCA IX Ki hCA II / Ki hCA XII 
Chlorambucil >50000 >50000 >50000 >50000   
2a 73.0 9.0 172 689 0.05 0.01 
2b 5950 747 8970 7340 0.08 0.10 
2c 8400 450 4610 10160 0.10 0.04 
5a 5580 553 2740 9380 0.20 0.06 
5c 6140 265 4130 9570 0.06 0.03 
5c 5670 504 3850 13600 0.13 0.04 
Tirapazamine >50000 >50000 >50000 >50000   
8 567 7.1 383 14600 0.02 <0.01 
11 428 8.1 307 624 0.03 0.01 
Temozolomide >50000 >50000 >50000 >50000   
15a 91.3 9.2 37.1 9300 0.25 <0.01 
15b >50000 >50000 >50000 >50000   
15c 539 90.5 271 12400 0.33 0.01 
15d 743 15.7 176 92.7 0.09 0.17 
ATRi VE-821 >50000 >50000 >50000 >50000   
12 >50000 >50000 >50000 >50000   
ATRi VE-822 >50000 >50000 >50000 >50000   
13 >50000 >50000 >50000 >50000   
Phenformin >50000 >50000 >50000 >50000   
18 4435 501 20.2 1.7 24.8 295 
Acetazolamidec 250 12.1 25.3 5.7 0.48 2.12 
aValues reported (in nM) are the average of three different estimations with errors between 5–10% of the 
reported values. Reported values >50000 indicates no binding of the compound towards the CA isoforms. 
bSelectivity ratios of the cytosolic hCAII over the tumor-associated hCAIX and hCAXII isoforms.  
cNon-specific CAi acetazolamide is included as a reference. 
Chlorambucil derivatives 
Chlorambucil (4-[p-[bis(2-chloroethyl)amino]phenyl]butyric acid) is a nitrogen mustard 
that acts as a bifunctional alkylating agent used for decades to treat cancers originating 
in the blood and lymphatic system, e.g. chronic lymphocytic leukemia and lymphomas 
[38]. Even though reported data suggest chlorambucil efficacy to increase in an acidic 
microenvironment [39], the CAIXi moiety (benzenesulfonamides) with different linkers 
(i.e. amide, carbamate) might allow for specific targeting of the compounds to these 
areas in the tumor. The six CAIXi conjugated chlorambucil derivatives (2a, 2b, 2c, 5a, 5b, 
and 5c, Scheme 1 and Scheme 2) lead to reduced cell viability as compared to the 
parental compound, which was only marginally effective (Table 2, Supplementary Fig. 
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S1). The therapeutic efficacy of these compounds however was not increased in the 
CAIX+ MDCK cells as compared with the CAIX− MDCK cells. Furthermore, none of the six 
compounds showed an increased efficacy upon hypoxia exposure (0.2% O2). In contrast, 
some of the chlorambucil dual-target derivatives were less cytotoxic (i.e. higher IC50, 
Table 2) in CAIX expressing cells independent of oxygen levels, which contradicts the 
studies demonstrating an increased efficacy of chlorambucil in an acidic micromilieu 
[39]. All together from these results it can be concluded that the CAIXi conjugated 
chlorambucil derivatives do not show an increased efficacy in a CAIX or hypoxia 
dependent manner. 
 
Table 2. Estimated IC50 of the cytotoxic parental compounds (bold) and their CAIXi conjugated derivatives 
obtained with cell viability assays for MDCK CAIX- and MDCK CAIX+ cells exposed to normoxic and hypoxic 
conditions. 
 Normoxia (µM)a  Hypoxia (µM)a 
Compound CAIX- CAIX+ CAIX- CAIX+ 
Chlorambucilb 93 >100 ~100 >100 
2a ~100 87 ~100 95 
2b 18 98 14 92 
2c 18 ~100 18 ~100 
5a 8 56 8 62 
5b 86 98 52 100 
5c 89 99 81 ~100 
Tirapazaminec >300 >300 <50 95 
8 >300 >300 ~300 >300 
11 >300 >300 >300 >300 
Temozolomided 775 >1000 ~1000 >1000 
15a >1000 >1000 >1000 >1000 
15b 719 >1000 ~1000 >1000 
15c >1000 >1000 >1000 >1000 
15d >1000 >1000 >1000 >1000 
aNo IC50 reached is indicated with >. Estimated IC50 value higher than the maximum concentration included is 
indicated with ~. 
bIncluded concentrations for chlorambucil were 1, 10, and 100 µM. 
cIncluded concentrations for tirapazamine were 50, 100, 200, and 300 µM. 
dIncluded concentrations for temozolomide were 100, 400, 700, and 1000 µM.  
Tirapazamine derivatives 
The hypoxia-activated prodrug tirapazamine (3-amino-1,2,4-benzotriazine-1,4-dioxide) 
has been tested in several clinical trials in combination with chemo- and/or 
radiotherapy [40]. The cytotoxicity of tirapazamine results from activation by reductive 
enzymes that add an electron to the parent drug to produce a radical species that 
causes DNA damage. Nevertheless, no definitive conclusions regarding its clinical 
efficacy can be drawn since addition of tirapazamine to standard treatment (i.e. radio-
chemotherapy) did not result in an increased benefit in phase III clinical trials. In 
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addition, tirapazamine treatment was often characterized by toxic side-effects, such as 
nausea, vomiting, and diarrhea, which limited its therapeutic gain [40]. Targeting 
tirapazamine towards the CAIX expressing (hypoxic) areas in tumors by conjugating 
tirapazamine with the benzenesulfonamide CAIXi might thereby prove a valuable 
approach to reduce normal tissue toxicity and increase the efficacy of the compounds 
(8 and 11) in CAIX expressing (hypoxic) cells. Cell viability assays (Table 2, 
Supplementary Fig. S2) confirmed that the parental compound was specifically effective 
in hypoxic cells, and more effective in CAIX− cells (IC50 < 50 versus 95 μM, p = 0.037). 
The CAIXi conjugated tirapazamine derivatives however abrogated the effect observed 
for the parental compound, both during hypoxia and normoxia, which was independent 
of CAIX levels (Table 2). 
Temozolomide derivatives 
The current treatment of glioblastoma is based on radiotherapy combined with 
temozolomide, which has been shown to increase survival in phase III clinical trials [41]. 
Temozolomide is a methylating agent that spontaneously hydrolyzes to its active 
metabolite 3-methyl-(triazen-1-yl)imidazole-4-carboxamide (MTIC) at physiological pH 
[42]. The acidic extracellular pH in tumors might therefore reduce spontaneous 
temozolomide conversion and thereby decrease its efficacy. Inhibiting CAIX function is 
known to decrease extracellular acidification in vitro [24, 25, 28, 43], and we 
hypothesized that conjugating temozolomide with a sulfonamide or sulfamate moiety 
(15a, 15b, 15c, and 15d) will specifically target hypoxic tumors and increase 
temozolomide conversion and thereby its efficacy. Nevertheless, while temozolomide 
resulted in lower cell viability in CAIX− cells, consistent with the pH-dependent 
mechanism of activation, the CAIXi conjugated temozolomide derivatives 15a, 15c, and 
15d were ineffective in reducing cell viability in both MDCK cell lines during normoxic 
and hypoxic conditions within the concentration range tested in the present study 
(Table 2, Supplementary Fig. S3). In contrast, 15b was similarly effective as the parental 
temozolomide compound (Table 2). 
This dual-target compound was therefore investigated further in clonogenic survival 
assays in which the medium of the cells was acidified because of CAIX function during 
hypoxic conditions (Supplementary Fig. S1)[44]. Temozolomide was again more 
effective in reducing clonogenic cell survival in the CAIX− MDCK cells as compared with 
the CAIX+ MDCK cells (Fig. 1), similarly to its efficacy on cell viability. During hypoxia 
however temozolomide caused no difference in clonogenic survival as compared to 
normoxia, even though hypoxia is required to activate CAIX and cause extracellular 
acidification [43, 45] and is therefore hypothesized to reduce temozolomide conversion 
and efficacy. In contrast, the CAIXi conjugated derivative 15b significantly reduced 
clonogenic cell survival in hypoxic versus normoxic conditions in the CAIX+ cells 
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(surviving fraction is 46.1 ± 3.1 versus 26.1% ± 7.9 during normoxia and hypoxia 
respectively, p < 0.05). Nevertheless, the effect of 15b on survival was not significantly 
different from the parental temozolomide compound. In addition, the low binding 
affinity of the compound (Table 1) combined with its relatively low efficacy in the CAIX+ 
as compared to the CAIX− cells minimizes its potential for further development. These 
results furthermore suggest that temozolomide efficacy is not affected by CAIX 
dependent changes in extracellular pH during hypoxia. A reduction of temozolomide 
conversion and efficacy might require lower pH levels, i.e. pH < 6.6, which may have not 
been achieved in the present experiments [8, 9, 39]. 
 
 
Figure 1. Clonogenic cell survival of confluent MDCK CAIX- and CAIX+ cells during normoxia (21% O2) and 
hypoxia (0.02% O2) when exposed to temozolomide (TMZ) and the CAIXi conjugated derivative 15b. Surviving 
fraction (%) was normalized to vehicle control. Average ± SEM of three independent biological repeats is
shown. Asterisks indicate statistical significance (*p<0.05; ***p<0.001). 
ATR inhibitor derivatives 
Preclinical experiments have shown that Ataxia Telangiectasia and Rad3-related protein 
inhibitors (ATRi) reduce the DNA repair capacity resulting in enhanced cell death and 
decreased tumor growth when combined with either chemo- or radiotherapy [46-48]. 
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However, ATRi are not highly tumor specific, thus targeting these compounds towards 
the CAIX expressing areas of a tumor might increase their therapeutic benefit. The 
effect on cell viability of the parental ATRi (VE-821 and VE-822) and their CAIXi 
conjugated derivatives (12 and 13) was tested in combination with radiotherapy to 
induce DNA damage where a higher radiation dose was applied to anoxic cells, since 
those are more radioresistant [49, 50]. The parental ATRi and the CAIXi conjugated 
derivatives in combination with radiation decreased cell viability as compared to 
radiation only in the CAIX+ cells (p<0.05) under both normoxic and anoxic conditions, 
but not in the CAIX− cells (Fig. 2). The only exception is the derivative 13, which had no 
significant effect on cell viability during anoxic conditions in both cell lines as compared 
to radiation alone (p=0.09 and p=0.08 for CAIX− and CAIX+ cells, respectively). More 
importantly, the CAIXi conjugated derivative 12 was more effective than its respective 
parental ATRi (VE-821) in the CAIX+ (p<0.01 during normoxia and anoxia), but not the 
CAIX− cells (p=0.52 and p=0.72 for normoxia and anoxia, respectively), suggesting a CAIX 
specific effect. In contrast, the CAIXi conjugated derivative 13 in combination with 
radiation was less effective in reducing cell viability than the parental compound VE-822 
in CAIX+ cells (p<0.001 and p<0.01 during normoxic and anoxic conditions, respectively). 
Although radiation induced similar effects on cell viability during normoxic and anoxic 
conditions, the efficacy of derivative 12 did not increase further during anoxic 
conditions as compared to normoxic conditions, even though CAIX expression is 
upregulated under hypoxic conditions (Supplementary Fig. S1) and these conditions are 
essential for CAIXi binding [43, 45]. Although derivative 12 indeed proved to be more 
effective in CAIX+ than in CAIX− cells in combination with radiation, its efficacy might 
however not be solely dependent on binding to CAIX, which is consistent with 
unfavorable Ki values of the compound (Table 1). Exposing both cell lines to ATRi 
without irradiation decreased cell viability of both cell lines during normoxic and anoxic 
conditions, although this effect appeared to be slightly more pronounced in the CAIX− 
cells (Supplementary Fig. S5). Differences in ATRi response between the cell lines when 
combined with radiation might be explained by a lower number of cells in the resistant 
S-phase of the cell cycle [51], or by a decreased DNA repair capacity in cells with lower 
intracellular pH [52-54], i.e. those that do not express CAIX. This may also explain the 
difference in sensitivity to cytotoxic drugs between both cell lines, although further 
investigations are required to prove this causal relationship. 
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Figure 2. Relative cell viability (%) in MDCK CAIX- and CAIX+ cells exposed to ATR inhibitors (VE-821 and VE-
822) or the CAIXi conjugated derivatives (12 and 13) in combination with radiation during normoxia (21% O2) 
and anoxia (<0.02% O2). Normoxic cells were irradiated with 2 Gy and anoxic cells with 4 Gy to induce similar 
effects on cell viability. Cells were exposed to 500 nM VE-821 and 12, and to 50 nM VE-822 and 13. Average ± 
SEM of three independent biological repeats is shown. Asterisks indicate statistical significance (*p<0.05;
**p<0.01; ***p<0.001). 
Phenformin derivatives 
Phenformin (1-(diaminomethylidene)-2-(2-phenylethyl)guanidine) is a drug used to 
treat diabetes, but was withdrawn from the North-American market in the 1970s by the 
Food and Drug Administration (FDA) due to a high risk of developing lactic acidosis [55]. 
Treating patients with a similar but less potent drug metformin was found to be 
associated with a decrease in cancer incidence and an increased life span of cancer 
patients [56]. The repurposing of these compounds as anti-cancer agents is therefore 
being investigated where phenformin is found to be more lipophilic, thereby requiring 
less active transport than metformin [57]. The proposed mechanism of action of 
phenformin is its ability to inhibit mitochondrial respiration, which will consequently 
result in a decreased ATP production, thereby reducing tumor cell growth and 
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improving tumor oxygenation as a result of decreased oxygen consumption [58, 59]. 
Conjugating phenformin with CAIXi might make the drug more tumor-specific leading to 
reduced normal tissue toxicity. Since tumor cells are more sensitive to phenformin 
treatment due to their altered energy metabolism, human colorectal HCT116 cells, with 
or without CAIX knockdown [24, 28] were used to study the effect of phenformin and its 
CAIXi conjugated derivative 18 on mitochondrial respiration. Western blotting confirms 
low expression of CAIX in CAIX KD cells under hypoxic conditions as compared with 
control cells (Supplementary Fig. S1B). As expected, CAIX levels were low in both cell 
lines under normoxic conditions. Phenformin significantly reduced Oxygen Consumption 
Rate (OCR) in both cell lines (p<0.05), independent of CAIX expression levels (Fig. 3). In 
contrast, the CAIXi conjugated derivative 18 was ineffective in reducing OCR, even when 
a fourfold higher concentration was used. 
 
 
Figure 3. Oxygen consumption rate (OCR) of HCT116 cells with CAIX (shSCR) or without CAIX expression
(shCAIX) exposed to phenformin or the CAIXi conjugated derivative 18. OCR was normalized to baseline OCR
levels before compound injection. Average ± SEM of four independent biological repeats is shown. Asterisks
indicate statistical significance (*p<0.05). 
Conclusion 
Overall our hypothesis that newly designed dual-target drugs are more selective for 
CAIX expressing cells and are able to modulate their own efficacy by inhibiting CAIX 
function was not confirmed. Of all derivatives included, only one (i.e. the ATRi derivative 
12) proved more effective than its parental compound when combined with irradiation 
in CAIX+ cells versus CAIX− cells. Nevertheless, the effect of this compound may not only 
be related to binding of the compound to CAIX due to limited binding affinity and the 
lack of further increase in its efficacy under hypoxic conditions. The rest of the 
derivatives included in this study did not show an increased efficacy in CAIX+ versus 
CAIX− cells, or an efficacy that depended on oxygen levels, i.e. hypoxia versus normoxia. 
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Nevertheless, since the parental compounds proved effective in these experiments the 
conjugation of the CAIXi moiety with the cytotoxic compounds may have caused 
conformational changes, thereby altering the compounds efficacy. In addition, these 
conformational changes may have also limited the binding of the CAIXi moiety 
(sulfonamide, sulfamide or aminoxysulfonamide) into the Zn2+ containing active pocket 
of CAIX, which explains the lack of CAIX specificity and binding affinity for human CAs 
(Table 1) of the compounds. Alternative strategies to target the CAIX expressing cells in 
a tumor, e.g. antibody targeting or an increased number of CAIXi conjugated molecules 
[60], might therefore be more promising options to pursue in the future. 
Experimental section 
Chemistry 
General 
Unless otherwise specified, reagents and solvents were of commercial quality and were 
used without further purification. All reactions were carried out under an inert 
atmosphere of nitrogen. TLC analyses were performed on silica gel 60 F254 plates (Merck 
Art.1.05554). Spots were visualized under 254 nm UV illumination, or by ninhydrin 
solution spraying. Melting points (mp) were determined on a Büchi Melting Point 510 
and are uncorrected. 1H and 13C NMR spectra were recorded on Bruker DRX-400 
spectrometer using DMSO-d6 as a solvent and tetramethylsilane as an internal standard. 
For 1H NMR spectra, chemical shifts are expressed in δ (ppm) downfield from 
tetramethylsilane, and coupling constants (J) are expressed in Hertz. Electron Ionization 
mass spectra were recorded in positive or negative mode on a Waters MicroMass ZQ. 
All compounds that were tested in the biological assays were analyzed by High-
resolution ESI mass spectra (HRMS) using on a Q-ToF I mass spectrometer fitted with an 
electrospray ion source in order to confirm the purity of >95%. 
4-(4-(Bis(2-chloroethyl)amino)phenyl)butanoyl chloride (1) 
Oxalyl chloride (32.8 mmol, 2.0 equiv.) was added slowly over a period of 1.0 h at 5–10 
°C to a stirred solution of chlorambucil (16.4 mmol, 1.0 equiv.) in DCM (25.0 mL, 5.0 vol) 
and a catalytic amount of N, N-dimethylformamide. The reaction mixture was stirred at 
ambient temperature for 2–3 h, after which excess oxalyl chloride and DCM were 
removed under reduced pressure. The chlorambucil acid chloride that was obtained 
was a pale green solid in quantitative yield, which was used as such for the synthesis of 
Compounds 2a–c. 
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4-(4-(Bis(2-chloroethyl)amino)phenyl)butan-1-ol (3) 
Compound 1 (15.5 mmol, 1.0 equiv.) was dissolved in DCM (125 mL) and methanol (75 
mL, 3 vol) was slowly added over a period of 1 h at 15–20 °C. The reaction mixture was 
stirred at ambient temperature for 2 h. The reaction mixture was concentrated and the 
residue was dissolved in ethyl acetate (125 mL, 5 vol) and washed successively with a 
5% aq. NaHCO3. Evaporation of the solvent under reduced pressure resulted in the 
chlorambucil methyl ester (16.4 mmol, 1.0 equiv.) in 95% yield as a light brown oil, 
which was added to a suspension of lithium aluminium hydride (32.8 mmol, 2 equiv.) in 
anhydrous THF (100 mL, 4 vol) at 0–5 °C for a period of 1 h. The reaction mixture was 
thereafter allowed to stir at ambient temperature for 2–3 h. Next, the reaction mixture 
was cooled to 0–5 °C and quenched slowly with ethyl acetate (250 mL, 10 vol) followed 
by water (100 mL, 4 vol). The reaction mixture was filtered through celite and ethyl 
acetate (50 mL, 2 vol) was used to wash the celite bed. The organic layer was washed 
with water (100 mL, 4 vol), dried over anhydrous Na2SO4, and filtered. Evaporation of 
the solvent under reduced pressure resulted in 99% yield of the crude alcohol as a pale 
yellow oil, which was used in the next step. 
4-(4-(Bis(2-chloroethyl)amino)phenyl)butyl carbonochloridate (4) 
DMF (1.4 g) and sodium carbonate (75.79 mmol, 1.1 equiv.) were added to a solution of 
triphosgene (37.89 mmol, 0.55 equiv.) in toluene (300 mL, 15 vol) at ambient 
temperature. The reaction mixture was cooled to 0–5 °C and maintained at the same 
temperature for 30 min. Next, a solution of 3 (68.9 mmol, 1.0 equiv.) in toluene (100 
mL, 5 vol) was added to the stirred reaction mixture at 0–5 °C during 30 min. This 
reaction mixture was stirred for 4–5 h at room temperature. The reaction mixture was 
filtered thereafter and the solid was washed with toluene (100 mL, 5 vol). Evaporation 
of the solvent under reduced pressure resulted in the chloroformate 4 with a 64% yield 
as a yellow viscous liquid, which was used for the synthesis of carbamates (compounds 
5a–c). 
General procedure for the preparation of compounds (2a–c and 5a–c) 
To a solution of aminoalkylbenzene sulfonamide (1.0 equiv.) in acetonitrile (225 mL, 15 
vol) and N,N-diisopropylethylamine (2.5 equiv.) a solution of compound 1 (2a–c) or 
compound 4 (5a–c) (1.0 equiv.) in acetonitrile (75 mL, 5 vol) was added over a period of 
1 h and stirred overnight at ambient temperature. After completion, the reaction 
mixture was concentrated and the residue obtained was dissolved in ethyl acetate (150 
mL, 10 vol). The organic layer was successively washed with 2 N HCl solution (100 mL × 
2) in water, dried over anhydrous Na2SO4, and filtered. After evaporation of the solvent 
under reduced pressure a pale yellow solid was obtained as a crude product. This crude 
product was purified with column chromatography using a silica gel (40% ethyl acetate 
in hexane) to obtain compound 2a–c and 5a–c in a 51–87% yield. 
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General procedure for amination of 3-Chlorobenzotriazine-1,4-di-N-oxides (7 and 10) 
4-(2-Aminoethyl) benzene sulfonamide (8.25 mmol, 3.0 equiv.) was added to a stirring 
solution of 3 chlorobenzotriazine-1,4-di-N-oxide (2.75 mmol, 1.0 equiv.) in 
dimethoxyethane (30 mL) and the mixture was stirred overnight at reflux temperature. 
The next day mixture was cooled to room temperature and concentrated under 
vacuum, after which the residue was dissolved in ammonium hydroxide solution and 
extracted with ethyl acetate. The organic layer was dried over Na2SO4, filtered and 
concentrated under vacuum. The residue was purified by chromatography using a silica 
gel with methylene chloride-methanol 98:2 v-v as an eluent to obtain the expected 
compound as a yellow powder with an 85–94% yield. 
General procedure for oxidation (8 and 11) 
Hydrogen peroxide (12.9 mmol, 10 equiv.) was added dropwise to a stirred solution of 
trifluoroacetic anhydride (12.9 mmol, 10 equiv.) in DCM at 0 °C. This reaction mixture 
was stirred at 0 °C for 5 min, warmed to room temperature for 10 min, and cooled to 5 
°C. Next, the mixture was added to a stirred solution of mono oxide (1.29 mmol, 1.0 
equiv.) in DCM at 0 °C and stirred at room temperature for 2–3 days. The reaction 
mixture was carefully diluted with water and basified with aqueous NH4OH and 
extracted with CHCl3. The organic fraction was dried over anhydrous Na2SO4, filtered 
and evaporated to obtain the residue. This residue was purified by chromatography 
using a silica gel with methylene chloride-methanol 98:2 v-v as an eluent to obtain the 
expected compound as an orange red powder with a 46–96% yield. 
General procedure for synthesis of ATRi derivatives (12 and 13) 
A solution of VE-821 or VE-822 (0.54 mmol, 1.0 equiv.) and triethylamine (1.62 mmol, 
3.0 equiv.) in 10 mL of methylene chloride was added to a mixture of chlorosulfonyl 
isocyanate (0.68 mmol, 1.2 equiv.) and tert-butanol (0.648 mmol, 1.2 equiv.) in 2 mL of 
methylene chloride. The mixture was stirred at room temperature for 1.0 h, diluted 
with ethyl acetate, and washed with water. The organic layer was then dried over 
anhydrous Na2SO4, filtered and concentrated under vacuum. The residue was purified 
by chromatography with a silica gel and methylene chloride-methanol 98:2 as an eluent. 
This intermediate was thereafter diluted in a solution of trifluoro acetic acid in 
methylene chloride (20% vol.) and stirred at room temperature for 6 h. Next, the 
mixture was concentrated under vacuum and co-evaporated with diethyl ether multiple 
times to obtain the expected compound with a 58–65% yield. 
General procedure for synthesis of temozolomide derivatives 
To a slurry of 3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5] tetrazine-8-carboxylic 
acid (1.0 mmol, 1.0 equiv.) in DCM, BOP (1.0 mmol, 1.0 equiv.), amine (1.1 mmol, 1.1 
equiv.) and triethylamine (2.5 mmol, 2.5 equiv.) were added. This reaction mixture was 
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stirred overnight at room temperature and filtered to obtain the expected compounds 
with a 41–95% yield. 
4-(4-(Bis(2-chloroethyl)amino)phenyl)-N-(4-sulfamoylphenyl)butanamide (2a) 
mp: 155–157 °C; 1H NMR (400 MHz, DMSO-d6), δ 10.22 (s, 1H), 7.73 (d, J = 4.4, 4H), 7.23 
(s, 2H), 7.05 (d, J = 8.7, 2H), 6.67 (d, J = 8.7, 2H), 3.70 (d, J = 8.6, 8H), 2.54–2.50 (m, 2H), 
2.34 (t, J = 8.6, 2H), 1.90–1.78 (m, 2H); 13C NMR (101 MHz, DMSO-d6), δ 171.68, 144.46, 
142.23, 138.03, 129.53, 126.65, 118.51, 111.90, 52.22, 41.17, 35.84, 33.54, 26.87; MS 
(ESI+) m/z 458.11 [M+H]+, 460.10 [M+2]+. HRMS (ESI+) [M+H]+ calculated for 
[C20H26N3O3SCl2]+: 458.1072, found: 458.1075.  
4 -(4-(bis(2-chloroethyl)amino)phenyl)-N-(4-sulfamoylbenzyl)butanamide (2b) 
mp: 130–132 °C; 1H NMR (400 MHz, DMSO-d6), δ 8.41 (t, J = 5.9, 1H), 7.76 (d, J = 8.3, 
2H), 7.41 (d, J = 8.3, 2H), 7.31 (s, 2H), 7.02 (d, J = 8.6, 2H), 6.66 (d, J = 8.6, 2H), 4.31 (d, J 
= 5.9, 2H), 3.69 (s, 8H), 2.45 (t, J = 7.5, 2H), 2.15 (t, J = 7.5, 2H), 1.82–0.72 (m, 2H); 13C 
NMR (101 MHz, DMSO-d6), δ 172.15, 144.42, 143.92, 142.54, 129.86, 129.33, 127.46, 
125.68, 111.89, 52.22, 41.67, 41.17, 34.84, 33.66, 27.39; MS (ESI+) m/z 472.12 [M+H]+, 
474.12 [M+2]+. HRMS (ESI+) [M+H]+ calculated for [C21H28N3O3SCl2]+: 472.1228, found: 
472.1236. 
4-(4-(Bis(2-chloroethyl)amino)phenyl)-N-(4-sulfamoylphenethyl)butanamide (2c) 
mp: 108–110 °C; 1H NMR (400 MHz, DMSO-d6), δ 7.89 (t, J = 5.6, 1H), 7.74 (d, J = 8.3, 
2H), 7.38 (d, J = 8.3, 2H), 7.30 (s, 2H), 7.00 (d, J = 8.6, 2H), 6.66 (d, J = 8.6, 2H), 3.70 (d, J 
= 8.9, 8H), 3.29 (dd, J = 13.0, 5.6, 2H), 2.78 (t, J = 7.5, 2H), 2.41 (t, J = 7.5, 2H), 2.08–1.98 
(m, 2H), 1.76–1.65 (m, 2H); 13C NMR (101 MHz, DMSO-d6), δ 171.95, 144.39, 143.80, 
142.01, 129.89, 129.21, 125.67, 111.87, 52.23, 41.17, 34.87, 33.61, 27.32; MS (ESI+) 
m/z 486.14 [M+H]+, 488.14 [M+2]+. HRMS (ESI+) [M+H]+ calculated for [C22H30N3O3SCl2]+: 
486.1385, found 486.1387. 
4-(4-(Bis(2-chloroethyl)amino)phenyl)butyl (4-sulfamoylphenyl)carbamate(5a) 
mp: 156–158 °C; 1H NMR (400 MHz, DMSO-d6), δ 10.01 (s, 1H), 7.76–7.69 (m, 2H), 
7.64–7.56 (m, 2H), 7.22 (s, 2H), 7.04 (d, J = 8.7, 2H), 6.66 (d, J = 8.7, 2H), 4.12 (t, J = 6.0, 
2H), 3.77–3.63 (m, 8H), 1.70–1.54 (m, 4H); 13C NMR (101 MHz, DMSO-d6), δ 153.50, 
144.40, 142.34, 137.48, 130.06, 129.30, 126.77, 117.50, 111.89, 64.43, 52.22, 41.17, 
33.68, 28.09, 27.62; MS (ESI+) m/z 488.12 [M+H]+, 490.12 [M+2]+. HRMS (ESI+) [M+H]+ 
calculated for [C21H28N3O4SCl2]+: 488.1178, found: 488.1184. 
4-(4-(Bis(2-chloroethyl)amino)phenyl)butyl (4-sulfamoylbenzyl)carbamate(5b) 
mp: 98–100 °C; 1H NMR (400 MHz, DMSO-d6), δ 7.76 (t, J = 8.5, 3H), 7.41 (d, J = 8.5, 2H), 
7.31 (s, 2H), 7.02 (d, J = 8.6, 2H), 6.66 (d, J = 8.6, 2H), 4.23 (d, J = 6.1, 2H), 3.98 (s, 2H), 
3.75–3.63 (m, 8H), 2.47 (s, 2H), 1.55 (m, 4H); 13C NMR (101 MHz, DMSO-d6), δ 156.63, 
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144.37, 143.97, 142.61, 130.13, 129.26, 127.27, 125.70, 111.88, 63.84, 52.23, 43.37, 
41.18, 33.68, 28.31, 27.64; MS (ESI+) m/z 502.13 [M+H]+, 504.13 [M+2]+. HRMS (ESI+) 
[M+H]+ calculated for [C22H30N3O4SCl2]+: 502.1334, found: 502.1338. 
4-(4-(Bis(2-chloroethyl)amino)phenyl)butyl (4-sulfamoylphenethyl)carbamate(5c) 
mp: 100–102 °C; 1H NMR (400 MHz, DMSO-d6), δ 7.77–7.70 (m, 2H), 7.37 (d, J = 8.2, 
2H), 7.30 (s, 2H), 7.19 (t, J = 5.5, 1H), 7.02 (d, J = 8.6, 2H), 6.66 (d, J = 8.6, 2H), 3.94 (d, J 
= 5.5, 2H), 3.69 (s, 8H), 3.21 (dd, J = 13.3, 6.6, 2H), 2.76 (dd, J = 16.9, 9.8, 2H), 2.46 (s, 
2H), 1.52 (s, 4H); 13C NMR (101 MHz, DMSO-d6), δ 156.30, 144.37, 143.58, 142.03, 
130.15, 129.19, 125.67, 111.88, 63.51, 52.23, 41.28, 35.09, 33.67, 28.32, 27.63; MS 
(ESI+) m/z 516.15 [M+H]+, 518.15 [M+2]+. HRMS (ESI+) [M+H]+ calculated for 
[C23H32N3O4SCl2]+: 516.1491, found: 516.1490. 
3-(4-Sulfamoylphenethylamino) benzo [e][1,2,4] triazine 1-oxide (7) 
Compound 7 was synthesized from 6 by a general amination method and resulted in a 
yellow solid with a yield of 94%. mp: 250–252 °C; 1H NMR (400 MHz, DMSO-d6), δ 8.15 
(s, 1H), 8.13 (s, 1H), 8.03 (s, 1H), 7.82–7.71 (m, 3H), 7.60 (d, J = 8.0, 1H), 7.47 (d, J = 8.0, 
2H), 7.38–7.30 (m, 1H), 7.28 (s, 2H), 3.60 (d, J = 6.2, 2H), 3.01 (dd, J = 6.2, 2H); 13C NMR 
(101 MHz, DMSO-d6) δ 158.80, 143.70, 142.07, 135.76, 129.25, 125.92, 124.66, 119.93, 
41.92, 34.09; MS (ESI+) m/z 346.10 [M+H]+. HRMS (ESI+) [M+H]+ calculated for 
[C15H16N5O3S]+: 346.0974, found: 346.0973. 
3-((4-Sulfamoylphenethyl)amino)benzo[e][1,2,4]triazine 1,4-dioxide (8) 
Compound 8 was synthesized from 7 by a general oxidation method, resulting in an 
orange red solid with a yield of 96%. mp: 210–212 °C; 1H NMR (400 MHz, DMSO-d6), δ 
8.31 (t, J = 6.1, 1H), 8.22 (d, J = 8.1, 1H), 8.13 (d, J = 8.1, 1H), 7.97–7.89 (m, 1H), 7.75 (d, 
J = 8.3, 2H), 7.61–7.53 (m, 1H), 7.47 (d, J = 8.3, 2H), 7.29 (s, 2H), 3.67 (dd, J = 7.2, 6.1, 
2H), 3.03 (t, J = 7.2, 2H); 13C NMR (101 MHz, DMSO-d6), δ 149.67, 143.19, 142.16, 
138.19, 135.48, 130.07, 129.26, 127.04, 125.71, 121.13, 116.89, 41.76, 34.18; MS (ESI+) 
m/z 362.09 [M+H]+. HRMS (ESI+) [M+H]+ calculated for [C15H16N5O4S]+: 362.0923, found: 
362.0928. 
3-(4-Sulfamoylphenethylamino)-7,8-dihydro-6H-indeno [5,6-e][1,2,4] triazine 1-oxide 
(10) 
Compound 10 was synthesized from 9 by using a general amination method, which 
resulted in a yellow solid with a 85% yield. mp: 238–240 °C; 1H NMR (400 MHz, DMSO-
d6), δ 7.95 (s, 1H), 7.82 (s, 1H), 7.74 (t, J = 10.0, 2H), 7.49–7.39 (m, 3H), 7.28 (s, 2H), 
3.57 (dd, J = 13.0, 6.8, 2H), 3.02–2.90 (m, 6H), 2.11–1.99 (m, 2H); 13C NMR (101 MHz, 
DMSO-d6), δ 157.56, 153.64, 142.79, 141.97, 130.10–127.99, 125.35, 112.78, 41.77, 
32.35, 31.60, 25.25; MS (ESI+) m/z 386.13 [M+H]+. HRMS (ESI+) [M+H]+ calculated for 
[C18H20N5O3S]+: 386.1287, found: 386.1291. 
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3-((4-Sulfamoylphenethyl) amino)-7,8-dihydro-6H-indeno [5,6-e][1,2,4] triazine 1,4-
dioxide (11) 
Compound 11 was synthesized from 10 by using a general oxidation method resulting in 
an orange red solid with a yield of 46%. mp: 218–220 °C; 1H NMR (400 MHz, DMSO-d6), 
δ 8.19 (s, 1H), 7.98 (d, J = 24.2, 2H), 7.75 (d, J = 7.8, 2H), 7.46 (d, J = 7.7, 2H), 7.29 (s, 
2H), 3.65 (d, J = 6.2, 2H), 3.12–2.92 (m, 6H), 2.17–1.99 (m, 2H); 13C NMR (101 MHz, 
DMSO-d6), δ 154.56, 149.25, 145.07, 143.22, 142.15, 129.23, 125.71, 41.76, 32.74, 
31.80, 25.24; MS (ESI+) m/z 402.12 [M+H]+. HRMS (ESI+) [M+H]+ calculated for 
[C18H20N5O4S]+: 402.1236, found: 402.1234. 
6-(4-(Methylsulfonyl)phenyl)-N-phenyl-3-(sulfamoylamino)pyrazine-2-carboxamide (12) 
Compound 12 was synthesized from commercially purchased VE-821 by using the 
general procedure described above, which resulted in a yellow solid with an overall 
yield of 58%. mp: 233–235 °C; 1H NMR (400 MHz, DMSO-d6), δ 11.27 (s, 1H), 10.82 (s, 
1H), 9.28 (s, 1H), 8.64 (d, J = 8.6, 2H), 8.08 (d, J = 8.6, 2H), 7.83–7.76 (m, 2H), 7.68 (s, 
2H), 7.48–7.39 (m, 2H), 7.23 (dd, J = 14.0, 6.6, 1H), 3.30 (s, 3H); 13C NMR (101 MHz, 
DMSO-d6), δ 164.59–163.27, 149.32–147.73, 144.46–143.38, 141.16, 139.57, 137.17–
136.45, 128.69, 127.46, 125.15, 122.08, 43.46; MS (ESI+) m/z 448.07 [M+H]+. HRMS 
(ESI+) [M+H]+ calculated for [C18H18N5O2S2]+: 448.0749, found: 448.0748. 
5-(4-(Isopropylsulfonyl) phenyl)-3-(3-(4-((methylamino) methyl) phenyl) isoxazol-5-yl) 
pyrazin-2-carboxamide (13) 
Compound 13 was synthesized from commercially purchased VE-822 by using the 
general procedure described above, which resulted in a yellow solid with an overall 
yield of 65%. mp: 242–244 °C; 1H NMR (400 MHz, DMSO-d6), δ 8.94 (s, 1H), 8.38 (d, J = 
8.5, 2H), 8.02 (d, J = 8.2, 2H), 7.93 (d, J = 8.5, 2H), 7.79 (s, 1H), 7.54 (d, J = 8.2, 2H), 7.20 
(s, 2H), 6.96 (s, 2H), 4.17 (s, 2H), 3.54–3.38 (m, 1H), 2.58 (s, 3H), 1.17 (t, J = 14.1, 6H); 
13C NMR (101 MHz, DMSO-d6), δ 167.67, 162.00, 151.75, 142.47, 141.04, 139.53, 
137.62, 135.78, 129.00, 127.17, 125.69, 124.47, 102.16, 54.22, 53.49, 34.94, 15.19; MS 
(ESI+) m/z 543.15 [M+H]+. HRMS (ESI+) [M+H]+ calculated for [C24H27N6O5S2]+: 543.1484, 
found: 543.1484. 
3-Methyl-4-oxo-N-(4-sulfamoylphenethyl)-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-
8-carboxamide (15a) 
Compound 15a was synthesized from 14 by reacting it with 4-(2-aminoethyl) benzene 
sulfonamide using the general procedure for synthesizing temozolomide derivatives 
described above. This reaction resulted in a white solid with a yield of 50%. mp: 195–
197 °C; 1H NMR (400 MHz, DMSO-d6), δ 8.83 (s, 1H), 8.58 (t, J = 5.9, 1H), 7.74 (d, J = 8.3, 
2H), 7.44 (d, J = 8.3, 2H), 7.30 (s, 2H), 3.86 (s, 3H), 3.58 (dd, J = 13.4, 6.8, 2H), 2.96 (t, J = 
7.1, 2H); 13C NMR (101 MHz, DMSO-d6), δ 159.67, 143.64, 142.05, 139.20, 134.45, 
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130.30, 129.14, 128.46, 125.73, 36.16, 34.78; MS (ESI+) m/z 378.10 [M+H]+. HRMS (ESI+) 
[M+H]+ calculated for [C14H16N7O4S]+: 378.0984, found: 378.0986. 
3-Methyl-4-oxo-N-(sulfamoyloxy)-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-
carboxamide (15b) 
Compound 15b was synthesized from 14 by reacting it with aminoxysulfonamide using 
the general procedure for synthesizing temozolomide derivatives described above. This 
reaction resulted in a white solid with a yield of 41%. mp: 195–197 °C; 1H NMR (400 
MHz, DMSO-d6), δ 8.81 (s, 1H), 7.80 (s, 1H), 7.67 (s, 1H), 7.30 (s, 2H), 3.86 (s, 3H); 13C 
NMR (101 MHz, DMSO-d6) δ 161.51, 139.16, 134.57, 130.51, 128.37, 45.72. 
3-Methyl-4-oxo-N-(4-sulfamoylbenzyl)-3,4-dihydroimidazo [5,1-d][1,2,3,5]tetrazine-8-
carboxamide (15c) 
Compound 15c was synthesized from 14 by reacting it with 4-(aminomethyl) benzene 
sulfonamide hydrochloride using the general procedure for synthesizing temozolomide 
derivatives described above. This reaction resulted in a white solid with a yield of 88%. 
mp: 185–187 °C; 1H NMR (400 MHz, DMSO-d6) δ 9.20 (t, J = 6.2, 1H), 8.87 (s, 1H), 7.77 
(d, J = 8.3, 2H), 7.50 (d, J = 8.3, 2H), 7.31 (s, 2H), 4.55 (d, J = 6.3, 2H), 3.87 (s, 3H); 13C 
NMR (101 MHz, DMSO-d6), δ 159.96, 143.85, 142.63, 142.63, 138.96, 134.69, 130.11, 
129.28, 128.62, 127.68, 125.77, 41.94, 36.23; MS (ESI+) m/z 364.08 [M+H]+. HRMS (ESI+) 
[M+H]+ calculated for [C13H14N7O4S]+: 364.0828, found: 364.0826. 
3-Methyl-4-oxo-N-(5-sulfamoyl-1,3,4-thiadiazol-2-yl)-3,4-dihydroimidazo[5,1-
d][1,2,3,5]tetrazine-8-carboxamide (15d) 
Compound 15d was synthesized from 14 by reacting it with 5-amino-1, 3,4-thiadiazole-
2-sulfonamide hydrochloride using the general procedure for synthesizing 
temozolomide derivatives described above. This reaction resulted in a light yellow solid 
with a yield of 95%. mp: 128–130 °C; 1H NMR (400 MHz, DMSO-d6), δ 8.63 (s, 1H), 8.06 
(s, 1H), 7.81 (s, 1H), 7.35 (s, 2H), 3.83 (s, 3H); 13C NMR (101 MHz, DMSO-d6), δ 171.73, 
170.89, 165.39, 161.04, 157.91, 139.53, 134.24, 127.88; MS (ESI+) m/z 358.01 [M+H]+. 
HRMS (ESI+) [M+H]+ calculated for [C8H8N9O4S2]+: 358.0141, found: 358.0140. 
Synthesis of 4-(2-(3-carbamimidoylguanidino)ethyl)benzenesulfonamide hydrochloride 
salt (18) 
4-(2-Aminoethyl)benzenesulfonamide 16 (0.5g, 1.0 equiv.) and cyanoguanidine 17 
(0.21g, 1.0 equiv.) were suspended in n-butanol (5.0 mL) and treated with a 6.0 M 
aqueous hydrochloric acid solution (1.0 equiv., 0.4 mL). The mixture was treated at 100 
°C overnight and the solvents were removed under vacuum. The residue was thereafter 
crystallized from isopropyl alcohol (IPA) to obtain compound 18 as a white solid with a 
75% yield. mp: 154–159 °C; 1H NMR (400 MHz, DMSO-d6), δ 7.87 (d, 2H, J = 8.4, Ar-H), 
7.82 (brs, 2H, exchangeable with D2O), 7.50 (d, 2H, J = 8.4, Ar-H), 7.38 (brs, 1H, 
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exchangeable with D2O), 6.62 (brs, 2H, exchangeable with D2O), 3.15 (t, 2H, J = 6.7), 
2.98 (t, 2H, J = 6.7); 13C NMR (101 MHz, DMSO-d6), δ 164.0, 143.7, 142.0, 130.3, 127.0, 
119.3, 61.4, 34.1; MS (ESI+) m/z 285.11 [M+H]+. 
CA inhibition assays 
To measure the CA-catalyzed CO2 hydration activity an Applied Photophysics stopped-
flow instrument was used [61]. To maintain ionic strength Na2SO4 (20 mM) was used 
with HEPES (20 mM, pH 7.5) as a buffer and Phenol red (0.2 mM) as an indicator 
working at the maximum absorbance of 557 nm, which was used to follow the initial 
rates of the CA-catalyzed CO2 hydration for a duration of 10–100 s. To determine the 
kinetic parameters and inhibition constants varying CO2 concentrations were included 
(1.7–17 mM). Initial velocity was assayed with at least six traces of the initial 5–10% of 
the reaction for each compound. Compounds were dissolved in distilled-deionized 
water (0.01 nM). The combined enzyme solutions and compounds were incubated for 
15 min at room temperature to allow for the E-I complex formation prior to 
measurements. The nonlinear least-squares method of PRISM 3 was used to estimate 
the inhibition constants and the mean of three independent estimations is reported. 
The CA isoforms included are recombinant proteins obtained in house. 
Biological assays 
Cells 
All cell lines used were cultured in DMEM supplemented with 10% fetal bovine serum. 
Canine kidney epithelial MDCK cells overexpressing human CAIX (CAIX+) or a scrambled 
control vector (CAIX−) have been described before [37, 44]. The HCT116 constitutive 
CAIX knockdown cell line and its scrambled control have also been described before and 
were kindly provided by Professor Adrien Harris (Weatherall Institute of Molecular 
Medicine, University of Oxford, John Radcliffe hospital, Oxford, UK) [24, 28, 62]. Cells 
were exposed to hypoxic or anoxic conditions in a hypoxic chamber (MACS VA500 
microaerophilic workstation, Don Whitley Scientific, UK) with 0.2 or ≤0.02% O2, 
respectively, and 5% CO2 and residual N2 to upregulate and activate CAIX. Normoxic 
cells were grown in normal incubators with 21% O2, 5% CO2 at 37 °C. 
Cell viability assays 
The efficacy of the cytotoxic derivatives was compared to their respective parental 
compounds in cell viability assays using alamarBlue® (Invitrogen). In short, MDCK cells 
were seeded in 96-well plates and allowed to attach overnight. The next day plates 
were exposed to hypoxia and DMEM was replaced with pre-incubated hypoxic DMEM. 
In contrast, testing the ATRi was performed in anoxic conditions to decrease the 
radiosensitivity of the cells. In parallel normoxic 96-well plates were incubated in 
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normal incubators with 21% O2 and 5% CO2. Compounds were dissolved in DMSO 
(0.5%, Sigma-Aldrich) and final concentrations were made with pre-incubated hypoxic 
or normoxic DMEM and added to the wells after 24 h of exposure. To test the ATR 
inhibitors cells were exposed to the compounds 1 h prior to irradiation and the 96-well 
plates were irradiated (225 kV Philips X-ray tube) with 2 Gy (normoxia) or 4 Gy (anoxia). 
Cells were exposed to compounds for a total of 2 h for chlorambucil and tirapazamine, 
or 72 h for temozolomide and the ATR inhibitors, after which medium was washed off 
and replaced with fresh medium. For chlorambucil, tirapazamine, and ATR inhibitor 
derivatives cells were allowed to grow for an additional 72 h under normoxic conditions 
prior to measurement, whereas cells exposed to temozolomide derivatives remained in 
hypoxic conditions prior to measurement. Cells were allowed to convert alamarBlue® 
for 2 h during normoxic conditions, which corresponds with their metabolic function 
and is a measure for cell viability. 
Clonogenic assays 
Clonogenic survival of MDCK cells was determined with high cell numbers to allow for 
CAIX-dependent extracellular acidification [44]. These cells were exposed to 
temozolomide or 15b for 24 h during normoxic or hypoxic conditions after which cells 
were trypsinized and reseeded in triplicate with known cell numbers. Cells were allowed 
to grow for 7 days to form colonies that were quantified after staining and fixation with 
0.4% methylene blue in 70% ethanol. Surviving fraction was normalized to vehicle (0.5% 
DMSO). 
Basal respiration measurements 
Oxygen Consumption Rates (OCR) were determined using the Seahorse XF96 
extracellular Flux analyzer (Agilent Technologies). Cells were seeded in a XF96 cell plate 
with normal growth medium at an optimized cell density of 1.5 × 104 cells/well. Plates 
were placed in a 5% CO2 incubator at 37 °C in order to let the cells attach. Subsequently 
cells were incubated for 18 h under hypoxic conditions (0.2% O2). Culture medium was 
exchanged with DMEM containing 25 mM d-glucose, 4 mM l-glutamine and 1 mM 
sodiumpyruvate (GIBCO, Thermo Fisher) 60 min prior to the assay and plates were 
placed in a CO2-free incubator at 37 °C. Prior to the first injection, baseline OCR was 
determined using a mixing period of 5 min and a measurement period of 3 min followed 
by 3 loops of mixing and measuring for 3 min each. Medium containing vehicle (PBS, 
Lonza), Phenformin Hydrochloride (Sigma-Aldrich), or the CAIXi conjugated phenformin 
derivative 18 were injected followed by several mixing and measurements cycles. 
Subsequently cells were washed with PBS and lysed in a 0.05% SDS (Sigma-Aldrich) 
solution. Protein quantification for normalization purposes was performed using 
Pierce™ BCA Protein Assay Kit (Thermo Fisher). 
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Western blot 
To validate CAIX expression in the genetically modified cell lines protein immunoblotting 
was performed after 24 h of hypoxia exposure (0.2% O2) as described previously [43]. 
Primary antibodies used included the anti-CAIX M75 antibody (kindly provided by 
Professor Silvia Pastorekova, Institute of Virology, Slovak Academy of Science, Slovak 
Republic), and anti-β-actin (MP Biomedicals, #691001) as a reference protein. 
Statistical analyses 
GraphPad Prism (version 5.03) was used for all statistical analyses. For the cytotoxic 
compounds IC50 values were estimated with the curve of the log(inhibitor) vs. 
normalized response (Variable slope). Means between groups were compared using 
unpaired t-tests, where p < 0.05 indicated statistical significance. 
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Supplementary data 
 
Supplementary Figure S1. CAIX protein expression during normoxia and hypoxia of the MDCK (A) and HCT116
(B) cells and pH measurements of MDCK cells (C). Expression of ß-actin was included as a reference protein. 
CAIX+ MDCK cells are overexpressing CAIX, and CAIX- cells are control cells lacking both human and canine
CAIX expression. HCT116 scrambled control vector cells (SCR) show hypoxia-dependent CAIX expression, 
whereas CAIX knockdown (KD) cells do not. During normoxic conditions HCT116 SCR cells have no detectable
levels of CAIX, since the dot (B) is an artefact on film. The pH of the culture medium was measured of the
MDCK cells after 24 hours of normoxic or hypoxic exposure (C). Mean ± SEM of three independent biological 
repeats are shown. Asterisks indicate statistical significance (*p < 0.05; **p < 0.01). 
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Supplementary Figure S2. Relative cell viability of CAIX+ and CAIX- MDCK cells exposed to increasing 
concentrations of chlorambucil or the CAIXi conjugated derivatives during normoxic (N) and hypoxic (H)
conditions. Relative cell viability was normalized to vehicle control (0.5% DMSO). Average ± SEM of three
independent biological repeats is shown. 
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Supplementary Figure S3. Relative cell viability of CAIX+ and CAIX- MDCK cells exposed to increasing 
concentrations of tirapazamine or the CAIXi conjugated derivatives during normoxic (N) and hypoxic (H)
conditions. Relative cell viability was normalized to vehicle control (0.5% DMSO). Average ± SEM of three
independent biological repeats is shown. 
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Supplementary Figure S4. Relative cell viability of CAIX+ and CAIX- MDCK cells exposed to increasing 
concentrations of temozolomide or the CAIXi conjugated derivatives during normoxic (N) and hypoxic (H)
conditions. Relative cell viability was normalized to vehicle control (0.5% DMSO). Average ± SEM of three
independent biological repeats is shown. 
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Supplementary Figure S5. Relative cell viability (%) in MDCK CAIX- and CAIX+ cells exposed to ATR inhibitors 
(VE-821 and VE-822) or the CAIXi conjugated derivatives (12 and 13) without radiation during normoxia (21%
O2) and anoxia (<0.02% O2). Cells were exposed to 500 nM VE-821 and 12, and to 50 nM VE-822 and 13. 
Average ± SEM of three independent biological repeats is shown. Asterisks indicate statistical significance (*p
< 0.05; **p < 0.01; ***p<0.001). 
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NMR spectra 1: 4-(4-(bis(2-chloroethyl)amino)phenyl)-N-(4-sulfamoylphenyl)butanamide (2a). 
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NMR spectra 2: 4-(4-(bis(2-chloroethyl)amino)phenyl)-N-(4-sulfamoylbenzyl)butanamide (2b). 
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NMR spectra 3: 4-(4-(bis(2-chloroethyl)amino)phenyl)-N-(4-sulfamoylphenethyl)butanamide(2c). 
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NMR spectra 4: 4-(4-(bis(2-chloroethyl)amino)phenyl)butyl (4-sulfamoylphenyl)carbamate(5a). 
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NMR spectra 5: 4-(4-(bis(2-chloroethyl)amino)phenyl)butyl (4-sulfamoylbenzyl)carbamate(5b). 
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NMR spectra 6: 4-(4-(bis(2-chloroethyl)amino)phenyl)butyl (4-sulfamoylphenethyl)carbamate(5c). 
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NMR spectra 7: 3-(4-sulfamoylphenethylamino) benzo [e][1,2,4] triazine 1-oxide (7).  
  
Dual target CAIX specific cytotoxic drug delivery 
139 
 
 
NMR spectra 8: 3-((4-sulfamoylphenethyl)amino)benzo[e][1,2,4]triazine 1,4-dioxide (8). 
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NMR spectra 9: 3-(4-sulfamoylphenethylamino)-7,8-dihydro-6H-indeno [5,6-e][1,2,4] triazine 1-oxide (10). 
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NMR spectra 10: 3-((4-sulfamoylphenethyl) amino)-7,8-dihydro-6H-indeno [5,6-e][1,2,4] triazine 1,4-dioxide 
(11). 
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NMR spectra 11: 6-(4-(methylsulfonyl)phenyl)-N-phenyl-3-(sulfamoylamino)pyrazine-2-carboxamide (12). 
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NMR spectra 12: 5-(4-(isopropylsulfonyl) phenyl)-3-(3-(4-((methylamino) methyl) phenyl) isoxazol-5-yl) 
pyrazin-2-carboxamide (13). 
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NMR spectra 13: 3-methyl-4-oxo-N-(4-sulfamoylphenethyl)-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-
carboxamide (15a). 
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NMR spectra 14: 3-methyl-4-oxo-N-(sulfamoyloxy)-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide 
(15b). 
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NMR spectra 15: 3-methyl-4-oxo-N-(4-sulfamoylbenzyl)-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-
carboxamide (15c). 
  
Dual target CAIX specific cytotoxic drug delivery 
147 
 
 
NMR spectra 16: 3-methyl-4-oxo-N-(5-sulfamoyl-1,3,4-thiadiazol-2-yl)-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetra-
zine-8-carboxamide (15d). 
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NMR spectra 17: 4-(2-(3-carbamimidoylguanidino)ethyl)benzenesulfonamide hydrochloride salt (18) 
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Abstract 
Despite preclinical evidence of nitric oxide donors influencing both tumor perfusion and 
hypoxia, they have not been shown in trials to improve the treatment results of all 
patients with non-small cell lung cancer. Biomarkers are therefore needed to select 
patients for treatment with NO donors. In this window-of-opportunity study 
nitroglycerin is shown to reduce uptake of the hypoxia-PET tracer HX4 in approximately 
two thirds of patients with hypoxic loco-regional disease. In a quarter of patients, 
hypoxic tumors and nodes become normoxic after treatment with nitroglycerin. 
Dynamic contrast enhanced CT-scans demonstrate that this effect on hypoxic tracer 
uptake is negatively correlated with tumor perfusion in hypoxic tumors. Using in vitro 
experiments, we show that the metabolism of 2-nitroimidazoles is not influenced by 
nitroglycerin itself and that nitroglycerin does not inhibit mitochondrial respiration at in 
human achievable concentrations. Therefore, 2-nitroimidazole based imaging 
biomarkers can be used to evaluate the nitroglycerin treatment efficacy in an individual 
patient. These results support the hypothesis that hypoxia scans and/or DCE-CT scans 
could form a tool to select patients for a nitroglycerin patch adjuvant to anti-cancer 
treatment (radiotherapy, chemotherapy, targeted agents or immunotherapy). An 
animation summarizing our results is available at https://youtu.be/udJSBYaRv9w. 
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Introduction 
Inspired by numerous publications highlighting the different biological effects of nitric 
oxide (NO) on cancer cells in the past decades, NO donors have been recognized as a 
potentially valuable -and mostly cheap- addition to current standard treatment 
strategies. Different clinical trials, some of them randomized, have explored the 
addition of NO donors to standard treatment in various cancer types. However, the 
obtained results are inconsistent. Some trials report favorable results for different 
cancer types, while others are not able to replicate these results and even mention the 
possibility of a detrimental effect in some patients [1-4].    
Of all proposed mechanisms of action attributed to NO donors, their potential influence 
on cancer cell hypoxia is among the most widely cited [3, 5]. There are different ways in 
which the oxygen concentration in cancer cells could be influenced by NO. Firstly, as a 
vasodilating agent, NO could enhance the blood flow and thereby increase oxygen 
transfer to the tumor. Secondly, NO has been shown to influence blood cell rheology, 
normalizing the blood viscosity and thereby improving the flux of blood cells through 
the aberrant vasculature of the tumor. Thirdly, blocking of the mitochondrial respiration 
and in this manner decreasing oxygen consumption [6-9]. However, there are concerns 
of NO donors eliciting the opposite effect by inducing steal effects caused by systemic 
vasodilatation, thereby actually decreasing tumor perfusion [10]. This makes the effect 
of NO donors in an individual patient difficult to predict. 
The development of predictive biomarkers would enable an individualized approach of 
the adjuvant use of nitroglycerin to standard treatment for non-small cell lung cancer 
(NSCLC) [11]. In a window-of-opportunity trial design [12], we tested whether the effect 
of the NO donor nitroglycerin on the levels of hypoxia in an individual patient`s tumor 
could be visualized using the 2-nitroimidazole positron emission tomography (PET) 
tracer [18F]-HX4 while measuring the perfusion effect of nitroglycerin using dynamic 
contrast-enhanced CT (DCE-CT) scans [13-18]. Secondly, because it is unclear whether 
the NO donor itself could affect the intracellular metabolism of 2-nitroimidazoles, and 
hereby lead to false positive results on hypoxia scans, we verified this in a separate in 
vitro experiment. Also, we assessed whether nitroglycerin had any effects on 
mitochondrial respiration in these cultures as this has been previously stated by other 
authors. Finally, this work should validate a potential imaging biomarker for future trials 
with nitroglycerin [11, 19]. 
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Results  
Inclusion and scans performed 
Forty-two patients were included in the trial before inclusion was halted in July 2016. 
The current analysis comprises the final analysis of all DCE-CT and HX4 PET scans 
performed (Table S1). Thirty-two patients received a baseline HX4 scan, of whom 25 
also had an HX4 scan after application of a nitroglycerin patch. Twenty-eight patients 
received a baseline DCE-CT. After confirmation of the quality and timing of the DCE-CT, 
22 scans were adequate for analysis. Eighteen patients underwent a DCE-CT after 
nitroglycerin of which 13 were suitable for analysis. For 12 patients, all scans (both 
baseline and post-nitroglycerin) were available for analysis. Twenty patients had both a 
baseline HX4 scan and a baseline DCE-CT scan (Table S2). The median interval between 
the baseline and second HX4 and DCE-CT scans was 4 and 5 days respectively (range 2-7 
days). None of the patients received any cancer treatment in the interval between both 
scans.  
All data is publicly available at http://www.cancerdata.org [20].  
Hypoxia is present at baseline in > 50% of NSCLC lesions and correlates with 
tumor volume and perfusion.   
In total 32 patients received a baseline HX4 scan (Table S1). Seventeen patients (53%) 
exhibited a HX4 tumor to blood ratio (HX4-TBR) > 1.4 in the gross tumor volume of the 
primary tumor (GTVp) and 14 out of 25 patients (56%) with pathologic lymph nodes had 
a HX4-TBR > 1.4 in the gross tumor volume of the lymph nodes (GTVln). In total 22/32 
patients (69%) showed hypoxia in primary tumor and/or lymph nodes. Hypoxic tumors 
were significantly larger than non-hypoxic tumors at a median volume of 72.9 vs 11 cm3 
(p=0.006). Likewise, hypoxic nodal volumes were larger than non-hypoxic volumes: 58.2 
vs 9.4 cm3 (p=0.021). There was a significant correlation between tumor volume and 
baseline HX4-TBR for both primary tumor and nodes (r=0.599, p<0.001 and r=0.688, 
p<0.0001 respectively).  
In the 20 patients who had both baseline HX4 scans and DCE-CT scans, the baseline 
level of tumor hypoxia (HX4-TBR) did not correlate with baseline tumor blood flow (r=-
0.334, p=0.15) or blood volume (r=-0.08, p=0.738). However, in the 11 hypoxic tumors a 
significant negative correlation was found between baseline HX4-TBR and tumor blood 
flow (r=-0.618, p=0.043) and blood volume (r=-0.736, p=0.010) (Fig. 1).  
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Figure 1. Correlation between blood volume, blood flow and HX4-TBR.  
A. Negative correlation between tumor blood flow (BF) and HX4-TBR in hypoxic volumes. B. Negative 
correlation between tumor blood volume (BV) and HX4-TBR in hypoxic volumes. 
Nitroglycerin reduces HX4 uptake in a subset of NSCLC lesions 
We first evaluated the effect of nitroglycerin on HX4 uptake in the 22 patients with 
hypoxic volumes (Fig. 2A, Table 1). Fifteen of these patients, carrying a total of 19 
hypoxic volumes (12 GTVp, 7 GTVln), underwent a second HX4 scan. In 11 volumes (58%) 
a decrease in the TBR was seen. After nitroglycerin administration, 4/15 patients (27%) 
with baseline hypoxic volumes could not be classified as hypoxic anymore (Table 1). 
To determine in individual patients whether this effect was larger than test-retest 
variability, we evaluated whether it exceeded the coefficient of repeatability (CoR): 17% 
for the TBR and 7.8% for the HX4-HF at a threshold for hypoxia of TBR>1.4 [17]. In this 
group of 19 hypoxic lesions, the HX4-HF dropped by >7.8% in 4 volumes (21%) belonging 
to 3 patients (Fig. 2B). The TBR decreased by >17% in 4 volumes (21%) in 3 patients, but 
also increased by >17% in 4 volumes (21%) belonging to 4 patients (Fig. 3A).   
In the 12 non-hypoxic tumors and 11 nodal volumes, we noticed in 4 volumes (17%) a 
rise of the TBR with >17%, while in 1 volume the TBR declined by > 17% (4%). Three of 
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the originally non-hypoxic primary tumors (25%) and 1 nodal volume (9%) became 
hypoxic (TBR>1.4) after the administration of nitroglycerin (Fig. 3B and Table 1).  
  
Table 1. HX4 uptake parameters for non-hypoxic volumes (tumor and nodes pooled, n=23) and for hypoxic 
volumes (tumor and nodes pooled, n=19) before and after nitroglycerin patch (ie. only patients with both 
HX4-scans). Abbreviations: GTV= Gross Tumor Volume, SUV=Standardized Uptake Value, TBR= tumor-to-
background ratio of HX4, HF= high uptake fraction of HX4, HV= high-uptake volume of HX4.  
Parameter Baseline  Nitroglycerin  Baseline vs 
Nitroglycerin 
  Median ± SD Range Median ± SD Range p-value 
Non-hypoxic volumes     
GTV (cm3) 9.6 ± 12 1.28- 41.65       
HX4-SUV mean 0.63 ± 0.17 0.35 - 1.01 0.64 ± 0.17 0.18 - 1.01 0.984 
HX4-SUV max 0.86 ± 0.25 0.4 - 1.44 0.92 ± 0.28 0.23 - 1.39 0.911 
HX4-TBR 1.19 ± 0.16 0.639 - 1.37 1.22 ± 0.22 0.64 - 1.66 0.098 
HX4-HF (%) 0 0 0 ± 0.14 0 – 6.6 0.068 
HX4-HV (cm3) 0 0 0 ± 0.06 0 - 0.21 0.068 
Hypoxic volumes      
GTV (cm3) 56.98 ± 70.53 4.53 - 253.7    
HX4-SUV mean 0.67 ± 0.22 0.46 - 1.21 0.74 ± 0.22 0.41 - 1.28 0.276 
HX4-SUV max 1.26 ± 0.36 0.76 - 2.09 1.25 ± 0.5 0.61 - 2.47 0.507 
HX4-TBR 1.76 ± 0.36 1.42 - 2.69 1.65 ± 0.56 1.17 - 2.91 0.968 
HX4-HF (%) 8 ± 13.5 0.06 - 40 2 ± 18.3 0 - 55 0.601 
HX4-HV (cm3) 3.1 ± 15.3 0.08 - 46 1.5 ± 11.4 0 - 44.7 0.314 
Nitroglycerin`s effect on hypoxia correlates negatively with an effect on tumor 
perfusion in hypoxic tumors.  
Thirteen patients had both a baseline and a nitroglycerin DCE-CT scan. In this group of 
patients, neither median blood flow nor median blood volume changed significantly by 
application of a nitroglycerin patch (p=0.507 and 0.552 respectively). There was also no 
difference in response to nitroglycerin when evaluating the perfusion parameters 
between the groups of baseline hypoxic and non-hypoxic tumors (Table 2). On an 
individual patient level the blood flow increased in 5 (38%) and blood volume in 7 
tumors (54%) (Fig. S1).  
As expected there was a significant correlation between the change in blood flow and 
blood volume (r=0.599, p=0.031).   
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Figure 2. Uptake of HX4 before and after nitoglycerin administration.  
A. Images of an HX4 PET/CT scan before and after nitroglycerin administration of the same patient. B. 
Evolution of HX4 high-uptake fraction (HX4-HF) after application of nitroglycerin patch in baseline hypoxic
lesions. Red = decline > coefficient of repeatability (CoR) of HX4 (17%), grey = stable: change < CoR, blue = rise 
> CoR. p=0.01. 
 
Twelve of these 13 patients also received a baseline and nitroglycerin HX4 scan. In 6 
patients (50%) the primary tumor was classified as hypoxic at baseline. In 4/6 patients 
with a baseline hypoxic tumor, nitroglycerin increased the tumor blood flow (range: 0.5-
16.4 ml/100ml/min). In 3 out of these 4 patients, the HX4-TBR decreased (range: -0.1 to 
-0.43). In 2 of these patients the HX4-HF decreased (by 7% and 26% respectively), while 
rising in 2 (by 3% and 12% respectively).  
In 4/6 hypoxic patients, the HX4-TBR decreased (range: -0.1 to -0.4) after application of 
a nitroglycerin patch. This led to a decreased high-uptake volume of HX4 (HX4-HV) in 
3/6 tumors (range: -0.2 to -37.8 cm³) and in 2 patients, the decline in HX4-TBR 
exceeded the CoR of 17%.  
Conversely, in 5/6 patients with non-hypoxic tumors a decrease in the blood flow to the 
tumor was noticed (range: -0.6 to -25.4 ml/100ml/min). In 3 of these tumors the HX4-
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TBR increased by >17% (Fig. 3). In 2 patients the tumor became hypoxic after 
administration of nitroglycerin.  
 
 
Figure 3. Tumor to background ratio (TBR) of HX4 after application of nitroglycerin patch.   
A. Evolution of TBR of HX4 (HX4-TBR) after application of nitroglycerin patch in baseline hypoxic lesions,
p=0.052 B. Evolution of HX4-TBR after application of nitroglycerin patch in non-hypoxic lesions, p=0.551. Red 
= decline > CoR of HX4 (17%), grey = stable: change < CoR, blue =rise > CoR. Red striped line indicates cut-off 
for hypoxia: HX4-TBR=1.4. 
 
In the group of tumors with baseline hypoxia we found a significant negative correlation 
between the change in blood volume and HX4-HF (r=-0.829, p=0.042) and HX4-TBR (r=-
0.829, p=0.042, Fig. 4) and the change in HX4-HV (r=-1.000, p<0.0001). In non-hypoxic 
tumors there was no correlation between the HX4-TBR and either of the perfusion 
parameters.   
 
Table 2. Perfusion parameters in patients with both a baseline DCE-CT scan and DCE-CT scan after 
nitroglycerin for non-hypoxic tumors (n=6) and hypoxic tumors (n=6) 
Parameter Baseline  Nitroglycerin  Baseline vs 
Nitroglycerin 
  Median ± SD Range Median ± SD Range p-value 
Non-hypoxic volumes      
Blood Flow (ml/100ml/min) 61 ± 39.6 36.1 - 149.5 55.3 ± 34.6 28.8 - 126.7 0.173 
Blood Volume (ml/100ml) 6.57 ± 2.61 2.69 – 9.64 6.94 ± 3.06 2.39 – 9.59 0.917 
Hypoxic volumes      
Blood Flow (ml/100ml/min) 42.8 ± 23.6 29.6 - 93.8 46.5 ± 23.8 30.1 - 93.4 0.249 
Blood Volume (ml/100ml) 5.56 ± 3.08 5.48 – 13.06 7.78 ± 3.18 5.36 – 1.41 0.345 
  
Likewise, in the 6 tumors with the lowest blood flow (defined as tumors with a blood 
flow < median blood flow of 56 ml/100ml/min), significant negative correlations 
between the effect on blood flow and HX4-TBR (r=-0.943, p=0.005) and HX4-HF (r=-
0.943, p=0.005) and between the effect on blood volume and hypoxic volume (r=-0.943, 
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p=0.005) were found. In the 6 tumors with a blood flow> median, these correlations 
were not present. 
 
 
Figure 4. Negative correlation between nitroglycerin effect on blood volume (ΔBV) and HX4-TBR (ΔHX4-TBR). 
 
Treatment with nitroglycerin at an in vivo achievable concentration does not reduce the 
oxygen consumption in vitro   
In order to investigate if the decrease of the hypoxic fraction can be explained by the 
effect of NO on oxygen consumption by mitochondria, we investigated the potentially 
inhibitory effects of nitroglycerin on mitochondrial respiration. H522, H1299 and H1299 
NfsA cells were treated with either vehicle or nitroglycerin at concentrations of 352 pM, 
352 nM and 35.2 µM as the respective IC50 concentrations could not be reached. These 
concentrations are based on the paper from Mc Allister, taking in account that our 
patch is 2 times smaller in size [21]. The concentration of 352 pM is in the range of the 
plasma concentration. In all investigated cell lines nitroglycerin, did not cause a decline 
of the OCR percentage (Fig. 5A) at used concentrations. In order to make the cells more 
dependent on oxidative phosphorylation and thereby elicit more distinctive effects of 
nitroglycerin, cells were pre-exposed to galactose. However, also under these 
conditions, no differences could be observed (Fig. S2).  
Nitroglycerin reduction does not affect pimonidazole binding in vitro 
To assess if nitroglycerin affects tumor cell’s reductase capacity, resulting in a decreased 
uptake of 2-nitroimidazoles, H1299 parental and nitroreductase overexpressing cells 
were exposed to pimonidazole under normoxic conditions. Pimonidazole reduction 
occurred only upon hypoxic exposure in H1299 parental cells, whereas a clear 
pimonidazole signal was detected upon normoxia in H1299 NfsA cells which was equally 
strong in cells exposed to hypoxia. Nitroglycerin, at the highest used concentration 
(35.2 mM), did not affect pimonidazole binding in any experimental condition (Fig. 5B). 
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Figure 5. In vitro exposure of nitroglycerin does not lead to decreased cellular respiration or pimonidazole
binding.  
A. Nitroglycerin does not affect cellular respiration. Relative inhibition of mitochondrial respiration of H522
cells, H1299 or H1299 NfsA upon treatment with nitroglycerin (NG): 352 pM (plasma concentration); 352 nM;
35.2 µM or vehicle control (VC). Measurements were normalized for protein concentration and the % of
baseline oxygen consumption rate (OCR) before adding nitroglycerin or vehicle. Results are shown for median 
± range of at least 3 independent experiments. B. Upon nitroglycerin exposure, pimonidazole binding is not
decreased under hypoxic conditions, neither under normoxic conditions for H1299 or H1299 NfsA cells. Data 
represents relative pimonidazole binding of 3 independent experiments 
Discussion  
In recent years, NO donors have attracted attention as possible anti-cancer agents, to 
be used either as a single agent or combined with conventional modalities such as 
chemotherapy and radiotherapy. Possible mechanisms of action proposed by different 
authors include enhanced tumor perfusion and chemotherapy delivery, anti-tumoral 
immunogenic effects, upregulation of p53 or radio-sensitization by either increased 
formation of intracellular free radicals, decreased tumor hypoxia via increasing 
perfusion and/or inhibition of the mitochondrial respiration [4, 9, 22-24] 
Consequently, a number of clinical trials, without an up-front biomarker-based selection 
or stratification, have been conducted to study the effect of the addition of the NO 
donor nitroglycerin to standard therapy [5, 25-29]. Yasuda et al. were the first to 
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perform a randomized phase II trial in which 120 patients with stage IIIB-IV NSCLC were 
randomized between 4 cycles of cisplatin-vinorelbin chemotherapy combined with a 
nitroglycerin 25 mg patch or placebo. They found a significantly improved overall 
response rate, time-to-progression and overall survival in favor of patients treated with 
nitroglycerin, while treatment toxicity remained equal [5]. After this first positive trial 
with all Asian patients, Reinmuth et al. published a similar trial with 66 Caucasian 
patients with stage IIIB-IV NSCLC. Instead of a predetermined 4 cycles of cisplatin-
vinorelbin chemotherapy they continued treatment until disease progression. The trial 
was halted prematurely due to slow accrual and despite a numerically higher overall 
response rate in the nitroglycerin arm, the authors could not find any statistically 
significant survival benefit of the addition of nitroglycerin to standard chemotherapy 
[25]. The Dutch NVALT-12 trial randomized 223 patients with or without a 15 mg 
nitroglycerin patch and chemotherapy treatment with paclitaxel-carboplatin-
bevacizumab (PCB). They too failed to demonstrate a statistically significant difference 
in overall and progression free survival between the 2 groups [27]. In a four-arm phase 
II-trial investigating irinotecan/cisplatin (IP) versus irinotecan/capecitabine (IX) with or 
without isosorbide-5-mononitrate (ISMN) in 146 patients with chemo-naïve stage IIIB-IV 
NSCLC, Han et al. also failed to prove that adding this NO-donor to chemotherapy had 
an impact on the overall response rate [26]. The Australasian NITRO trial randomizing 
patients with advanced NSCLC to platinum-based doublet chemotherapy with or 
without a 25 mg patch of nitroglycerin was closed for accrual after an interim analysis 
showed an equal PFS, OS and ORR in both groups [28]. Lastly, Arrieta et al. published 
the results of a small phase II trial treating 35 patients with stage III NSCLC with 6 cycles 
of cisplatin-vinorelbin chemotherapy. Cycles 3 and 4 were given concurrently with 
radiotherapy to a median total dose of 60 Gy (54 Gy to the lymph nodes). A 25 mg 
patch of nitroglycerin was applied in all patients for 5 days around each chemotherapy 
cycle and every day during radiotherapy. They achieved a median OS of 26.5 months, 
which is in line with the results of recent trials on concurrent chemo-radiation for stage 
III NSCLC [29]. We can therefore conclude that the addition of NO donors to standard 
therapy has not been shown to have a major impact on the survival of unselected 
patients with NSCLC. We hypothesize that a biomarker-based selection for additional 
treatment with nitroglycerin could increase the potential benefit for individual patients. 
Since a potential effect on tumor perfusion and hypoxia are most cited as mechanisms 
behind a treatment effect [30], we hypothesize that these could serve as key 
biomarkers to select patients for nitroglycerin treatment.  
In our clinical study we observed a reduction of HX4 uptake of varying magnitude upon 
application of a nitroglycerin patch in approximately two thirds of patients with hypoxic 
loco-regional disease. In a quarter of patients with baseline hypoxia, the tumor and 
nodes become normoxic after treatment with nitroglycerin. One possible explanation 
for this observation could have been a blocking effect of NO-donors on the oxidative 
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phosphorylation. Several authors have previously proposed this phenomenon as a 
possible radiosensitizing effect of NO-donors [31]. Such an inhibition reduces the 
amount of oxygen used for oxidative phosphorylation by the mitochondria, increasing 
the amount of intracellular oxygen and enhancing the possibility of free radical 
formation upon irradiation of the cell [8]. Our in vitro experiments in several NSCLC cell 
lines do not support an inhibitory effect of nitroglycerin on mitochondrial respiration 
under aerobic oxygen concentrations at in vivo achievable concentrations [32-34]. A 
normal plasma concentration of nitroglycerin 2-4 hours obtained after application of a 
Transiderm Nitro 5 mg patch as used in our trial, is reported to be 0.16±0.03 μg/l 
(Product Monograph Transiderm Nitro, Novartis 2011). Even forcing the cellular 
metabolism to be more dependent on oxidative phosphorylation using galactose pre-
incubation [35, 36] in order to elicit a more pronounced effect of NO release by 
nitroglycerin, did not result in decreased oxygen consumption (Fig. 4A, Fig. S2). 
Therefore, an acute effect of blocking the oxidative phosphorylation chain in human 
tumors with conventional doses of nitroglycerin seems unlikely.  
To investigate the possibility that nitroglycerin itself affects reductase capacity of tumor 
cells as a mechanism explaining the decreased HX4 uptake, in vitro tests were carried 
out. The binding of pimonidazole was not affected upon nitroglycerin treatment under 
both normoxic and hypoxic conditions in parental and nitroreductase overexpressing 
cells, suggesting an extracellular mechanism of nitroglycerin, such as improved 
perfusion, to explain its effects on tumor hypoxia seen on HX4 PET imaging.  
When studying the entire patient population however, the baseline uptake of HX4 and 
perfusion parameters were not correlated. Only in hypoxic tumors negative correlations 
between the baseline level of hypoxia (HX4-TBR and HX4-HF) and tumor perfusion (BF 
and BV) were found. Furthermore, in hypoxic tumors the effect of nitroglycerin on 
hypoxia was negatively correlated with an effect on perfusion, which was not present in 
non-hypoxic tumors.  
This suggests that improved perfusion upon nitroglycerin treatment is at least in part 
responsible for the decreased HX4 uptake in certain lesions. However, the perfusion 
effects of nitroglycerin seem to be not strictly limited to a general enhancement of 
perfusion. Interestingly, an increased tumor blood flow after nitroglycerin treatment was 
almost exclusively found in patients with hypoxic tumors at baseline. The majority of 
non-hypoxic tumors showed various levels of decreased perfusion after application of a 
nitroglycerin patch. One in four non-hypoxic volumes became hypoxic after treatment 
with nitroglycerin.  This observation correlates with warnings in literature that NO should 
be considered a “double edged sword” in cancer treatment [37]. As nitroglycerin is not a 
targeted agent focusing its actions solely on the tumor vasculature, its systemic effects 
on peripheral vessels could for instance cause a steal phenomenon in already well 
perfused tumors, shifting blood away from the tumor to the systemic vasculature [10, 
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38]. Thus, nitroglycerin could serve as a regulator, enhancing therapeutic effects in 
poorly perfused tumors while having no or even a deleterious effect on well-perfused 
tumors. By performing window-of–opportunity trials aimed at the pre-selection of 
patients most likely to benefit, these potentially deleterious effects could possibly be 
minimized, while optimizing the chance of a positive effect for the individual patient [12].  
When studying the uptake of fluorinated 2-nitroimidazoles, a point of concern is the 
definition of a meaningful variation in uptake. HX4 is a relatively new tracer which has 
been shown in a rat tumor model to have a favorable pharmacokinetic profile 
compared to other tracers. An adequate spatial reproducibility of HX4 uptake in rats has 
also been found earlier [39, 40]. Reproducibility of HX4 uptake in humans was also 
tested and a high stability of SUV, TBR, hypoxic volume and hypoxic fraction values was 
found. Applying the coefficient of repeatability of 17% for the HX4-TBR and 7.8% for the 
hypoxic fraction at a threshold of TBR>1.4 for hypoxia, we still see a meaningful decline 
in high hypoxic fraction in about one third of the hypoxic volumes. When looking at the 
CoR determined by Zegers et al, it should also be noted that this was a multicenter 
study with a median post-injection scan interval of only 99 minutes and short 
acquisition time per bed position, while we performed imaging at the optimal scanning 
time point at 4 hours for HX4 using a prolonged acquisition per bed position [41]. This 
means the CoR of 17% will most probably be an overestimation when compared to our 
current single-center, single scanner series with a median post-injection scan–time of 4 
hours [17]. 
In our study, we found that smaller tumor volumes were less likely to be classified as 
hypoxic. Whether this is a true finding or one merely caused by the limited spatial 
resolution of PET-scanning is unknown. There were also only a limited number of 
patients who were able to undergo all HX4 and DCE-CT scans, which is due to logistic 
issues as well as patient acceptance of the burden of undergoing all scans. Since the 
above mentioned correlations between the effects of nitroglycerin on perfusion and 
hypoxia are based on a limited number of patients, these results must be interpreted 
with caution.  
Variations in the published DCE-CT scanning techniques and considerable interobserver 
variability have been reported when analyzing perfusion parameters. Therefore, a cut-
off for repeatability of the blood flow and blood volume parameters is difficult to 
establish from literature [42, 43]. To at least make our results as consistent as possible, 
all of our DCE-CT scans were performed under supervision of an experienced radiologist 
(MD), while one person (AE) analyzed all the acquired scans. Rigorous quality control of 
the imaging parameters and timing before analysis further limited the final number of 
scans deemed suitable.   
We also acknowledge the limitations of the in vitro studies. Investigating the interplay 
between mitochondrial oxygen consumption and a NO donor is difficult. While 
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investigating the mitochondrial respiration upon nitroglycerin exposure we gave a single 
exposure of nitroglycerin solution, which does not correlate with the clinical situation in 
which a NO donor is administered continuously for hours every day. This is because our 
cell system is not optimized to give a low concentration in combination with a gradual 
exposure and clearance of the nitroglycerin. Additionally, for nitroglycerin often 
stabilizers in the form of saccharides are used which can bias effects on mitochondrial 
respiration. Concentrations of nitroglycerin (352 pM), corresponding with the observed 
plasma concentrations by McAllister et al. [21], exposure did not result in a decreased 
mitochondrial respiration in our experiments; even increasing the dose 100.000 fold to 
35.2 µM did not lead to a significant decrease of the oxygen consumption in cells. 
Additionally, due to the previously reported nitroglycerin tolerance, which already 
occurs after a time period of 3 hours of exposure, investigating long exposure of low 
nitroglycerin concentrations was not feasible [44].  
In spite of the above mentioned limitations, we have demonstrated that in a subgroup of 
hypoxic volumes there is a meaningful effect of nitroglycerin on the uptake of the 2-
nitroimidazole HX4 in human NSCLC, which is not due to an artefact on the cellular 
metabolism of 2-nitroimidazoles or an effect on the mitochondrial oxygen consumption 
rate, but correlates with an effect on perfusion in a subgroup of patients. Moreover, this 
perfusion effect seems to vary depending on the baseline tumor perfusion and 
oxygenation status, which is a point of concern when designing and interpreting the 
results of clinical trials investigating nitroglycerin as an adjunct to standard treatment. 
The actual effect in terms of improvement of individual tumor control and survival 
remains to be determined in the analysis of clinical trial NCT01210378. Also, the 
influence of intra-tumor heterogeneity with respect to hypoxia and perfusion on the 
potential results of nitroglycerin treatment remains to be determined. The current 
results do support the hypothesis that hypoxia scans and/or DCE-CT scans could form a 
tool to select patients for treatment with a nitroglycerin patch adjuvant to anti-cancer 
treatment (radiotherapy, chemotherapy, targeted agents or immunotherapy) to increase 
drug uptake and/or decrease hypoxia. Since the current procedure of scanning and 
evaluating the effects of nitroglycerin in individual patients using multiple scans is 
burdensome and laborious, future research should also be aimed at identification of 
subjects using single scans, radiomics-based signature and/or blood biomarkers [45, 46].  
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Material and Methods 
Clinical experiments 
Patient’s characteristics and study design  
Patients diagnosed with non-small cell lung cancer stage Ib-IV referred to Maastro Clinic 
for radical radiotherapy were eligible for inclusion in trial NCT01210378. In this trial, 
standard radiotherapy is combined with a nitroglycerin patch (Transiderm Nitro 5 mg, 
Novartis) on each day of irradiation. These patches are placed on hairless skin. They 
contain 25 mg/10 cm2 and release 0.2 mg of nitroglycerin per hour. Patient 
characteristics are summarized in Supplementary Table S2. To study the mechanisms 
underlying a potential treatment effect, patients enrolled in this trial were also 
requested to undergo facultative scans to measure the effect of nitroglycerin on both 
tumor hypoxia and perfusion. Hypoxia was evaluated by hypoxia PET-scans using the 2-
nitroimidazole [18F]-HX4 (flortanidazole, 3-[18F]fluoro-2-(4-((2-nitro-1Himidazol-1-
yl)methyl)-1H-1,2,3-triazol-1-yl)-propan-1-ol, from here on referred to as HX4). Tumor 
perfusion was investigated by dynamic contrast enhanced CT-scanning (DCE-CT).  
Prior to the start of radiotherapy DCE-CT and HX4 scans were made to measure 
baseline tumor perfusion and hypoxia, respectively. At least 48 hours later these DCE-CT 
and HX4 scans were repeated, the so-called nitroglycerin scans, at a minimum of 1 hour 
after application of a Transiderm Nitro 5 mg patch, following the window-of-
opportunity concept (Fig. 6) [12].  
 
 
Figure 6. Flow chart of study design.  
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HX4 PET image acquisition 
The production of HX4 has been extensively described in previous publications [14-18, 
39, 40, 47-49]. Four hours after intravenous injection of 429±57 MBq of HX4 a PET/CT 
scan was performed consisting of a single bed position centered on the primary tumor 
(Gemini TF 64 scanner, Philips Healthcare, Best, the Netherlands). Spatial resolution was 
+/-5 mm FWHM. CT-based attenuation correction and scatter correction (SS-SIMUL) 
was performed and PET images were reconstructed using 3D-ordered subset iterative 
time-of-flight reconstruction (BLOB-OS-TF) with 3 iterations and 33 subsets in a 144 x 
144 matrix with voxel sizes of 4 x 4 mm. Patients were scanned in treatment position for 
both imaging modalities were positioned using a laser alignment system on a flat 
tabletop with their arms resting in an arm rest positioned above the head.  
DCE-CT-image acquisition 
DCE-CT scans were acquired as previously described [15]. We used a second-generation 
dual source CT scanner (SOMATOM Definition Flash; Siemens Healthcare). Patients 
received 60 or 65 ml of iodinated contrast medium (Iopromide 300; Bayer Healthcare, 
Berlin, Germany) at a flow rate of 7 ml/s (iodine delivery rate 2.1 g/s), followed by a 
saline chaser of 30 or 40 ml at the same flow rate. The scan consisted of a first pass 
volumetric perfusion acquisition with a serial acquisition every 1.5 s at 80 kVp of the 
part of the thorax centered on the primary tumor (scan length 12 cm) for a period of 
approximately 50 seconds (33 consecutive scans). Patients were imaged in expiration 
breath-hold and asked to continue shallow breathing if holding their breath was no 
longer possible.  
Reconstruction was done using a B20f filter with a slice thickness of 5 mm and a slice 
increment of 3 mm. CT images were registered afterwards to correct for breathing 
motion, a noise reduction was performed and a deconvolution approach was used for 
the kinetic modelling of the perfusion parameters implemented in commercially 
available software (Siemens VPCT body; Siemens Healthcare). 
Tumor delineation and image analysis 
In each patient the gross tumor volume of the primary tumor (GTVp) and the involved 
lymph nodes (GTVln) were delineated and checked by at least 2 radiation oncologists on 
a planning FDG PET/CT scan. We performed a rigid registration of the planning CT to the 
HX4/ CT to enable the use of the GTVs on the HX4 PET/CT and a registration of the DCE-
CT blood flow and blood volume maps to the planning CT. The registration software was 
developed in-house [50]. For HX4 image analysis, the mean uptake of HX4 in a volume 
of interest in the aorta was chosen as background. GTVp and GTVln were analyzed 
separately. We determined the following values for each patient: maximum and mean 
standardized uptake values (SUVmax and SUVmean) of HX4 and the maximum tumor-to-
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blood ratio (TBR), defined as the SUVmax in GTVp and/or GTVln divided by the SUVmean in 
the aorta.  
A TBR>1.4 was chosen as the cut-off signal intensity defining presence of hypoxia [17, 
18]. The fraction and volume of a GTV with a TBR>1.4 was considered as the HX4 high-
uptake fraction (HX4-HF) and HX4 high-uptake volume (HX4-HV), respectively. For the 
DCE-CT imaging the average perfusion parameters blood flow (ml/100 ml/min) and 
blood volume (ml/100 ml) were calculated within GTVp. 
Molecular experiments 
Cell culture 
Human non-small cell lung adenocarcinoma H522 cells were cultured in RPMI 1640 
(Lonza). Human non-small lung carcinoma cell lines H1299 wild-type and H1299 
overexpressing the bacterial nitroreductase NfsA (H1299 NfsA) (kindly provided 
by Adam Patterson, Auckland University, New Zealand) were cultured in high glucose 
(4,5g/L) DMEM (Lonza). NfsA overexpression in H1299 cells was obtained via a method 
as described by Prosser et al. [51]. Both media types were supplemented with 10% fetal 
bovine serum (Sigma-Aldrich).  
Cellular respiration assays  
Oxygen consumption rates (OCRs) were determined using an extracellular Flux analyzer 
(Seahorse XF96, Seahorse Bioscience). In a 96-well XF96 cell culture plate 3.0 x 104 H522 
and 1.5 x 104 H1299 or H1299 NfsA cells/well were seeded respectively in 80 μl culture 
medium and placed in a 5% CO2 incubator at 37°C to attach. Medium was exchanged to 
DMEM containing 2 mM L-glutamine and either 10 mM glucose or galactose medium in 
order to prime the cells to use oxidative phosphorylation. The microplates were placed 
20 hours in a 5% CO2 incubator at 37 °C. Culture medium was exchanged 30 minutes 
before the assay with 175 μl assay medium containing 175 μl biocarbonate-free DMEM 
pH 7.35 +/- 0.05 (Sigma-Aldrich) supplemented with 1.85 g/L NaCl (Sigma-Aldrich), 2 
mM L-glutamine (Gibco) and 3 mg/L Phenol Red (Sigma-Aldrich) and containing either 
10 mM of glucose or galactose. Plates were placed in a CO2-free incubator at 37°C. 
Here, prior to the first injection, baseline OCR was determined using a mixing period of 
5 minutes and a measurement time of 3 minutes followed by 3 loops of mixing and 
measuring for 3 minutes each. Medium containing vehicle (purified water) or 
nitroglycerin (352 pM, 352nM and 35.2 µM) (both kindly provided by Novasep) were 
injected followed by several mixing and measurements cycles.  
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In vitro assessment of pimonidazole binding by flow cytometry  
Cells (H1299 and H1299 NfsA) were seeded in a 6-wells plate at a density of 2.5x104 
cells per well. The day after, cells were incubated for 16 hours under normoxic (21% O2, 
37°C) or hypoxic (0.2% O2, 37°C) conditions. This was followed by the exposure to 35.2 
µM nitroglycerin (8 mg/l) or vehicle to the cells for 1 hour under either normoxia or 
hypoxic conditions. Note: a normal plasma concentration achieved by a Transiderm 
Nitro 5 mg patch is 0.16 ± 0.03 μg/l [21]. Subsequently, cells were incubated for 2 hours 
under either normoxia or hypoxia with 20 µM pimonidazole (Bio-connect) followed by 
trypsinization and fixation with (4% PFA) for 1 hour at room temperature. Cells were 
washed with PBS containing 1% BSA, permeabilized with 0.2% Triton X-100 in PBS for 30 
minutes at RT. Subsequently samples were incubated with 10% BSA in PBS for 30 
minutes at room temperature after which they were incubated with a rabbit anti-
pimonidazole antibody (Hypoxyprobe) (1:50) in PBS 1% BSA for 2 hours at 37°C. 
Samples were washed with PBS and incubated with a goat anti-rabbit Alexa 488 
antibody (1:500) for 30 minutes. After 3 times washing with PBS containing 1% BSA cells 
were resuspended in 1% BSA containing PBS and FACS analyses were performed.   
Statistics 
The clinical data are reported as median ± 1 standard deviation (SD). Differences 
between paired measurements were assessed using the Wilcoxon Signed rank test. 
Correlation coefficients were calculated using Spearman’s correlation coefficient (SPSS, 
IBM, Germany). The results of the molecular experiments were presented as median ± 
range of at least 3 individual experiments. Means were compared using a Mann-
Whitney-U-test (SPSS, IBM, Germany). For both the clinical data as the molecular data 
p-value of ≤0.05 was assumed to be statistically significant.  
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Supplementary data 
 
Supplementary Figure S1: Perfusion parameters in 13 patients with both a baseline DCE-CT scan and DCE-CT 
scan after nitroglycerin.  
A= tumor blood flow at baseline (blue columns) vs after nitroglycerin per patient. B= tumor blood volume at 
baseline (blue columns) vs after nitroglycerin per patient. Green columns= increase, Red columns= decrease.   
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Supplementary Figure S2. Nitroglycerin at plasma concentrations does not affect cellular respiration upon
galactose exposure.  
Relative inhibition of mitochondrial respiration of H1299, H1299 NfsA or H522 cells upon treatment with
nitroglycerin (NG, 352 nM or 35.2 µM) compared to vehicle (VC). Measurements were normalized for protein
concentration and the percentage of baseline OCR before adding nitroglycerin or vehicle. Results are shown
for median ± range of at least 3 independent experiments.  
 
Supplementary Table S1. Overview of the performed scans and analyses 
Scans Number of 
patients 
Analysis 
Baseline HX-4 PET 32 Baseline hypoxia in GTVp and GTVln 
Baseline HX-4 PET + Nitroglycerin HX4 PET 25 Nitroglycerin effect on hypoxia in GTVp and 
GTVln 
Baseline DCE-CT 22 Baseline perfusion in GTVp 
Baseline DCE-CT + Baseline HX-4 PET 20 Correlation between baseline hypoxia and 
perfusion in GTVp 
Baseline DCE-CT + Nitroglycerin DCE-CT 13 Nitroglycerin effect on perfusion in GTVp  
Baseline DCE-CT + Baseline HX-4 PET + 
Nitroglycerin DCE-CT + Nitroglycerin HX4 PET 
12 Correlation between nitroglycerin effect on 
perfusion and effect on hypoxia in GTVp  
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Supplementary Table S2. Patient characteristics 
Parameters   Cases (n) Percentage (%) 
Number of patients 34 
Age years, median ±SD (range) 62±11 (40-82) 
Gender 
Male 21 62 
Female 13 38 
WHO-PS 
0 6 18 
1 28 82 
Smoking status 
Active 6 18 
Quit 26 76 
Never 1 3 
Unknown 1 3 
Stage        
I 2 6 
II 2 6 
III 19 56 
IV 11 32 
T-stage 
x 1 3 
1 0 0 
2 10 29 
3 10 29 
4 13 38 
N-stage 
0 7 21 
1 1 3 
2 13 38 
3 13 38 
M-stage 
M0 23 67 
M1a 4 12 
M1b 7 21 
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Abstract 
Glutathione transferases (GSTs) are often overexpressed in tumors and frequently 
correlated to bad prognosis and resistance against a number of different anticancer drugs. 
To selectively target these cells and to overcome this resistance we previously have 
developed prodrugs that are derivatives of existing anticancer drugs (e.g., doxorubicin) 
incorporating a sulfonamide moiety. When cleaved by GSTs, the prodrug releases the 
cytostatic moiety predominantly in GST overexpressing cells, thus sparing normal cells 
with moderate enzyme levels. By modifying the sulfonamide it is possible to control the 
rate of drug release and specifically target different GSTs. Here we show that the newly 
synthesized compounds, 4-acetyl-2-nitro-benzenesulfonyl etoposide (ANS–etoposide) and 
4-acetyl-2-nitro-benzenesulfonyl doxorubicin (ANS–DOX), function as prodrugs for GSTA1 
and MGST1 overexpressing cell lines. ANS–DOX, in particular, showed a desirable 
cytotoxic profile by inducing toxicity and DNA damage in a GST-dependent manner 
compared to control cells. Its moderate conversion of 500 nmol/min/mg, as catalyzed by 
GSTA1, seems hereby essential since the more reactive 2,4-dinitrobenzenesulfonyl 
doxorubicin (DNS–DOX) (14000 nmol/min/mg) did not display a preference for GSTA1 
overexpressing cells. DNS–DOX, however, effectively killed GSTP1 (20 nmol/min/mg) and 
MGST1 (450 nmol/min/mg) overexpressing cells as did the less reactive 4-
mononitrobenzenesulfonyl doxorubicin (MNS–DOX) in a MGST1-dependent manner (1.5 
nmol/min/mg) as shown previously. Furthermore, we show that the mechanism of these 
prodrugs involves a reduction in GSH levels as well as inhibition of the redox regulatory 
enzyme thioredoxin reductase 1 (TrxR1) by virtue of their electrophilic sulfonamide 
moiety. TrxR1 is upregulated in many tumors and associated with resistance to 
chemotherapy and poor patient prognosis. Additionally, the prodrugs potentially acted as 
a general shuttle system for DOX, by overcoming resistance mechanisms in cells. Here we 
propose that GST-dependent prodrugs require a conversion rate “window” in order to 
selectively target GST overexpressing cells, while limiting their effects on normal cells. 
Prodrugs are furthermore a suitable system to specifically target GSTs and to overcome 
various drug resistance mechanisms that apply to the parental drug. 
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Introduction 
Cancer is one of the leading causes of death in privileged countries. In patients suffering 
from cancer, the choice of therapy depends on several factors, such as the 
histopathology of the tumor, the stage of the disease, and the patient’s condition. 
Chemotherapy is commonly used as anticancer treatment, but patients often suffer from 
severe side effects, which are of major concern. Especially highly proliferating cells, 
present in the bone marrow, hair follicles, and gastrointestinal mucosa, are affected by 
conventional chemotherapeutics leading to common side effects like myelosuppression, 
alopecia, and mucositis [1]. Further, there are additional and more specific side effects 
depending on the cytostatic drug used. Doxorubicin (DOX), e.g., a common 
topoisomerase II inhibitor that is used to treat patients with different solid and 
hematological malignancies, can also cause cardiotoxicity [2] and eventually congestive 
heart failure [3]. Another major problem that can limit the effectiveness of cancer 
treatment is drug resistance. Drug resistance is related to numerous changes in the 
tumor and its microenvironment [4] and can reflect both tumor and normal tissue [5]. An 
approach to reduce side effects and drug resistance is the usage of prodrugs. Prodrugs 
are chemically modified, preferably nontoxic, versions of the active anticancer agent. 
Upon entrance into cancer cells the prodrug can be activated whereupon the active 
cytostatic molecule is released. Activation is typically catalyzed by an enzyme that is 
highly abundant in cancer cells, leading to predominant high concentrations in tumor 
cells while sparing normal cells [6].A suggested enzyme family to be targeted to activate 
prodrugs in cancer cells is glutathione transferases (GSTs) [7-15]. The GSTs are often 
highly overexpressed in tumors and frequently correlated to drug resistance and bad 
prognosis [16, 17]. GSTs are divided into three different groups, cytosolic, mitochondrial, 
and microsomal GSTs, each containing various isoforms. These isoforms have specific as 
well as overlapping substrate specificities in catalyzing conjugation, reduction, and 
isomerization reactions, thereby contributing to cellular protection against chemical 
insult, oxidative stress, and lipid peroxidation. Furthermore, GSTs are suggested to have 
essential functions in cell signaling [12, 15, 18-20]. 
In an attempt to take advantage of the overexpression of GSTs in different tumors we 
previously presented a new strategy using two different forms of prodrugs that can be 
activated and thereby release DOX in GST overexpressing cells. We showed that these 
prodrugs, 4-mononitrobenzenesulfonyl doxorubicin (MNS–DOX) and 2,4-dinitrobenzene-
sulfonyl doxorubicin (DNS–DOX), could be activated by two different GSTs, microsomal 
glutathione transferase 1 (MGST1) and glutathione transferase pi (GSTP). MGST1, which is 
located in the ER membrane, and the outer membrane of mitochondria as well as the 
cytosolic GSTP are often overexpressed, connected to drug resistance and correlated to 
bad prognosis in many different cancers. Our study showed that the prodrugs tested were 
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more toxic to GST overexpressing cells compared to control cells, indicating that the GSTs 
tested could activate the prodrugs and release DOX [8]. 
 
 
Figure 1. Chemical structures and conversion of prodrugs.  
A. Chemical structures of DOX and etoposide as well as the prodrugs MNS–DOX, DNS–DOX, ANS–DOX, and 
ANS–etoposide are depicted. B. Conversion of the prodrug yields a free doxorubicin/etoposide, sulfur dioxide
and an acetylmononitro/dinitro benzene moiety conjugated to GSH. These prodrugs are hypothesized to
enter the cell via a passive diffusion. In the cell, GSTs are able to activate the prodrugs via their sulfonamidase
and sulfonamide cleavage activity. 
 
To follow up on these findings we herein expanded our efforts to glutathione 
transferase alpha 1 (GSTA1) and included the newly synthesized DOX derivative 4-
acetyl-2-nitro DOX (ANS–DOX) in the study (Fig. 1). GSTA1 is expressed in most cells at 
moderate levels and has been shown to possess both GST and glutathione peroxidase 
activity protecting against oxidative stress [15]. However, GSTA1 has also been shown to 
be overexpressed in various cancers such as colon cancer [21], lung cancer [22, 23], 
exfoliated human bladder cancer[24], and clear cell renal cell carcinoma [25] and is 
connected to nitrogen mustard and Bleomycin resistance [26, 27]. Overexpression was 
furthermore found to support proliferation of cells in benign adrenocortical adenomas 
from patients with Cushing’s syndrome [28]. In contrast to MGST1 and GSTP1, GSTA1 
overexpression was not associated with a major resistance to doxorubicin [29, 30], thus 
potentially being a more effective enzyme to target for these prodrugs. 
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Scheme 1. Synthesis of ANS–DOX (1) and ANS–Etoposide (2); See Materials and Methods for Details 
 
Furthermore, the prodrug concept may include additional functional facets contributing 
to its cytotoxic profile, which we wished to address within this study. An efficient 
accumulation and activation within the cancer cell, for example, might lead to GSH 
depletion, which in turn sensitizes the cells to the activated drug or induces oxidative 
stress as a concomitant factor. Additionally, intracellular nucleophiles other than GSH 
might be efficiently targeted due to the electrophilic nature of the sulfonamide bond in 
the prodrugs. A prime candidate is the selenoprotein thioredoxin reductase 1 (TrxR1), 
which is the central enzyme of the redox regulatory and antioxidant thioredoxin (Trx) 
system. It is often upregulated in cancers and has been identified as a promising target 
for anticancer therapy [31]. Due to an accessible and highly reactive Sec-residue within 
its active site, it is considered to be a target of many electrophilic compounds with 
TrxR1 inhibition being linked to cancer cell death [32]. Reducing the antioxidant capacity 
of cancer cells through targeting of the Trx and GSH systems simultaneously has 
previously been suggested as a principle of anticancer therapy and might thus be 
synergistic factors contributing to prodrug induced toxicity [33-35]. 
In addition, we investigated whether etoposide could be converted into a novel prodrug 
using a similar strategy as for DOX. The parental compound etoposide is used as a 
cytostatic drug for the treatment of Ewing’s sarcomas, lung cancer, lymphomas, and, in 
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addition, in combination with carboplatin to treat primary brain tumors such as 
glioblastomas [36-40]. Etoposide can act against topoisomerase II and thereby influence 
the chromosome segregation and replication in the exposed cancer cell resulting in 
apoptosis [40, 41] A major problem with etoposide is that it can induce major side 
effects such as bone marrow suppression, fatigue, skin rash, diarrhea, severe delayed 
toxicity, and even leukemia. It is therefore an attractive candidate for the development 
of prodrugs to potentially reduce these side effects [42, 43]. 
In this study we show that GSTs are a suitable enzyme class for the development of novel 
prodrugs and that different GSTs can be targeted selectively. Specifically, we synthesized 
and characterized a new derivative of DOX, ANS–DOX as substrate for various GST, and 
studied its potential as prodrug in both GSTA1 and MGST1 overexpressing cells. 
Additionally, we show that the working mechanism of prodrugs involves a reduction of 
the GSH levels as a consequence of activation, as well as disruption of redox regulatory 
pathways via TrxR1 inhibition, which might synergize with the mechanism of the 
activated drug and augment toxicity toward cancer cells. We also ascertained whether 
etoposide is a suitable candidate for the development of novel prodrugs by 
characterizing the etoposide based prodrug, 4-acetyl-2-nitro-benzenesulfonyl etoposide 
(ANS–etoposide), in the same cellular systems. In summary, our data show that the GST 
catalyzed conversion rate can be precisely manipulated by adjusting the reactivity of the 
prodrugs; this is also shown to be important for both GST specificity and cell killing 
potential. Additionally, we suggest that prodrugs may overcome multiple drug resistance 
mechanisms and that they can target redox pathways, particularly those regulated via 
TrxR1, thus potentially targeting cancer cells that are resistant to the parental drug. 
Materials and Methods 
Chemicals and Growth Media 
Cell culture media and additives, including Dulbecco’s modified Eagle’s medium (DMEM), 
Fetal Bovine Serum (FBS), Geneticin (G418), Phosphate-Buffered Saline (PBS), and 
penicilin–streptomycin were obtained from GIBCO. Hygromycin B was obtained from 
Invitrogen. 1-Chloro-2,4-dinitrobenzene (CDNB), reduced glutathione, and doxorubicin 
were purchased from Sigma-Aldrich, whereas etoposide was purchased from Vepesid, 
Bristol-Myers. Coommassie Plus protein assay was purchased from Thermo Scientific. 
Horseradish peroxidase labeled goat antirabbit IgG was obtained from DakoCytomation. 
Other reagents for SDS-polyacrylamide gel electrophoresis and Western blot analysis 
were obtained from Sigma-Aldrich. Development of the blots was done by the usages of 
Amersham EL Western blotting reagents obtained from GE healthcare. Additionally, 3-
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(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and crystal violet were 
purchased from Sigma-Aldrich. 
Synthesis of the prodrugs 
Prodrugs were synthesized as depicted in Scheme 1 for ANS–DOX (upper panel) and 
ANS–etoposide (lower panel). DNS–DOX was synthesized as previously described by 
Johansson et al.[8] Emission spectra were obtained using an EnSpire 2300 Multilabel 
Reader (PerkinElmer). All spectra were measured in a 96-well optical bottom plate 
(Fisher Scientific, #265301) with 10 μM DOX, ANS–DOX, and DNS–DOX in a 200 μL 
volume. Measurements were taken at room temperature in 0.1 M potassium 
phosphate buffer pH 6.5. Excitation wavelength was 480 nm, and emission was 
recorded between 500 and 700 nm. 
Synthesis of ANS–DOX (1) 
N,N-Diisopropylethylamine (60 μL, 340 μmol) was added to a solution of doxorubicin 
hydrochloride (15 mg, 26 μmol) in dimethylformamide (520 μL) at 0 °C. 4-Acetyl-2-
nitrobenzenesulfonyl chloride (15 mg, 58 μmol) was added to the reaction mixture. 
After stirring for 2 h, the reaction mixture was diluted with CHCl3 and washed with 
saturated NaHCO3(aq). The organic layer was dried over Na2SO4 and evaporated in 
vacuo. The residue was purified by a neutral flash silica gel column chromatography and 
eluted with CHCl3–acetone (3:1, v/v) to give the desired ANS–DOX (12 mg, 16 μmol, 
60%). 1H NMR (500 MHz, DMSO-d6): δ 8.26 (1H, s, AcNs), 8.16 (1H, d, dox, J = 1.8 Hz), 
8.14 (1H, d, dox, J = 1.8 Hz), 8.11–8.10 (1H, d, AcNs, J = 8.0 Hz), 8.10–8.08 (1H, d, AcNs, J 
= 8.0 Hz), 7.86–7.80 (2H, m, dox), 7.59–7.58 (1H. d, dox, J = 8.6 Hz), 5.38 (1H, s, dox), 
5.15 (1H, s, dox), 4.82–4.83 (1H, t, dox), 4.55 (2H, s, dox), 4.11–4.07 (1H, d-d, dox, J = 
6.9, 6.3 Hz), 3.96 (3H, s, dox), 3.62–3.57 (1H, d-q, dox, J = 4.5, 4.5, 5.1, 4.0 Hz), 3.50 (1H, 
s, dox), 2.90–2.89 (2H, d, dox, J = 6.3 Hz), 2.47 (1H, s, dox), 2.12–2.07 (2H, m, dox), 
1.93–1.87 (1H, s-t, dox, J = 4.6, 3.4, 4.6 Hz), 1.40–1.37 (1H, d-d, J = 5.1, 5.1 Hz), 1.21 
(3H, s, AcNs), 1.09–1.08 (3H, d, dox, J = 5.7 Hz), 1.17–1.16 (1H, t, dox). 13C NMR (125 
MHz, DMSO-d6): δ214.21, 195.984, 186.90, 186.85, 161.25, 156.56, 154.86, 147.94, 
140.73, 137.79, 135.84, 135.07, 134.56, 131.96, 130.54, 124.26, 120.40, 119.45, 
111.15, 111.09, 100.33, 79.71, 75.41, 70.47, 69.39, 67.19, 64.16, 57.07, 56.36, 50.82, 
32.66, 32.61, 30.13, 27.37, 17.46. LRMS (ESI) m/z: [M – H–] calcd for C35H34N2O16S, 
770.16; found, 769.04. 
Synthesis of ANS–Etoposide (2) 
Etoposide (10 mg, 17 μmol) was dissolved in CH2Cl2 (200 μL). To the solution was added 
Et3N (3 μL, 34 μmol) and 4-acetyl-2-nitrobenzenesulfonyl chloride (5 mg, 19 μmol), and 
the mixture was stirred at room temperature for 30 min. The mixture was purified by 
preparative layer chromatography eluted with EtOAc/toluene (3:1, v/v) to give the 
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desired ANS–etoposide (10 mg, 12 μmol, 71%). 1H NMR (300 MHz, CDCl3): δ 8.38 (1H, 
s), 8.22 (1H, s), 6.85 (1H, s), 6.53 (1H, s), 6.24 (2H, s), 6.03–6.00 (2H, dd, J = 0.98, 7.81), 
4.93 (1H, d, J = 3.42), 4.77 (1H, q, J = 4.88), 4.66 (2H, dd, J = 7.32, 11.23), 4.44 (1H, t, J = 
9.23), 4.29 (1H, t, J = 8.30), 4.21 (1H, dd, J = 3.91, 11.23), 3.72–3.27 (12H, m), 2.85–2.82 
(6H, m), 1.41 (3H, d, J = 5.37). 13C NMR (75 MHz, CDCl3); δ 194.5, 174.7, 152.2, 148.9, 
148.4, 147.5, 141.2, 139.8, 135.1, 131.7, 130.9, 128.5, 127.2, 124.1, 123.9, 110.6, 109.1, 
107.6, 101.8, 79.7, 74.5, 73.1, 68.0, 66.4, 56.0, 41.1, 37.5, 26.9, 20.2. LRMS (ESI) m/z: 
[M + Na+] calcd for C37H37NNaO18S+, 838.16; found, 838.47. 
Activation of prodrugs 
The conversion of DNS–DOX and ANS–DOX to DOX was measured using a Shimadzu RF 
510L fluorescent spectrophotometer from Analytical Instruments Division, Kyoto Japan, 
using an excitation at 480 nm and emission at 550 nm. The enzymatic activation of 
ANS–DOX (10 μM) or DNS–DOX (10 μM) to DOX by GSTA1 and GSTP1 (kind gift from B. 
Mannervik, Stockholm University) was determined in 0.1 M potassium phosphate buffer 
(pH 6.5) with 5 mM GSH. For MGST1, 0.1 M potassium phosphate buffer pH 6.5 
containing 0.1% Triton X-100 and 5 mM GSH was used. A standard curve of 0.025, 0.05, 
0.1, 0.25, 0.5, 0.1, and 2.5 μM DOX was constructed to convert the increase in 
fluorescence to a metabolic rate. All measurements were taken in triplicate. 
Measurement of GST activity with CDNB 
The specific activity of all purified enzymes was measured in a 100 μL cuvette with a 
Cary 60 UV–visible spectrophotometer (Agilent Technologies, Santa Clara, USA) by 
following the change in absorbance at 340 nm. For MGST1, 5 mM GSH (Sigma-Aldrich, 
St. Louis, MO) and 0.5 mM CDNB (Merck, Darmstadt, Germany) as second substrate 
were used, respectively, in 0.1 M potassium phosphate buffer pH 6.5 containing 0.1% 
Triton X-100. The molar extinction coefficient used for CDNB conjugation was 9.6 mM–
1cm–1[44]. GSTA1 and GSTP1 were measured with 1 mM GSH and 1 mM CDNB in 0.1 M 
potassium phosphate buffer pH 6.5 at 30 °C. The change in absorbance, after correction 
for the nonenzymatic reaction, was used to calculate the concentration of the active 
enzyme based on previously published values. All measurements were taken in 
triplicate, and slopes were fitted using the Cary WinUV software package (Agilent 
Technologies, Santa Clara, USA). 
To study the involvement of MGST1 in drug resistance, the MCF7 cells (human 
mammary adenocarcinoma) were used. The cells were either transfected with a vector 
overexpression rat MGST1 or a control vector expressing an antisense sequence against 
rat MGST1, as described previously [7]. To study GSTA1, V79 cells (Chinese hamster lung 
fibroblasts) were used. These cells were stably transfected with a vector overexpressing 
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GSTA1, and the activity of these was compared with cells expressing control vectors. 
The GSTA1 containing pCEP4GSTA1 vector is based on the mammalian expression 
vector pCEP4 (Invitrogen, Inc.) and was used to transfect the V79MZ clone of the V79 
cells using a FuGENE6 reagent. The construction of these cells was previously described 
in Sundberg et al. [45]. These cell lines were cultured in DMEM, supplemented with 10% 
fetal bovine serum (FBS), 100 U/mL penicillin–100 μg/mL streptomycin (PEST), and 1 
mM sodium pyruvate. Additionally 1 mg/mL Geneticin (G418) or 100 μg/mL hygromycin 
was added for selection for the MCF7 or V79 cells, respectively. Targeting of TrxR1 by 
the prodrugs was studied in V79 and GSTA1 overexpressing V79 cells as well as in 
HEK293 cells (human embryonic kidney). HEK293 cells were cultured in EMEM (Eagle’s 
Minimum Essential Medium, ATCC no. 30-2003). Growth media was supplemented with 
10% FBS, PEST, and 25 nM sodium selenite. All cells used in this study were cultured in a 
humidified environment at 37 °C and with a 5% CO2 level. 
Protein determination and Western Blotting (WB) 
Cells were cultured in a T-75 cm2 bottles. When the cells reached 70% confluence, they 
were washed with 1× PBS, trypsinized, and resuspended in culture media. The cells 
were centrifuged for 5 min at 2000 rpm, and the formed pellet was resuspended in lysis 
buffer (0.1 M potassium phosphate buffer pH 7.5 containing 1% Triton X-100 and 1% 
SDS). The samples were kept on ice during the whole procedure. The cell suspension 
was transferred into a 1.5 mL Eppendorf tube. Subsequently, the sonication was 
performed using the Soniprep 150 MSE, the duration of 10 s, for 3 times at 6 A on ice. 
The protein determination was performed by using the Coomassie Plus protein assay by 
Thermo Scientific, Rockford, USA. Twenty micrograms of protein was loaded on a 15% 
SDS polyacrylamide gel in a WB system. After running the protein separation, the 
proteins were transferred to a nitrocellulose membrane, after which they are labeled 
using a polyclonal rabbit IgG against rat MGST1, which was generated in-house (R. 
Morgenstern), or against human GSTA1 (1:1000) (Fine chemicals AB Malmö, Sweden), 
as the primary antibody. As secondary antibody, horseradish peroxidase labeled goat 
antirabbit IgG obtained from DakoCytomation, Glostrup, Denmark, was used. The blots 
were developed by using Amersham EL Western blotting reagents obtained from GE 
Healthcare, Buckinghamhire, UK. 
GST Activity in isolated microsomes and total cell lysate 
MGST1 activity was determined in isolated microsomes. The microsomes were 
prepared by centrifuging the cells at 2000 rpm for 5 min and resuspended in distilled 
water containing 0.25 M sucrose and sonicated for 2 × 10 s at 4 A on ice. This 
suspension was further centrifuged for 10 min at 3000 rpm, followed by transferring the 
supernatant into a new Eppendorf tube. A mixture of 0.8 M CaCl2 and 0.5 M MgCl2 (1:1 
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Mg–Ca) was added and incubated for 10 min. The samples were then centrifuged for 10 
min at 7000 rpm, after which the cytosolic fraction in the supernatant was removed. 
The pellet, containing the microsomes was resuspended in 0.15 M Tris-HCl buffer (pH 8, 
containing 1 mM EDTA) and an additional 20 μL Mg–Ca mixture was added. 
Subsequently the samples were centrifuged for 10 min at 13000 rpm, and the pellet 
was resuspended in 0.25 M sucrose (in distilled water containing 1 mM EDTA, pH 7.5). 
The samples were kept on ice during the complete procedure. All centrifugation steps 
were performed at 4 °C. 
The activity of GSTA1 was measured in total cell lysate from GSTA1 overexpressing V79 
cells. The cells were centrifuged at 2000 rpm for 5 min, and the cell suspension was 
transferred into a 1.5 mL Eppendorf tube. The cell lysate from the V79 cells was obtained 
by the usage of a lysis buffer containing 0.1 M potassium phosphate buffer (pH 6.5) with 
1% Triton X-100. After which, the sonication was performed using the Soniprep 150 MSE 
for the duration of 10 s, for 3 times at 6 A on ice. The samples were kept on ice during the 
complete procedure. Afterward, the protein determination was performed by using the 
Coomassie Plus protein assay by Thermo Scientific, Rockford, USA. 
The enzymatic GST activity of isolated microsomes and total cell lysate was determined 
in 0.1 M potassium phosphate buffer pH 6.5 containing 0.1% Triton X-100 and 5 mM 
GSH. As substrate, 0.5 mM CDNB was used, and the reaction was carried out at room 
temperature. Absorbance change, representing the product formation rate, was 
measured at a wavelength of 340 nm, using a single beam, Philips PU 8700 UV/visible 
spectrophotometer (Philips Scientific and Analytical Equipment, Cambridge, UK). All the 
enzymatic activities were corrected for the nonenzymatic reaction. 
Short-term toxicity test 
To measure the short-term (24 h) cytotoxicity of the prodrugs in the cell lines, a MTT 
((3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)) test was used as 
previously described [7, 46]. Briefly, the cells were seeded at a density of 1 × 104 
cells/well for the MCF7 cells and 2 × 104 cells/well for V79 cell in a 96-well plate. After 1 
day, the cells were exposed to DOX, DNS–DOX, ANS–DOX, etoposide, ANS–etoposide, or 
vehicle (DMSO) for 24 h at various concentrations in DMEM without phenol red. After 
24 h the media was removed, and the cells were incubated in 0.5 mg/mL MTT for 4 h at 
37 °C. The formazan crystals formed were dissolved in DMSO. The absorbance was 
measured with a spectrophotometer at 590 nm minus reference at 650 nm[8]. 
Long-term toxicity test 
The colony forming efficiency (CFE) assay was used as a long-term (7 days) toxicity test 
to determine the MGST1 overexpressing cells ability to form colonies after the exposure 
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to the toxic agents [47]. The control cells and the MGST1 overexpressing MCF7 cells 
were seeded in a 6-well plate, with a density of 2000 cells per well. Twenty-four hours 
after seeding, the cells were exposed to DOX or ANS–DOX in serum-free DMEM (SFM) 
for 3 h at different concentrations. After the incubation period the SFM was changed to 
complete medium and refreshed at day 3. After 7 days the media was removed and 
cells were washed with PBS and analyzed with the CFE test. The cells were fixated with 
10% formaldehyde for 20 min and stained with 0.01% crystal violet for 5 min. Colonies 
were counted using a light-microscope (a colony ≥ 16 cells). Since the GSTA1 
overexpression V79 cells do not form proper colonies we used the MTT test to monitor 
the long-term effects of the drugs on these cells. These MTT tests were performed in 
the following manner: 200 cells per well were seeded on day 0 in complete medium in a 
96-well plate; subsequently, on day 2 the cells were exposed to DOX or ANS–DOX, in 
SFM for 3 h at different concentrations. Whereupon the medium was changed to 
complete medium, and the MTT assay was performed on day 7 as described above. 
Analysis of the uptake and activation of ANS–DOX in GSTA1 overexpressing cells 
The vector control cells and GSTA1 overexpressing cells were seeded in 96-well plates. 
After 24 h the cells were exposed to either 20 μM DOX or ANS–DOX for 15, 30, 60, and 
120 min. After the exposure cells were incubated with 40 ng/mL Hoechst for 30 min to 
stain the nuclei and subsequently fixated in 2% ice-cold paraformaldehyde for 10 min in 
RT. The wells were covered with PBS, and fluorescence was measured using the Operetta 
High Content Imaging System. For cell quantification, seven fields of view for each cell 
culture well, covering edges and center, were recorded in bright field and two channels 
for fluorescence detection of DOX (excitation, 500 nm; emission, 595 nm) and Hoechst 
(excitation, 380 nm; emission, 445 nm). The excitation and exposure times were fixed for 
each channel, with all samples analyzed with the same settings. Determinations of 
fluorescence signals were subsequently performed using the Columbus (PerkinElmer) 
and Excel (Microsoft) computer programs. 
Activation of DNA damage signaling 
The activation of DNA damage signaling in cells exposed to ANS–DOX and DOX was 
investigated by WB. GSTA1 overexpressing and control cells were exposed to either 0.2 
μM DOX or 2 μM ANS–DOX for different time periods or for 3 h with the different 
concentrations. After incubation with the drugs at indicated time-points or 
concentrations, the cells were washed with PBS and lysed in 0.1 M potassium 
phosphate buffer pH 7.5 containing 1% Triton X-100, 1% SDS, and phosphatase and 
protease inhibitors from Roche. Protein samples were run on a 12% SDS polyacrylamide 
gel in a WB system. The proteins were then transferred to a nitrocellulose membrane. 
For the primary antibodies phospho-histone H2AX (Ser139) antibody 1:500 (Cell 
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Signaling), phospho-p53 (Ser15) antibody 1:1000 (Cell signaling), and Cdk2 (M2) (Santa 
Cruz) antibody as loading control 1:1000 were used. As a secondary antibody the 
horseradish peroxidase labeled goat antirabbit IgG (DakoCytomation) was used. 
Development of the blots was done via using Amersham EL Western blotting reagents 
(GE Healthcare). 
Comet assay 
The levels of DNA damage were measured after 3 h exposure to either ANS–DOX (1 and 
5 μM) or DOX (0.02 and 0.1 μM). The alkaline version of the comet assay was 
performed as described previously by Jarvis et al.[48] At least 50 comets were scored 
per treatment performed in triplicates using a Leica DMLB fluorescent microscope and 
Comet Assay 3 (Perceptive Instruments Ltd., Haverhill, UK). 
GSH measurements and sensitization to DOX upon GSH reduction by BSO 
GSTA1 overexpressing V79 cells were seeded in a 6-well plate the day before exposure 
to either 5 μM ANS–DOX or DNS–DOX. After 2 or 6 h, respectively, cells were washed 
with PBS and incubated on ice for 30 min with KPE lysis buffer (containing 0.1 M 
potassium phosphate buffer pH 7.5, 11.2 mM EDTA, and 1% Triton X-100). Cells were 
scraped and centrifuged at 14000 rpm for 10 min at 4 °C. Sulfosalicylic acid (1.3%) was 
added, and samples were stored at −80 °C unƟl further usage. GSH content was 
determined as previously described by Rahman et al.[49] Protein concentrations were 
determined by using the Bradford assay (BioRad). 
To study DOX sensitization upon a reduction in GSH levels, V79 control cells were 
seeded at a density of 2.5 × 103 cells/well in a 96-well plate and allowed to attach 
overnight. Subsequently, cells were exposed to 250 μM BSO (dl-buthionine-sulfoximine, 
Sigma-Aldrich) to reduce the GSH content. After 24 h medium was replaced with DOX 
containing medium and incubated for another 24 h at 37 °C, 5% CO2. The medium was 
removed and a MTT assay was performed as described previously [8]. 
In vitro characterization of TrxR1 inhibition 
Rat TrxR1 and human Trx1 were recombinantly produced and purified essentially as 
described previously [50, 51]. TrxR1 activity was measured in TE buffer (50 mM Tris, pH 
7.5, 2 mM EDTA) using 250 μM NADPH as well as either wild-type Trx1/insulin or 
juglone (5-OH-1,4-naphthoquinone) as substrates. In contrast to the Trx1 coupled 
reduction of insulin, which requires an intact Sec-residue in the C-terminal active site, 
redox-cycling with juglone is essentially Sec-independent but requires an intact N-
terminal active site. The behavior of the enzyme, when targeted by an inhibitor, toward 
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both substrates can be used to indicate whether an inhibitor preferentially targets the 
Sec-residue, while leaving the rest of the enzyme essentially intact [52-54].) To assess C-
terminal Sec-dependent activity of TrxR1, 20 nM recombinant enzyme was incubated 
with either 10 μM DNS–DOX or ANS–DOX for 10 min at room temperature in the 
presence or absence of 250 μM NADPH. Subsequently, 10 μM wild-type Trx1 and 160 
μM insulin (and 250 μM NADPH to the samples where it is not present) were added, 
and the reaction was followed by measuring NADPH consumption via a change in 
absorbance at 340 nm. Sec-independent activity was studied by incubating 20 nM of 
recombinant TrxR1 with either 10 μM DNS–DOX or ANS–DOX for 10 min at room 
temperature in the presence of 250 μM NADPH, upon which 40 μM juglone was added 
and the reaction was followed at 340 nm. To study whether the products of the 
converted prodrugs (free doxorubicin, sulfur dioxide, or the acetylmononitro/dinitro 
benzene moiety conjugated to GSH, see Fig. 1) can target TrxR1, 10 μM DNS–DOX was 
incubated with 5 mM GSH and 50 nM GSTA1 for 30 min. Subsequently, 20 nM TrxR1 
and 250 μM NADPH were added, and the mixture was incubated for 10 more minutes. 
Finally, 10 μM wild-type Trx1 and 160 μM insulin were added, and the reaction was 
followed at 340 nm. 
TrxR1 activity in cell lysates 
A total of 2 × 106 HEK293, V79, or GSTA1 overexpressing V79 cells were seeded per dish 
(ø 10 cm). Approximately 48 h (HEK293 cells) or 24 h (V79 and GSTA1 overexpressing 
cells) after seeding, cells were exposed to the compounds as indicated for 3 h, harvested 
by trypsinization, and washed in cold PBS. The samples were centrifuged at 900g for 5 
min, and the resulting cell pellet was resuspended in lysis buffer (50 mM Tris, pH 7.5, 2 
mM EDTA, 1% Triton X-100, and phosphatase and protease inhibitors from Roche). After 
a 30 min incubation on ice, the cell extracts were cleared by centrifugation at 16,000g for 
20 min. Protein concentrations of the supernatants were determined using the Bradford 
reagent (Bio-Rad). Cellular TrxR1 activity was subsequently determined using a modified 
version of the earlier described end-point insulin assay [55]. Briefly, total cellular protein 
(20 μg for HEK293 cells or 15 μg for V79 and GSTA1 overexpressing cells) was incubated 
with 20 μM wild-type Trx1 in the presence of 160 μM insulin and 250 μM NADPH using 
TE buffer for 20 min at 37 °C in a total volume of 50 μL. Samples without additional Trx1 
in the reaction buffer served as a background control. The reaction was stopped by 
addition of 200 μL of 6 M guanidine–HCl (Acros Organics) with 1 mM DTNB. Absorbance 
was measured at 412 nm in a 100 μL cuvette using a Cary 60 UV–visible 
spectrophotometer (Agilent Technologies, Santa Clara, USA). Data were plotted as 
percentage of untreated control after background subtraction. 
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Statistical analysis 
The cytotoxicity study data were analyzed by performing an F-test for equal variances, 
followed by a two-tailed student t test. The GST activity, Comet assay, and TrxR1 
inhibition data were analyzed by using a two-tailed student t test. GraphPad prism 
software windows version 5.03 (GraphPad Software, 2009, California, USA) was 
employed in order to perform nonlinear regression analysis, and sequentially, curve 
comparisons were performed by using an extra sum F-test. 
Results 
MGST1, GSTP1, and GSTA1 catalyzed conversion of DNS–DOX and ANS–DOX to 
DOX 
The modifications in DOX that yield ANS–DOX and DNS–DOX conveniently quench the 
fluorescence intensity of DOX 10- to 20-fold (Figure 2A). Taking advantage of the 
fluorescence increase upon conversion to the more fluorescent DOX by MGST1, GSTP1, 
and GSTA1, we measured the specific activity for each enzyme. Catalytic rates were in 
general agreement with previous results for DNS–DOX (Fig. 2B)[8]. Oxidative activation 
of MGST1 or loss of activity of GSTP1 upon storage account for the differences 
observed. GSTA1, which was not yet tested with DNS–DOX, showed a very high 
turnover of 13780 ± 120 nmol/min/mg that by far exceeded the activity of MGST1 (463 
± 7 nmol/min/mg) and GSTP1 (18.7 ± 2 nmol/min/mg). Subsequently we measured the 
turnover of all enzymes with the DOX derivative ANS–DOX. Having a less electron 
withdrawing acetyl group, as is also reflected in the difference of the nonenzymatic 
conversion rates (Fig. 2C), ANS–DOX showed 10 to 30 times lower conversion rates for 
all enzymes compared to DNS–DOX as expected [56]. ANS–DOX was thus activated with 
a rate of 38.7 ± 0.2 nmol/min/mg by MGST1 and 493 ± 3 nmol/min/mg by GSTA1, 
whereas no activity could be measured for GSTP1 under the experimental conditions 
(Fig. 2B). The presence of Triton X-100, furthermore, did not alter the ratio of 
nonenzymatic reactivity for the compounds drastically, suggesting that solubility and 
lipophilicity is not a major factor (Fig. 2C). A conversion rate of the etoposide based 
prodrug ANS–etoposide by the purified enzymes was not determined as the molecule 
lacks fluorescence. 
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Figure 2. Emission spectra of DOX and its derivatives, second order rate constants for the nonenzymatic ANS–
DOX and DNS–DOX conversion, and the catalyzed conversion of ANS–DOX, DNS–DOX, and CDNB by MGST1, 
GSTP1, and GSTA1.  
A. Emission spectra of DOX (dark gray), DNS–DOX (medium gray), and ANS–DOX (light gray) in 0.1 M 
potassium phosphate buffer pH 6.5 using excitation at 480 nm. B. Specific activities of MGST1, GSTP1, and
GSTA1 were determined using 5 mM GSH and 10 μM ANS–DOX, 10 μM DNS–DOX, or 0.5 mM CDNB in 0.1 M 
potassium phosphate buffer pH 6.5 (without or with 0.1% Triton X-100 in the case of MGST1). The specific
CDNB activities of GSTP1 and GSTA1 were compared to literature values to determine the amount of active
enzyme in the preparations, which in turn was used to calculate the specific activity toward ANS–DOX and 
DNS–DOX. N.D., not detectable. Values are means ± SEM (n = 3). (C) Second-order rate constants for the 
nonenzymatic reaction (knoncat) were obtained in 0.1 M potassium phosphate buffer pH 6.5 (without or with 
0.1% Triton X-100), using 5 mM GSH as well as 10 μM ANS–DOX or DNS–DOX, respectively. Values are means 
± SEM (n = 3). 
GSTA1 overexpression amplifies ANS–DOX induced toxicity but has no effect on 
DOX and DNS–DOX toxicity 
Based on our finding that purified GSTA1 catalyzed the conversion of DNS–DOX much 
more efficiently (30-fold) than MGST1 (see Fig. 2B), we studied the effect of this DOX 
derivative and pure DOX in GSTA1 overexpressing cells. Overexpression was confirmed 
by WB and activity measurements (Fig. 3A). Using a short-term (24 h; MTT) as well as 
Chapter 7 
194 
long-term (7 days) viability test, no difference in DOX toxicity could be seen between 
V79 control and GSTA1 overexpressing cells (Fig. 3B). The same behavior was 
surprisingly observed when exposing cells to DNS–DOX, which showed no GSTA1-
dependent toxicity in a short-term viability test (24 h; MTT) despite its high catalytic 
efficiency (13780 ± 120 nmol/min/mg) (Fig. 3C). In contrast, the less reactive ANS–DOX 
variant (493 ± 2 nmol/min/mg) induced toxicity to a significantly greater extent in 
GSTA1 overexpressing compared to control cells in short-term (24 h; MTT) as well as 
long-term viability test (7 days) (Fig. 3D). 
 
 
Figure 3. Characterization of GSTA1 overexpressing cell lines and their response to DOX, DNS–DOX, and ANS–
DOX treatment.  
A. Left panel: Western blot of GSTA1. Lanes 1–2: purified human GSTA1; 5 and 10 ng. Lane 3: vector control
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cell line. Lane 4: GSTA1 overexpressing cell line. Right panel: Specific GST activity in cell extracts from GSTA1 
overexpressing and control V79 cells. Activity was measured using 0.5 mM CDNB and 5 mM GSH. Values are
means ± SEM (n = 3; **P ≤ 0.01). B-D Cellular toxicity of (B) DOX (log(−3) μM corresponds to 0 μM DOX 
treatment), (C) DNS–DOX, and (D) ANS–DOX for short-term (24 h) or long-term toxicity assay (7 days) with 
indicated doses determined with MTT assay. GSTA1 overexpressing V79 cells (dark gray/GSTA1) and the
vector control (light gray/control). Data are from at least three independent experiments done in triplicates (n 
≥ 9) (means ± SE) *P ≤ 0.05, **P ≤ 0.01, and ***P ≤ 0.001). Log(−2) μM corresponds to 0 μM DOX treatment.
Curve comparison long-term toxicity assay: DOX (p=0.42); ANS–DOX (p<0.0001). 
Uptake, conversion, and DNA damage in GSTA1 overexpression cells after ANS–
DOX exposure 
In order to further investigate whether ANS–DOX is converted to DOX in a GSTA1-
dependent manner within the cells we exposed GSTA1 overexpressing and control V79 
cells to ANS–DOX as well as DOX and measured the final cellular DOX content at various 
time points. For this we exploited that the conversion of ANS–DOX yields more 
fluorescent DOX, which was detected using the Operetta High content imaging system. 
Using DOX as a control we could see a similar steady and rapid increase in cellular levels 
in both control cells and GSTA1 overexpressing cells (Fig. 4A). This further indicates that 
a cellular uptake of DOX (and also ANS–DOX) does not depend on the expression level 
of GSTA1, but that the different toxicity profiles are indeed dependent on GSTA1 
catalysis. Exposing cells to ANS–DOX we could clearly see an GSTA1 and time-
dependent increase in nuclear DOX fluorescence showing that ANS–DOX is 
intracellularly converted to DOX by GSTA1 (Fig. 4A). Visualizing single cells, it becomes 
clear that the control cells at early time points show a predominantly low cytosolic 
fluorescence (indicative of uncleaved prodrug) with nearly no nuclear DOX, whereas the 
GSTA1 overexpressing cells display a very strong nuclear DOX fluorescence (Figure 4B; 
compare merge control and GSTA1 overexpression). A similar pattern could be seen 
with MGST1 overexpressing cells (data not shown), but to a much lower extent, as 
expected, since GSTA1 has a much higher ANS–DOX conversion rate compared to 
MGST1 (Fig. 2B). 
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Figure 4. Cellular uptake of DOX and ANS–DOX in GSTA1 overexpressing cells.  
A. Representative figure of fluorescent intensity of DOX in the nuclei of cells treated with either 20 μM DOX or
20 μM ANS–DOX for the indicated time periods in GSTA1 overexpressing (dark gray) and vector control (light
gray) cells (n = 3; mean ± SEM). B. Representative fluorescence microscopy pictures of GSTA1 overexpression
and V79 control cells, treated with 20 μM ANS–DOX for 120 min. Upper panel: DOX fluorescence. Middle
panel: Hoechst staining of the nucleus. Lower panel: Merge images. 
DNA damage in GSTA1 overexpression cells after ANS–DOX exposure 
Looking at DNA damage we noted that GSTA1 overexpression protected the cells 
somewhat from DOX induced DNA damage in a time-dependent manner when 
compared to the control cells as seen by expression of the DNA damage markers p-
Histon-H2AX and p-p53. This effect could not be seen with ANS–DOX treatment, where 
control as well as GSTA1 overexpression cells showed significant induction of DNA 
damage markers (Fig. 5A, left panel). Notable, the GSTA1-dependent protection seems to 
somewhat disappear at higher concentration of DOX (Fig. 5A, right panel). This 
furthermore goes in line with the alkaline comet assay (Fig. 5B, right panel), confirming 
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that the cells having GSTA1 overexpression displayed less DNA damage compared to 
control cells at 0.2 μM DOX, but not at 0.1 μM DOX treatment. GSTA1 has potentially a 
small protective effect toward DOX, which, however, disappears at higher concentrations 
where GSTA1 might be overwhelmed. By exposing GSTA1 overexpression cells to ANS–
DOX, on the other hand, higher levels of DNA damage were observed compared to 
control cells (Fig. 5B) in line with the cell viability assays (see Fig. 3), the ANS–DOX to DOX 
conversion (see Figure 4), and also the DNA damage markers (see Fig. 5A). 
 
 
Figure 5. DNA damage in GSTA1 overexpressing cells after ANS–DOX and DOX exposure. 
A. Activation of DNA damage signaling was assessed by phosphorylation of p53 at Ser15 and Histon-γH2AX at 
Ser139 using Western blot. Cdk2 was used as a loading control. GSTA1 overexpressing and vector control cells
were treated with 0.2 μM DOX or 2 μM ANS–DOX for the indicated time periods or for 3 h with the indicated
concentration. B. DOX and ANS–DOX mediated DNA damage in GSTA1 overexpressing (light gray) and vector
control cells (dark gray) were determined after a 3 h exposure by comet assay. Experiments were performed
in triplicate, and data points represent means ± SEM **p< 0.01, ***p< 0.001 as compared with control levels
by using a two-tailed student t test. 
ANS–DOX reverses the MGST1-dependent resistance against DOX 
MGST1 was previously shown to promote resistance to DOX and to be a potential target 
in the activation of DOX based prodrugs, highlighting it as a suitable target to further 
validate ANS–DOX as a potential prodrug [8]. For this we utilized control MCF7 cells, 
known to have low endogenous levels of GSTs and MCF7 cells engineered to 
overexpress MGST1 (Fig. 6A) [57]. MCF7 cells are known to easily overexpress features 
associated with multidrug resistance, particularly using DOX as a model drug. Even if the 
cells used in this study were not especially adapted to generate a resistant phenotype, 
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they still displayed high resistance to DOX, suggesting that they employ several 
mechanisms to counter DOX induced cell death [27, 58-62]. Resistance to DOX was 
furthermore significantly promoted by MGST1 overexpression compared to control 
cells, in agreement with previous studies [8, 9]. This protective effect was indeed 
observed in short-term (24 h) exposure studies. However, only marginal effects were 
found in long-term follow-up CFE experiments (7 days) (Fig. 6B). Total reversal of 
MGST1-dependent resistance against DOX was shown in cells exposed to ANS–DOX 
even though no further toxicity was induced in MGST1 overexpressing cells compared 
to cells with low MGST1 (compare Fig. 6B,C). 
 
 
Figure 6. Characterization of MGST1 overexpressing cell lines and their response to DOX and ANS–DOX 
treatment.  
A. Left panel: Western blot of MGST1. Lane 1: cell lysate of wildtype MCF7 cells. Lane 2: MCF7 cells
overexpressing MGST1. Lane 3: MCF7 cells containing vector control. Lane 4 until lane 9: purified rat MGST1
enzyme; 5–50 ng. Right panel: Specific GST activity in isolated microsomes from MGST1 overexpressing and
control MCF7 cells. Activity was measured using 0.5 mM CDNB and 5 mM GSH. Values are means ± SEM (n = 
3; *** p≤ 0.001). B-C. Cellular toxicity of (B) DOX or (C) ANS–DOX after 24 h analyzed with short-term MTT 
assay (left) or long-term colony forming efficiency (CFE) assay (right; 7 days) with indicated doses. Data are
derived from at least three independent experiments done in triplicate (mean ± SEM, n ≥ 9, **p ≤ 0.01, ***p≤ 
0.001). CFE panels are representative data from one experiment measured in triplicate. MGST1
overexpressing MCF7 cells (dark gray/MGST1) and the vector control (light gray/control). 
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Prodrug ANS–Etoposide could overcome Etoposide-dependent resistance shown 
in GSTA1 overexpressing cells 
In addition to DOX and its derivatives we included etoposide and an etoposide based 
prodrug that was modified with a nitro acetyl-benzene moiety conjugated to the 
etoposide (ANS–etoposide) through a sulfonic acid ester linkage. In opposition to DOX 
treatment (see Fig. 3B), cells overexpressing GSTA1 showed significant resistance 
against etoposide. The GSTA1-dependent resistance against etoposide was reversed 
when exposing cells to ANS–etoposide, suggesting that the prodrug acts either 
independently of GSTA1 or that the enzyme-dependent activation of the drug cancels 
out the protection warranted by GSTA1 overexpression (Fig. 7A). It was previously 
noted that the V79 cells are generally more sensitive toward both DOX and etoposide 
than the MCF7 cells [63]. That was shown also here with both etoposide and ANS–
etoposide. However, MGST1 overexpression seemed to promote a weak ANS–
etoposide induced toxicity compared to control cells and in relation to the parental 
etoposide (Fig. 7B). Since etoposide is not fluorescent as DOX, no GST-dependent 
conversion rates could be obtained. 
 
 
Figure 7. Etoposide and ANS–etoposide toxicity in GSTA1 and MGST1 overexpressing cells.  
A-B. Cellular toxicity of (A) etoposide and (B) ANS–etoposide analyzed with the MTT assay after short-term 24 
h exposure with indicated doses, in at least three independent experiments measured in at least triplicate 
(mean ± SEM, n ≥ 9, *p ≤ 0.05, **p≤ 0.01, and ***p≤ 0.001). Left panel: MGST1 overexpressing MCF7 cells 
(dark gray/MGST1) and the vector control (light gray/control). Right panel: GSTA1 overexpressing V79 cells
(dark gray/GSTA1) and the vector control (light gray/control). 
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Reduction of GSH Levels through Prodrug Activation and Sensitization to DOX 
To study whether activation of the prodrugs leads to GSH depletion and thus 
sensitization to DOX, we treated GSTA1 overexpressing V79 cells with 5 μM ANS−DOX 
and DNS−DOX and measured the total GSH content aŌer 2 and 6 h of exposure. The 
early time point showed only a minor reduction of the GSH levels, which were 
replenished again at 6 h (Fig. 8A). This is not surprising as in this setup a maximum of 
2.5 nmol prodrug (5 μM) could only deplete about 50% of the approximately 5 nmol 
total GSH (500 μg total protein in the sample with a GSH content of about 10 nmol/mg 
protein). Nonetheless, this highlights that prodrug uptake and activation is a rapid 
process involving a decrease of the GSH pool. Furthermore, in the scenario of a high 
accumulation within the tumor, a more pronounced GSH reduction might contribute to 
the toxicity profile as the cells become sensitized to the activated DOX [64]. To validate 
this previously reported sensitization through a reduction in GSH we treated V79 cells 
with BSO and exposed them to DOX. Already a decrease in the GSH levels of about 65% 
(Control, 12 ± 6 nmol/mg protein, versus BSO treated, 4 ± 3 nmol/mg protein) resulted 
in a significant increase in DOX toxicity (Fig. 8B) and thus suggests that the concomitant 
reduction in GSH levels may indeed synergize with the activated drug. 
 
 
Figure 8. GSH depletion by prodrugs and sensitization to DOX.  
A. GSTA1 overexpressing V79 cells were treated with the prodrugs for 2 or 6 h, respectively. Cells were
subsequently lysed, and total GSH content was determined (Mean ± SEM, n = 3). B. Cells were depleted of 
GSH using BSO and treated with DOX as indicated. GSH levels of control cells, 12 ± 6 nmol/mg protein; GSH
levels of BSO treated cells, 4 ± 3 nmol/mg protein. Cellular toxicity was analyzed with the MTT assay after 24 h
exposure (mean ± SEM, n = 3). Curve comparison: p= 0.09. 
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Thioredoxin Reductase 1 inhibition as concomitant mechanisms of the prodrugs 
The electrophilic nature of the sulfonamide bond suggests that other intracellular 
nucleophiles, in addition to GSH, can also be the target of the prodrugs. A prime 
candidate is the selenoprotein TrxR1, which is the central enzyme in the antioxidant Trx 
system. Using recombinant TrxR1, DNS–DOX and ANS–DOX could both efficiently inhibit 
its activity toward Trx1, while having little effect on its ability to redox cycle with juglone 
(Figure 9A, left panel). Juglone, in contrast to Trx1, does not require an intact Sec-
residue at the C-terminal [52, 53]. Inhibition by the prodrugs was furthermore NADPH 
dependent, suggesting that the reduced, highly nucleophilic and reactive Sec-residue in 
the C-terminal active site is the prime target (Fig. 9A, right panel). This experiment was 
performed without a desalting step after a 10 min incubation of 20 nM TrxR1 with 10 
μM of DNS–DOX in the presence or absence of NADPH. Subsequently, the remaining 
DNS–DOX started to competitively inhibit TrxR1 as 10 μM Trx1, 160 μM insulin, and 250 
nM NADPH were added to measure the enzyme activity. In contrast to the prodrug, 
neither DOX, the sulfur dioxide, nor the GSH conjugated acetylmononitro/dinitro 
benzene moiety, which are the products of prodrug activation via GSH, are inhibitors of 
TrxR1 (Fig. 9A, right panel). The underlying mechanism thus potentially involves the 
covalent modification of the Sec-residue by the acetylmononitro/dinitro benzene 
moiety of the prodrug in a reaction similar to that of the prodrugs with GSH. To study 
whether TrxR1 is also targeted within the cell we utilized HEK293 cells and treated 
those with 2 and 10 μM of DNS–DOX and ANS–DOX as well as 1 μM auranofin. 
Auranofin is a well-known TrxR1 inhibitor and often used as a standard to compare the 
efficiency of compounds in targeting cellular TrxR1 [54, 65, 66]. Compared to auranofin, 
both DNS–DOX and ANS–DOX showed a surprisingly high degree of TrxR1 inhibition 
even at 2 μM (Fig. 9B). However, HEK293 cells with 0.013 ± 0.001 μmol/min/mg protein 
have a rather low GST-dependent CDNB activity compared to V79 cells (V79 control, 
0.05 ± 0.01 μmol/min/mg; GSTA1, 0.11 ± 0.01 μmol/min/mg; see Fig. 3B). This suggests 
overall lower GST levels in HEK293 cells and thus slower prodrug activation compared to 
V79 cells, leaving the prodrugs more time to target TrxR1. To test whether TrxR1 
inhibition is limited by prodrug activation via GST/GSH we treated V79 control cells and 
GSTA1 overexpressing V79 cells with DNS–DOX, ANS–DOX, and auranofin. As expected, 
TrxR1 inhibition was lower in V79 compared to HEK293 cells and even further lowered 
by GSTA1 overexpression (Fig. 9C). 
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Figure 9. TrxR1 inhibition by DNS–DOX and ANS–DOX.  
A. Inhibition of recombinant TrxR1 by auranofin, DNS–DOX, and ANS–DOX. Left panel: In vitro TrxR1 activity.
Twenty nanomolar recombinant TrxR1 was incubated with the drugs as indicated for 10 min in the presence
of NADPH. Enzyme activity was measured using either Trx1 or juglone as substrate (mean ± SEM, n = 3). Right 
panel: In vitro TrxR1 activity. Twenty nanomolar recombinant TrxR1 was incubated with 10 μM DNS–DOX 
either in the presence (+NADPH) or absence (−NADPH) of NADPH for 10 min. Subsequently, enzyme acƟvity
was measured using Trx1 as substrate. TrxR1 inhibition by the products of prodrug activation (DOX, SO2, and
GSH conjugated acetylmononitro/dinitro benzene moiety) was determined by first incubating 10 μM DNS–
DOX with 5 mM GSH and 50 nM GSTA1 for 30 min. Subsequently, 20 nM TrxR1 and 250 μM NADPH were 
added for 10 min. Enzyme activity was measured using Trx1 as substrate (mean ± SEM, n = 3). B. Cellular 
TrxR1 activity. HEK293 cells were treated with the drugs as indicated for 3 h. Enzyme activity was measured in
cell extract using a modified form of the Trx1 coupled insulin end point assay. Data are from two independent
experiments measured in triplicate (mean ± SEM, n = 6). C. TrxR1 inhibition in V79 control cells versus GSTA1
overexpressing V79 cells. Cells were treated with the drugs as indicated for 3 h, and enzyme activity was
measured in cell extract using a modified form of the Trx1 coupled insulin end point assay. Data are from
three independent experiments measured in duplicate (mean ± SEM, n = 6). *p≤ 0.05, **p≤ 0.01, and ***p≤ 
0.001 as compared with control levels by using a two-tailed student t test. 
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Discussion 
The difficulty to selectively target cancer cells and the development of resistance to 
treatments are among the major problems in current cancer therapy. Additionally, the 
efficiency of a drug may be limited by a lack of activation or inactivation, poor drug 
influx or excessive efflux, alterations in expression levels of the drug target, or the 
activation of adaptive pro-survival pathways [67]. We previously reported that MGST1 
and GSTP1 overexpression promotes resistance to DOX but that this resistance could be 
overcome using the prodrugs MNS–DOX and DNS–DOX, respectively (Fig. 1A) [8]. The 
major mechanism is the GST catalyzed release of DOX from these prodrugs, leading to 
selected accumulation and targeting of cells that have this particular GST 
overexpression, while potentially sparing other cells and minimizing side effects. While 
expanding our studies to other GSTs in order to further validate this concept we noticed 
that purified GSTA1 enzyme had an extremely high specific activity and conversion rate 
with DNS–DOX. Surprisingly, however, despite the efficient release of DOX there was an 
unexpected lack of cell toxicity augmentation in GSTA1 overexpression cells. We 
reasoned that there might be an enzyme-dependent “conversion rate window” that is 
optimal for the cells to be killed selectively by the prodrugs. This hypothesis is 
supported by our previous study showing that MGST1 overexpression augmented 
MNS–DOX toxicity while having only small effects on DNS–DOX toxicity despite a 100 
times higher conversion rate for DNS–DOX compared to MNS–DOX [8]. A similar 
behavior was observed in GSTP1 overexpressing cells, where DNS–DOX (converted with 
84 ± 12 nmol/min/mg) toxicity was augmented by GSTP1 overexpression to a greater 
extent than by MGST1 overexpression, which has a higher conversion rate [8]. Our 
reasoning is that a limited conversion rate capitalizes more optimal on the 
overexpression of the particular GST, leading to a stronger GST-dependent 
accumulation of the converted drug and thus a more selective cell killing. Highly 
reactive prodrugs, however, might already be converted at rates that are high enough 
to render a contribution from additional GST overexpression minor. This assumption is 
further strengthened by a recent study showing that limiting the prodrug reactivity can 
translate to a prolonged lifetime in the bloodstream and thus to a higher in vivo 
efficacy. For this, Nandurdikar et al. developed analogues of JS-K, an arylated 
diazeniumdiolate prodrug, where the nitro group substituents in the aromatic ring were 
replaced with less electron-withdrawing groups such as cyano or fluoro. Interestingly, a 
small decrease in reactivity promoted an increased efficacy, whereas too low reactivity 
resulted in a loss of effect [68]. 
To further test this hypothesis, we developed a DOX derivative with altered reactivity, 4-
acetyl-2-nitro-benzenesulfonyl doxorubicin (ANS–DOX), where a nitro group in the para 
position in DNS–DOX is replaced by an acetyl group (Fig. 1). The less electron 
withdrawing acetyl group reduced the reactivity about 10–30 times compared to DNS–
Chapter 7 
204 
DOX (Fig. 2B). In line with our hypothesis, ANS–DOX toxicity was indeed strongly 
augmented in a GSTA1-dependent manner despite its lower activity (Fig. 3), which could 
be further confirmed by the time and GSTA1-dependent increase in nuclear DOX 
fluorescence (after ANS–DOX conversion) as well as GSTA1-dependent DNA damage 
(Fig. 4 and 5). A similar behavior could be observed with MGST1, albeit to a smaller 
extent. ANS–DOX showed hereby a toxicity profile that seems at first independent of 
the MGST1 status. However, it is likely a combination of two opposing effects that 
cancel each other out; the MGST1-dependent conversion of ANS–DOX to DOX and 
MGST1 mediated resistance. Comparing the toxicity profiles of ANS–DOX with the 
previously studied DNS–DOX and MNS–DOX it becomes apparent that the toxicity of 
these prodrugs followed the conversion rates inversely [8]. 
Notably, ANS–DOX induced toxicity in the MCF7 cells at much lower concentrations 
than DOX in a manner that seems independent of the GST status. This effect was also 
previously reported for DNS–DOX in the treatment of MCF7 cells [8], suggesting that 
these modifications alter the properties of DOX in a way that allow it to circumvent 
multidrug resistance mechanisms present in the MCF7 cells and thus act as a delivery 
system for the parental drug. A general effect such an increased uptake and altered 
intracellular distribution due to a change in the lipophilicity of the drug (logP; ANS–DOX: 
2.2 vs. DOX: 0.6), might in part explain the behavior. However, this effect was 
predominant in MCF7 cells and not in the already more sensitive V79 cells in 24 h 
treatment experiments, suggesting that the prodrug might avoid one or more drug 
resistance mechanisms present in the MCF7 cells. A potential mechanism could be the 
avoidance of transmembrane transporter proteins such as P-glycoprotein (P-gp) [60], 
membrane multidrug transporters (MRP1), or the breast cancer resistance protein 
(BCRP)[69],(70) which were previously reported to be important for DOX resistance in 
MCF7 cells [70]. As a weak basic drug, the uptake, export, and intracellular behavior of 
DOX in MCF7 cells might furthermore be affected by a change in its propensity of being 
protonated [71, 72]. The concept of avoiding drug resistance by using various delivery 
systems was already tested for DOX. Common approaches utilize nanoparticles for 
delivery [73], such as polyester-based hyperbranched dendritic-linear (HBDL)-based 
nanoparticles, which could effectively overcome MGST1 mediated drug resistance in 
MCF7 cells [74] or mesoporous silica nanoparticles (MSNs) that were used to deliver 
DOX in a xenograft nude mouse model [59]. These and other targeted delivery systems 
such as homing peptides, immunoliposomes, or other nanoparticle approaches can 
furthermore be combined with the prodrug concept, thus providing the opportunity to 
merge an enhanced drug delivery with a selective activation mechanism, which might 
enable a more optimal targeting of cancer cells [75-77]. 
Accumulation of prodrugs in the tumor cells through selective targeting would 
furthermore promote complementary effects that in turn augment the toxicity induced 
by the freed parental drug. Prodrug activation, for instance, involves the covalent 
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addition of GSH to the sulfonamide moiety, which thus may reduce the GSH pool 
depending on the molar ratio of prodrug-to-GSH within the cell. Importantly, even a 
minor reduction might already improve cancer cell death in tumors through increased 
oxidative stress or a reduction of the detoxifying capacity in these cells [35, 78]. DOX, 
for instance, has already been shown to benefit significantly from decreased GSH levels, 
which might thus be part of the mechanism of ANS–DOX and DNS–DOX toxicity[64]. 
Additionally, prodrugs might target intracellular nucleophiles other than GSH through 
their electrophilic sulfonamide bond. A prime candidate in this context is the redox 
regulatory enzyme TrxR1. It is the key enzyme in the antioxidant Trx system, 
overexpressed in many tumors and easily inhibited by electrophilic compounds due to a 
reactive and accessible Sec-residue within its active site. In fact, not only is TrxR1 
considered to be an attractive anticancer target by itself [31], but inhibition of the 
enzyme has been suggested to be part of the mechanism of many drugs [32]. Despite a 
rapid activation via GSH/GST, both DNS–DOX and ANS–DOX could inhibit TrxR1 in vitro 
and in cell culture with the more reactive DNS–DOX being more efficient than ANS–
DOX. The ability to target TrxR1 was hereby dependent on the GST levels, as the 
activated drug is not targeting the enzyme. Nonetheless, the enzyme was inhibited in 
GSTA1 overexpressing V79 cells, suggesting that disruption of the Trx system is indeed a 
contributing factor. The mechanism may involve the induction of oxidative stress 
through a reduction in the antioxidant capacity or the disruption of redox signaling 
pathways. Furthermore, inhibition of TrxR1 is suggested to effectively synergize with 
targeting of the GSH system in the killing of cancer cells as both systems serve to back 
each other up [33, 34]. Designing prodrugs that concomitantly target the Trx and GSH 
systems in cancer cells while releasing a drug that benefits from these concomitant 
effects would thus be a suitable strategy to target cancer cells. 
In parallel we included etoposide and an etoposide based prodrug in this study to 
validate it as a candidate for the development of novel GST activated prodrugs. The 
structure of the drug was modified such that a nitro acetyl-benzene moiety became 
conjugated to the etoposide (ANS–etoposide) through a sulfonic acid ester linkage (Fig. 
1A). The choice of ANS as the prodrug modification principle rests also on the fact that 
sulfonic acid ester linkages are more labile and that DNS modified etoposide would thus 
be less stable. Treating MGST1 overexpressing cells with ANS–etoposide showed an 
enzyme-dependent increase in toxicity, which, however, was weakly concentration 
dependent and had a less potent toxic profile compared to etoposide, suggesting either 
a compromised uptake or a limited activation. GSTA1 overexpression, however, showed 
a significant resistance against etoposide induced toxicity compared to control cells. 
Whereas treating the cells with the prodrug ANS–etoposide, the etoposide-dependent 
resistance was totally abolished, indicating a GSTA1-dependent activation of the 
prodrug. Potentially, the GSTA1-dependent activation of ANS–etoposide might 
compensate for the etoposide-induced resistance caused by overexpression. The 
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GSTA1-dependent protection to etoposide toxicity could potentially be explained by the 
intracellular distribution of the enzyme and the mechanism of etoposide induced cell 
death, which has not been completely delineated yet. Jamil et al. showed, for instance, 
that low concentrations of etoposide could induce cell death via the mitochondrial arm 
of p53 [79], a cellular compartment where also GSTA1 was shown to be present [80]. 
Furthermore, it is not known whether the chemical modification of etoposide to ANS–
etoposide alters the DNA topoisomerase II inhibitory properties of the molecule (we 
know that the modification of DOX occurs at an amino group critical for toxic 
properties). Also, the chemical liability of the sulfonic acid ester bond could potentially 
lead to a rapid cellular, perhaps enzyme catalyzed, conversion to etoposide thus 
showing little difference compared to etoposide treatment. This idea needs to be tested 
with a less reactive mononitro derivative. 
Despite the above outlined benefits of GST/GSH activatable drugs, their development 
and use may have potential drawbacks as they may become highly toxic in sites rich in 
GSTs such as the liver [81]. To circumvent this problem we propose to use established 
drugs with known toxicity profiles, particularly those that are known to have low liver 
toxicity, as the basis for prodrugs. A very rapid activation of ANS–DOX in liver for 
example, may lead to the same toxicity as if the DOX would have been used directly. 
However, at the same time toxicity in all other cells, except the GSTA1 overexpressing 
cancer cells, would be reduced thus showing overall fewer side effects. Our 
experiments on V79 control cells and GSTA1 overexpressing V79 cells as a model system 
essentially showed that ANS–DOX was less toxic in the V79 control cells compared to 
DNS–DOX and DOX, whereas in GSTA1 overexpressing cells toxicity was similar no 
matter if DOX, ANS–DOX, or DNS–DOX was used (see Fig. 3). Nonetheless, future in vivo 
studies are needed to fully grasp the potential short-term and long-term side effects of 
these prodrugs. 
This study further explored the concept of using GST activated prodrugs in cancer 
treatment. We highlight that a low GST catalyzed conversion rate and a low background 
activity optimizes the GST-dependent accumulated of the activated drug and thus the 
augmentation of drug induced toxicity. Further, we show that rational modifications of 
the different DOX derivatives can affect not only the uptake and stability, but also the 
GST catalyzed conversion rate of this prodrug. We also show that decreased GSH levels 
and disruption of the Trx system via TrxR1 inhibition are concomitant factors of prodrug 
toxicity that likely synergize with the effects of the freed parental drug. Furthermore, 
we expanded the prodrug concept toward etoposide. Tailored modification might thus 
produce prodrugs that can be used to target specific types of cancers depending on 
their GST levels and composition as well as those displaying drug resistance [82, 83]. 
Designing different prodrug-types for different patient populations could contribute to 
a more personalized cancer therapy approach, were the therapeutic window is 
increased. Notably, TLK-286, a previously developed prodrug that targets GSTP1 
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overexpressing cancer cells went through to Phase III clinical trials showing the potential 
of this strategy [13, 14]. 
In conclusion, this study showed that the modification of existing drugs at the common 
amino or hydroxyl functional groups could be an effective way to develop novel 
selective drugs, which can overcome resistance mechanisms occurring in conventional 
treatments. Altering properties of DOX showed promising results to target resistant 
cancer cells and for the selective targeting of GST overexpressing tumors, thus 
potentially also reducing the side effects to normal tissue. 
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The success of cancer treatment is dependent amongst others on the resistance to the 
treatment and therapy tolerability of healthy tissues. Treatment resistance can be 
acquired during oncogenic/tumor formation, but can also arise during the treatment 
course. A tolerable treatment depends on the (over)sensitivity of normal tissues. 
Currently there is an urgent need to reduce both treatment resistance and normal 
tissue toxicity. The discovery of treatment-related biomarkers predicting outcome is of 
great interest in cancer therapy. A biomarker might help patients and clinicians to select 
the appropriate cancer treatment leading to a personalized cancer treatment approach. 
In this thesis, it was investigated how intrinsic or extrinsic changes of the tumor can 
contribute to a personalized patient treatment plan. The role of mitochondrial function, 
ROS and hypoxia modulation in tumors were investigated in view of the possibility of 
implementing them in a personalized treatment approach. To assess this, mitochondrial 
dysfunction has been acquired using different approaches such as mtDNA depletion 
(chapter 3 and 4), cytoplasmic hybrids (chapter 4), OXPHOS complex I inhibitors 
(chapter 4) and complex I inhibition in a dual-targeting approach (chapter 5). 
Additionally, repurposing drug (chapter 6) and prodrug approaches (chapter 7) have 
been evaluated. Molecular approaches have been used to investigate the effect of 
energetic stress and/or stress inducers (radiation and hypoxia) in relation to 
mitochondrial function (chapter 3 and 4). Different drug strategies (dual-targeting CAIX-
phenformin, repurposing nitroglycerin, prodrugs such as ANS-DOX) were investigated 
for the modulation of cancer treatment limiting parameters such as toxicity, hypoxia 
and drug resistance (chapter 5, 6 and 7). This chapter discusses the studies described in 
this thesis in relation to current literature and addresses also future perspectives.  
The influence of mitochondrial DNA and mitochondrial dysfunction 
on cancer therapy. 
During evolution mitochondria kept at least a part of their own DNA which consists out 
of 13 genes encoding for different subunits of the oxidative phosphorylation [1, 2]. 
Where mitochondria are often referred to as the ‘power plant of the cell’ they are 
important for several other cellular systems. They play an important role in calcium 
homeostasis, apoptosis, reactive oxygen species signaling and production, redox 
reactions and they contribute to the maintenance of the pyrimidines pool [3-7]. The 
human mitochondrial genome is a very dynamic system. It is almost completely coding 
and multiple copies of mtDNA occur within every mitochondrion.  
Multiple variations of mtDNA, like point mutations, deletions and copy number 
alterations have been reported in patients’ populations. Also in cancer patients mtDNA 
alterations have been observed (chapter 2). Both somatic and germline mutations were 
found to relate to cancer, either to cancer risk or in association with tumor progression 
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[8-12]. Petros et al. have demonstrated in a cohort study for prostate cancer an 
association with tumor progression for different germline mtDNA mutations in 
cytochrome oxidase. In a proof-of-principle study they showed for a germline mutation 
in ATP6, which codes for a subunit of ATP synthase (Complex V of the OXPHOS), a 7-fold 
larger tumor volume for mutants compared to wild-type tumors [13]. However, there 
are also studies that indicate that most mtDNA variations could potentially just be 
passenger mutations. These passenger mutations are mutations that have no influence 
on the cellular characteristics and don’t drive tumorigenesis and tumor progression [14, 
15]. Additionally, variations in mtDNA copy numbers levels have been reported to be 
associated with an increased risk for tumorigenesis in breast cancer [16], RCCs [17] and 
non-small cell lung [18] cancer patients but contradictory results also have been 
reported [19-21]. A recent meta-analysis observed an association in breast cancer and 
lymphomas with increased mtDNA copy numbers [22]. In contrast an increased mtDNA 
copy number was found to be negatively associated with hepatic malignancies [22]. 
Currently in cancer treatment, an increasing number of drugs are being developed or 
used which interact with the mitochondrial function and/or the mtDNA. For instance, 
chemotherapeutics can induce a reduction in mtDNA copy number levels [23, 24]. A 
conventional chemotherapeutic drug interacting with mitochondrial function is 
cisplatin, since it binds to mtDNA and impairs mtDNA synthesis [24, 25].  
mtDNA depletion is often an extreme method to investigate mtDNA related 
mitochondrial dysfunction, in both tumorigenic or normal tissue. In chapter 3 we used 
such mtDNA depleted models to study the effect of mitochondrial dysfunction on 
irradiation outcome. Several research groups observed different radiation responses in 
mtDNA models, from a radioresistant phenotype in various (tumor) cell lines in vitro 
[26, 27] to even an increased radiation response in an in vivo model [28]. In our study, 
also distinctive radiation responses were found. Cells depleted from their mitochondrial 
DNA displayed a more radiation resistant phenotype for an immortalized bronchial 
epithelial cell line while a more radiosensitive phenotype for two different tumor cell 
lines, although intrinsic radiosensitivity (surviving fraction after 2Gy) was not altered. 
Also for other treatment modalities, cells depleted from their mtDNA can show a more 
resistant phenotype, as for example has been observed for cisplatin exposure [25]. This 
mitochondrial dysfunction dependent cisplatin resistance might be dependent on 
glutathione levels [24]. In our study we observed that the antioxidant capacity of cells, 
i.e. altered GSH:GSSG ratio’s and mitochondrial super oxide dismutase (SOD2), could 
possibly explain a reduced response upon irradiation. Similar results have been 
reported by others [29, 30]. Additionally, our findings on clonogenic survival were in 
agreement with the observed increased residual DNA damage upon mtDNA depletion.  
DNA damage repair upon irradiation often has been suggested to be dependent on ATP 
[31-33]. Additionally, it has been shown that oxygen consumption and mitochondrial 
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ATP generation in irradiated normal cells was concurrent with the mitochondrial 
relocation of the cell-cycle dependent kinase CDK1 which could be inhibited by CDK1 
phosphorylation-deficient CI subunits [34]. Also for tumor cells it has been found that 
mitochondrial derived ATP is enhanced upon irradiation leading to increased survival 
[35]. Based on these reports, we investigated if we could observe any differences in ATP 
levels upon irradiation. However, for the mtDNA depleted cell lines investigated we did 
not observe any alterations in cellular ATP levels in agreement with Lu et al. [35]. This 
can be explained by the fact that tumor cells are very flexible in altering their 
metabolism and have the ability to acquire necessary nutrients from their environment 
and utilize them in order to maintain viability and generate new biomass (for an 
excellent recent review see [36]).  
Metabolic transformation of cancer 
Metabolic adaption and transformation of cells is a phenomenon often observed in 
cancer. We observed in chapter 3 a decrease of OXPHOS upon normoxic conditions and 
an increased glucose metabolism for the mtDNA depleted cell lines but no changes in 
ATP production. Tumor cells require large amounts of energy in order to stimulate their 
growth. Tumors hijack multiple systems in order to obtain enough energy for expansion. 
Multiple metabolic pathways are found to be deregulated such as glutamine, amino 
acid and lipid metabolism, the pentose phosphate pathway as well as glycolysis [36-43]. 
The aerobic glycolysis of tumors, already observed by Warburg [41] in the beginning of 
the 20th century, is currently exploited in the clinic using FDG-PET imaging to detect 
tumors and to monitor tumor progression [44]. However, recently the validity of the 
Warburg effect has been questioned. Although it is often suggested that in tumors the 
oxidative phosphorylation (OXPHOS) is absent due to the upregulation of glycolysis, like 
a crabtree effect, both metabolic profiles often co-exist in well-oxygenated tumor areas 
in order to meet the metabolic demands of the tumor. Observed changes in OXPHOS 
are not only heterogeneous between tissue types but also within samples obtained 
from the same tumor, suggesting that differences are not only caused by the 
environment of different tumor types but also are subject to physiological conditions 
such as hypoxia or genetic alterations [45]. 
CAIX and OXPHOS inhibition: how do they interact?  
It has been suggesting that in fastly proliferating tumor cells glucose metabolism is 
dominant since CDC42 expression (a gene involved in cell division) was found to be 
correlated with the expression of the glycolysis pathway [45]. In areas with reduced 
oxygen, the hypoxic areas, hypoxia inducible factor 1 alpha (HIF-1α) downregulates 
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OXPHOS [46] and promotes glycolysis via regulation of expression of the glucose 
transporters GLUT1 and GLUT3 and the lactate efflux transporter MCT4 [11, 47, 48]. 
Downregulation of OXPHOS gene expression was found to correlate with a worse 
prognosis in different patients populations e.g. bladder urothelial carcinoma, cervical 
squamous cell carcinoma, endocervical adenocarcinoma, glioblastoma multiforme etc. 
[49]. OXPHOS downregulation also was found to correlate with the induction of the 
epithelial-to-mesenchymal transition which is linked to invasion and metastasis 
formation [49-51]. HIF-1α stabilization can also occur under normoxic conditions. 
Succinate, which accumulates upon succinate dehydrogenase inhibition, causes 
reduction of the prolyl hydroxylases resulting in stabilization of HIF-1α under normoxic 
conditions, similar as has been described for VHL mutations [52]. The discovery of 
mutations in nuclear TCA genes such as succinate dehydrogenase [53, 54], fumarate 
hydratase [55, 56] and iso-citrate dehydrogenases [57-59] suggests a role for these 
mutations in oncogenic transformation and accelerated the interest in mitochondrial 
encoded genes. 
In chapter 4 we investigated if the increase of carbonic anhydrase IX (CAIX) could be 
observed in tumor cells displaying a mitochondrial dysfunction. The hypoxia regulated 
CAIX plays an important role in sustaining the cellular pH balance [60, 61]. Here we 
remarkably didn’t observe an increase in CAIX expression under both normoxic and 
hypoxic conditions for mtDNA depleted tumor cell lines (from chapter 3) as well as for a 
newly generated osteosarcoma model harboring a mtDNA m.3243A>G point mutation, 
i.e. a cybrid model (chapter 4). This mutation is responsible for the 
“mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes” (MELAS) 
syndrome [62, 63]. In contrast, we observed a decreased CAIX expression under hypoxic 
conditions in these models, which seemed to be dependent on the mutation 
percentage of the mtDNA. As one cell can contain up to thousands of copies of mtDNA, 
both mutated and wild-type mtDNA can co-exist ranging from 1 to 99% within the same 
mitochondrion, cell, tissue or organism making heteroplasmy levels another important 
factor to take in account. When a mutation is present in all copies of the mtDNA, this is 
referred to as homoplasmy. From the research field of mitochondrial diseases, we have 
learned that the mutation often should exceed a certain threshold in order for a patient 
to show pathological symptoms in case of severe inherited mitochondrial diseases 
(chapter 2). These thresholds can be mutation specific [64] as well as tissue specific 
[65]. Homoplasmic mtDNA variations also can be involved in less severe diseases (e.g. 
hearing lost) which need an additional trigger (exposure to the antibiotic 
aminoglycoside) to demonstrate their pathogenic phenotype [66, 67]. We expect a 
similar mechanism in case of treatment-related pathologies such as radiation-induced 
toxicity. 
Increased lactic acid levels are often observed in mitochondrial diseases and 
tumorigenic tissues [63, 68]. In tumors this increased lactate production is the result of 
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both the Warburg (aerobic glycolysis) and the Pasteur effect (anaerobic glycolysis) and 
has been found to be correlated with radiation resistance in a xenograft model and 
related to a worse prognosis in patients [69, 70]. Overall, enhanced glycolysis within 
tumors will result in an increased acidification of the intracellular pH. In order to 
maintain a physiological intracellular pH, this acidification will be counteracted by an 
increased carbonic anhydrase activity. Tumor cells under metabolic stress and hypoxia 
adjust their metabolism and cell signaling in order to increase their survival. In chapter 4 
we exposed cells to both metabolic stress and limited oxygen tensions. When cells 
suffer from both metabolic stress and hypoxia probably other mechanisms are altered 
possibly explaining the decreased HIF-1α stabilization and reduced levels of CAIX. One 
of these mechanism could be the AMPK signaling pathway as it is found to be involved 
in both mechanisms [71]. Deregulation of AMPK could contribute to an altered 
translation via inhibition of the mTOR pathway, leading to reduced amounts of HIF-1α 
protein and consequently result in decreased CAIX expression levels. Also, other 
mechanisms such as autophagy could potentially play a role as this process might 
already be upregulated to meet the cellular metabolic demands accompanied with a 
decreased need of HIF-1α signaling. Upregulation of autophagy was observed in cybrids 
containing a mitochondrial ND5 mutation [72] and is also observed under hypoxic 
conditions [73]. Mitochondria undergo also autophagy, named mitophagy [74], which 
can be induced by hypoxia. Mitochondrial NAD-dependent protein deacetylase sirtuin-3 
(SIRT3) is a protein with many interesting properties and is found to play a role in 
inducing fatty acid oxidation [75], AMPK activation [76, 77] and antioxidants as it is 
found to regulate SOD2 upon calorie restriction mechanisms [78], and is involved in the 
activation of hypoxia induced mitophagy [79]. Under hypoxic conditions SIRT3 is also 
involved in destabilization of HIF-1α under hypoxic conditions [80]. Based on our 
findings we can conclude that tumor cells exposed to a combination of metabolic stress 
and hypoxia probably adjust their metabolism and cell signaling in order to survive.  
Modulating the pH balance by using an OXPHOS modulating dual-
targeting drug approach 
Combining the important role of CAIX in maintaining the cellular pH balance and the 
predominant expression on hypoxic tumor cells correlating with a worse prognosis [81] 
makes it an appealing target for cancer treatment. In the past, several modalities have 
been developed to inhibit CAIX function in order to increase the treatment response 
[82, 83]. CAIX inhibitors could contribute to intracellular acidification and therefore 
induce cell death [84, 85]. A dual-targeting approach where homing strategy is 
combined with a therapeutic strategy could be a valuable tool to improve success rates 
of treatment while reducing normal tissue toxicity. Phenformin is a potential drug 
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candidate for modification in such a dual-targeting approach and its functionalized form 
has been investigated in chapter 5. Phenformin a is very potent drug developed for 
diabetes mellitus treatment, but was found to induce lactic acidosis in patients and was 
therefore subsequently withdrawn from the market. Currently, a closely related drug, 
metformin is still used in daily practice as the incidence rates of lactic acidosis are lower. 
Metformin displays improved treatment response rates in cancer patients, while studies 
in cancer patients for phenformin have yet to be performed, although preclinical 
studies are promising [86, 87]. The proposed mechanism of action of phenformin is its 
ability to inhibit mitochondrial respiration via complex I inhibition and activation of 
AMPK [88, 89]. As it reduces oxygen consumption it additionally will improve tumor 
oxygenation [90]. Targeting phenformin directly to the hypoxic areas of tumor is a 
promising approach as therapeutic doses and possible adverse effects could be 
reduced. Unfortunately, we were not able to observe decreased oxygen consumption in 
tumor cells with increased CAIX expression levels.  Our dual-targeting approach using 
phenformin failed to exhibit its complex I inhibiting properties. However, this doesn’t 
imply that a dual-targeting approach for phenformin or in general is not attractive, but 
further research is needed focused on making better suited compounds. Although 
methods to reduce tumor hypoxia can vary a lot in mechanisms, hypoxia modulation 
remains very important to improve treatment efficiency.  
Improvement of tumor oxygenation by a repurposing drug approach  
Neoangiogenesis maintains the blood flow in a tumor but as the tumor mass expands 
and the demand for oxygen and nutrients increases, tumors become hypoxic as these 
newly formed vessels are leaky and immature. One approach to counteract hypoxia in 
tumors would be the reduction of oxygen consumption in tumor cells and thereby 
reducing the limited diffusion of oxygen in a tumor. Treatments already used for other 
diseases could attribute to a well-tolerated and cheap therapy to alter the oxygen 
status of a tumor. Repurposing drugs like metformin, a drug developed for diabetes 
mellitus type 2, could lead to reduced costs in drug development and is currently 
investigated in clinical trials (see above). Metformin is just like phenformin a biguanide 
however it is less potent probably due to a lower lipophilicity and therefore uptake in 
cells and binding to the mitochondrial membrane is decreased [91, 92]. Although having 
a decreased potency, metformin treated patients harbor a lower incidence of lactic 
acidosis, making it currently more suitable to use in clinical practice. Recently, 
derivatives of metformin, mitometformin, were developed in order to target directly 
the mitochondria and increase the efficiency of the drug [93]. Another approach to 
reduce tumor hypoxia would be to mature vessel formation, and thereby improve the 
vasculature of a tumor. However, studies with an antibody against VEGF (bevacizumab) 
resulted in increased malignancy and metastatic cancers [94]. Next to these findings 
bevacizumab has also been linked to drug resistance, which has been described to be 
General discussion 
221 
associated with hypoxia-induced autophagy, evidenced by an increased BNIP3 
expression [95]. 
Potentially the increase of the tumor’s perfusion would be an alternative approach. 
Nitroglycerin is a nitric oxide (NO) donor and known for its vasodilation properties in 
angina pectoris [96]. Yasuda et al. performed a randomized phase II clinical trial in which 
cisplatin-vinorelbin chemotherapy was combined with nitroglycerin. An improved 
overall response rate and overall survival was observed in favor of patients treated with 
nitroglycerin, while treatment toxicity remained equal between the patient groups 
either receiving a nitroglycerin patch or placebo [97]. However, others didn’t observe 
additional benefit of applying nitroglycerin as adjuvant to standard cancer treatment 
[98, 99]. Therefore, we can conclude that the addition of nitroglycerin to standard 
therapy does not have a major impact on the survival of unselected patients with non-
small cell lung cancer (NSCLC). In chapter 6 we investigated in a clinical window-of-
opportunity trial the influence of the application of nitroglycerin in NSCLC patients on 
hypoxic tumors. Imaging hypoxia and perfusion was done before and after 
administration of nitroglycerin. We observed a decrease in the hypoxic fraction for 
patients with hypoxic tumors and tracer uptake was negatively correlated with tumor 
perfusion in these hypoxic tumors. Using in vitro experiments we showed that the 
metabolism of 2-nitroimidazoles is not influenced by nitroglycerin itself and that 
nitroglycerin does not inhibit mitochondrial respiration, as previously has been 
suggested [100-102] using human achievable concentrations [103]. Our data suggest 
that stratification of patients with hypoxic tumors for the use of nitroglycerin patch as 
adjuvant to anti-cancer treatment in this selected population could be beneficial for 
their treatment. However, repeated imaging acquisitions could be a burden for patients 
and therefore further research should be focused on investigating how this 
inconvenience could be reduced. Possibly a radiogenomics and/or blood biomarkers 
approach could be helpful in reducing the amount of scans and imaging modalities 
required.  
Hypoxia activated prodrugs (HAP) are another approach to reduce normal tissue side 
effects and target the hypoxic areas of a tumor at the same time. The first well-known 
hypoxia activated prodrug is tirapazamine. Phase III trials however didn’t show superior 
effects compared to standard of care, potentially due to the lack of patient selection 
[104]. PR-104A is another prodrug that was developed to be hypoxia activated and to 
generate a by-stander effect [105]. Unfortunately, activation of the prodrug PR-104A 
took also place in some human cell lines under aerobic conditions, suggesting the 
presence of an aerobic reductase able to activate the prodrug. Indeed aldo-keto 
reductase 1C3 could cause the fragmentation of PR-104 upon normoxic conditions [105, 
106]. TH-302 is a HAP being developed to directly target the hypoxic areas of tumor and 
thereby reducing the hypoxic fraction of a tumor and increasing the sensitivity to other 
treatment options like chemotherapeutic agents and radiotherapy while showing a 
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better normal toxicity profile, good preclinical [107, 108] and clinical applications [109]. 
In two phase III clinical trials, TH-302 failed to show improved outcomes again related to 
the lack of patient selection in these trials.  
The use of prodrugs to overcome chemoresistance 
In hypoxic tumors not only resistance to radiotherapy is often encountered as a 
problem for effective treatment, also for chemotherapeutics hypoxic tumors often have 
decreased response rates as many chemotherapeutics require oxygen for optimal 
response rates [110]. It has been suggested that upon hypoxia, alkylating agents have 
reduced efficiency due to the increased production of glutathione, which may compete 
with the target DNA for alkylation [111]. Drug efficiency may further be limited by lack 
of activation or inactivation, poor drug influx or excessive efflux, alterations in 
expression levels of the drug target, or the activation or adaptation of pro-survival 
pathways [112]. Mechanisms involved in the glutathione metabolism play an important 
role in chemoresistance, but not only in hypoxic tumors. Previously it has been reported 
that the development of prodrugs could decrease this resistant phenotype and reduce 
side effects of drugs.  
Glutathione S-transferases (GST) is a protein family of significant importance in 
chemotherapeutic resistance as overexpression is reported in various tumor types 
[113]. As GSTs serve Phase II detoxification enzymes and are involved in the regulation 
of oxidative stress, using them to activate the prodrugs could be a valuable concept in 
overcoming GST mediated drug resistance. Previously it was shown that 2 different 
prodrug derivatives could be activated by different types of GSTs [114]. In chapter 7 a 
prodrug was developed to reduce chemotherapeutic resistance of doxorubicin 
mediated by GSTA1. Indeed, our newly developed GST activated prodrug was able to 
overcome GSTA1 induced chemoresistance. Our prodrug involves the covalent addition 
of glutathione (GSH) to the sulfonamide moiety, which potentially reduces the GSH pool 
within the cell and causes an augmented effect of released parental drug. Already a 
slight decline in GSH reduces the detoxification capabilities of the cells and would 
improve oxidative stress mediated cytotoxicity [115, 116]. The same mechanism might 
be observed in the response upon radiotherapy in chapter 3, as we found that 
glutathione levels did potentially rescue the clonogenic survival upon radiation 
exposure. Next to GSTs, our developed prodrugs inhibit thioredoxin reductase 1 (TrxR1), 
another important antioxidant enzyme in the thioredoxin (Trx) system. TrxR1 itself has 
been suggested to be an interesting target for adjuvant cancer therapy [117]. As both 
the Trx and GSH system can serve as each other’s back-up system, designing prodrugs 
that target both systems at the same time while releasing a cytotoxic compound is a 
potentially interesting strategy to treat tumor cells. Our strategy for designing these 
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GSTs activated pro-drugs was also applied on etoposide. GSTA1 overexpression showed 
resistance against etoposide; by exposing GSTA1 cells to the prodrug this resistant 
phenotype was eliminated. It should be mentioned that GSTs are not only highly 
expressed in tumors but also in the liver [118]. Therefore, using only well-known 
cytostatic drugs with known toxicity profiles should be used for this approach. The GST 
mediated release for the prodrug would then be the same compared to the parental 
drug, but with limited toxicity in cells which don’t show GST overexpression.  
In the different studies discussed within this chapter we found that modulation of 
mitochondrial function and mitochondrial proteins can contribute to alterations of 
treatment responses. Mitochondrial proteins are involved in many complex mechanisms 
in cancer. Tumor tissues are very heterogeneous and adaptive towards their environment. 
Heterogeneity is not only observed within a tumor but also between tumors. Elucidating 
the exact functional consequences of changes in expression, abundance or regulatory 
capacity of mitochondrial proteins is challenging and makes the search for the perfect 
modulations for all tumors very arduous. However, stratification of patients will have 
added value to answer this challenge and identify certain subpopulations which can 
benefit from these treatment modulations (Fig 1.). 
 
 
Figure 1. A schematic representation on the contribution of patient stratification on improving response rates
in cancer patients.  
Adapted from [119].  
Future perspectives: therapeutic considerations and approaches 
More and more cancer treatment plans are tailor made since therapy integrates the 
genotype and phenotype of both cancerous and healthy tissue in a personal treatment 
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plan for the patient. Prodrugs are developed to be metabolized and exert their 
pharmacological ability in a specific region of interest. Investigating their specificity of 
only being metabolized in these regions is an important aspect of generating a safe new 
prodrug. Activation of the prodrug by the normal tissue should be limited but preferably 
even be absent. Different potential concepts can be used from nanomolecules (like 
Doxil (liposomal doxorubicin) [120]) to macromolecules with even the conjugation of an 
antibody to a cytotoxic agent [121]. This generates a wide range of applications for 
more specific drugs. 
Modulating drugs in order to add specific organelle targeting properties would be an 
interesting approach. The field of mitochondria and their role in cancer treatment 
response is currently gaining more and more attention from researchers. Currently 
drugs which specifically target the mitochondrial function are under investigation and 
form the future treatment options. Drugs interact with mitochondria in mainly three 
different manners. 1) Influencing ROS production and antioxidant capacity of the cells. 
Mitochondria are responsible for a large amount of ROS in cells, recently it has been 
shown in preclinical studies that an antioxidant preferentially targeting the 
mitochondria, namely mitoQ, could reduce those effects [122]. For instance, cisplatin 
causes in approximately 30% of the patients’ nephrotoxicity related to increased ROS 
production. 2) Inhibition of metabolism. A drug analogue developed to target the 
mitochondria even more specifically than its parental counterpart is mito-metformin. It 
was shown to be more potent in inhibiting CI, activating AMPK, enhancing 
radiosensitivity in pancreatic tumor cells and abrogating tumor growth in xenografts 
[93]. 3) Influencing drug metabolism and detoxification. A mitochondrial targeting form 
of doxorubicin was developed especially to target cells resistant to doxorubicin caused 
by the ABCB1/P-glycoprotein, a drug efflux protein. In both in vitro and in vivo 
proliferation and tumor growth was reduced while apoptosis was increased [123]. 
However, investigating new drugs even if they are modulated and bringing them into 
the clinic is expensive and timely. The application of new window-of-opportunity trials 
[124, 125] would help to identify promising drugs faster and the beneficiary patient 
population quicker. Also, repurposing drugs would benefit the patient and reduce costs 
of drug development. As already exploited in this thesis for nitroglycerin, such studies 
could also be performed for metformin or phenformin. As both of them already have a 
well-known toxicity profile applying these drugs in a window-of-opportunity trial would 
be a valuable new approach to see if they hold promise as cancer treatment for a 
particular subset of patients. Investigating which subsets of patients could benefit from 
newly developed drugs would contributes to a personalized cancer treatment approach 
and hopefully improve the prognosis of cancer patients (Fig 1.).  
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Currently cancer is still one of the deadliest diseases. Effective treatment of solid 
malignancies is dependent on the tolerability of normal tissues and its effectiveness to 
fight the malignant cells. A cancer treatment that reduces at the same time treatment 
resistance and normal tissue toxicity is highly desirable. Multiple hallmarks of cancer 
have been described which influence tumorigenesis and treatment response. 
Deregulation of cellular energetics is one of these hallmarks and the topic of this thesis. 
Under normal physiological conditions mitochondria play an important role in the 
regulation of cellular metabolism and therefore they are often referred to as the 
“power plants of a cell’. Besides nuclear genes also 37 genes located in the 
mitochondria’s own DNA (mtDNA) are involved in the regulation of mitochondrial 
function and cellular respiration. Mitochondria and mtDNA are heterogeneous and 
dynamic on different levels. Mutations in mtDNA can for instance be present only in a 
subpopulation of the mtDNA, and as every mitochondrion can contain multiple copies 
of mtDNA this can lead to a different distribution of mutations in tissues. Additionally, 
mitochondria play a very dynamic role in various processes, as they are able to use 
fusion and fission to maintain functional mitochondria upon metabolic and/or 
environmental stress. Several associations have been found between altered 
mitochondrial function and tumorigenesis and even cancer treatment. 
The aim of this thesis was to investigate the role of mitochondrial function, reactive 
oxygen species (ROS) and hypoxia modulation in tumors in view of the possibility of 
implementing them in a personalized treatment approach. Several molecular 
approaches have been used to investigate the effect of energetic stress and/or stress 
inducers (irradiation and hypoxia) in relation to mitochondrial function (chapter 3 and 
4). In chapter 3 we evaluated the effect of full mtDNA depletion, often used as an 
extreme model to investigate mitochondrial dysfunction, on radiotherapy response. 
Here, we found that mtDNA depleted cells derived from a variety of cell lines displayed 
a different response upon radiation, a phenomenon that has been previously reported 
by others. The antioxidant capacity of cells, in this case represented by decreased ratio 
of GSH:GSSG and mitochondrial super oxide dismutase (SOD2), could possibly explain a 
reduced response upon irradiation for different cell types and potentially influence the 
response towards radiotherapy in these cellular models. Hypoxia forms a well-known 
limitation for effective radiotherapy and corresponds with a decreased prognosis. 
Normally under hypoxic conditions, cells make a shift to glycolysis (the crab-tree effect) 
and show an increased extracellular acidification. Carbonic anhydrase (CA) IX is a 
hypoxia-regulated enzyme involved in maintaining the balance between a physiological 
intracellular pH and extracellular acidification. In chapter 4 we investigated the effect of 
mitochondrial dysfunction on CAIX in 3 different manners. The induction of 
mitochondrial dysfunction by depleting the mitochondrial own genome, introduction of 
a mtDNA point mutation (normally inducing mitochondrial encephalomyopathy, lactic 
acidosis, and stroke-like episodes” (MELAS)) and pharmacological inhibition of complex 
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(C) I of the oxidative phosphorylation (OXPHOS) led to a decreased CAIX expression 
(both protein and mRNA) under hypoxic conditions. Similar results were obtained for 
another HIF-1α downstream target, VEGF. In general, HIF-1α protein levels themselves 
were reduced upon hypoxia after the induction of a mitochondrial dysfunction, 
suggesting involvement of the oxidative phosphorylation in HIF-1α stabilization. 
However, the precise mechanisms still have to be further elucidated.  
Furthermore, different drug strategies (dual-targeting CAIX phenformin, repurposing 
nitroglycerin or prodrugs such as ANS-DOX) were investigated for the ability of 
influencing different cancer treatment limiting parameters such as toxicity, hypoxia and 
drug resistance (chapter 5, 6 and 7). CAIX is upregulated in several tumors and its 
expression is correlated with a worse patient prognosis. Therefore, it can be exploited 
for targeting purposes of drugs, thereby reducing their potential side effects. In chapter 
5 we used this approach to target both CAIX and the CI of the OXPHOS by using a 
compound related to the biguanide metformin. Although phenformin is a more potent 
compound than metformin it has an unfavorable toxicity profile, but therefore it is an 
interesting drug to use for a dual-targeting approach. The phenformin CAIXi conjugated 
derivative 18 has good binding affinities to CAIX and CAXII, however, the functionality of 
the compound in respect to inhibiting OXPHOS was absent in our experiments. It has 
been described that inhibition of OXPHOS could provide a better oxygenation of the 
tumor as oxygen consumption is reduced. Another approach to improve the oxygen 
status of the tumor would be by modulating the perfusion of the tumor. Nitroglycerin, 
normally used to treat angina pectoris, releases nitric oxide and exhibits vasodilating 
properties. In chapter 6 we observed a decreased hypoxic fraction after application of a 
nitroglycerin patch in tumors upfront characterized as being a ‘hypoxic tumor’ using 
HX4 hypoxia PET imaging. In these hypoxic tumors, the HX4 tracer uptake negatively 
correlated with perfusion. In vitro, we elucidated that the metabolism of the 2-
nitroimidazole HX4 is not influenced by nitroglycerin itself and that nitroglycerin does 
not inhibit mitochondrial respiration, as previously has been suggested by others at 
doses achievable in humans. Taken together, this could suggest that the additional 
application of nitroglycerin for the treatment of hypoxic tumor could be beneficial, 
although further studies need to be performed. 
Next to a dual-targeting (chapter 5) and drug repurposing (chapter 6) approach also a 
prodrug approach was tested. This prodrug approach is based on the principle that the 
prodrug is enzymatically activated under certain circumstances. In this thesis, a prodrug 
approach was evaluated in order to investigate the possibility of overcoming drug 
resistance. Unfortunately, many cancer patients suffer from resistance towards 
chemotherapeutics and thereby their treatment is less effective. Mechanisms involved 
in glutathione metabolism are often related to drug resistance, a phenomenon that is 
not exclusively observed in hypoxic tumors. Glutathione transferases (GST) are a class of 
enzymes involved in detoxification of substances and are often overexpressed in tumors 
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contributing to a drug resistant phenotype. GST mediated drug resistance could 
potentially be overcome by using a prodrugs approach. In chapter 7, we investigated 
prodrug formulations of two widely used chemotherapeutics, etoposide and 
doxorubicin, to overcome GST mediated resistance. For microsomal glutathione 
transferase (MGST1, found in the outer membrane of the mitochondria and in the 
membrane of the endoplasmic reticulum) overexpressing cells we observed that, 4-
acetyl-2-nitro-benzenesulfonyl etoposide (ANS−etoposide) (showed a MGST1 
dependent therapeutic efficacy. However, this effect was only slightly dose dependent 
and therapeutic efficacy was lower compared to the parental drug. This suggests that 
the modification reduced either the uptake of the drug or limited its activation. 
Overexpression of GSTA1-1, another subclass of GSTs, did show a resistant phenotype 
towards etoposide which could be counteracted by ANS-etoposide, suggesting 
that GSTA1-dependent activation of the prodrug took place. For doxorubicin, a drug 
known for its cardiac toxicity as a side effect, we showed that different sulfonamide 
moieties have an optimal GST dependent window and can be optimally activated by 
certain subclasses of GSTs. These prodrugs selectively target GST overexpressing cells, 
while limiting normal tissue side effects at the same time. However, not only GSTs 
interacted and were inhibited by the doxorubicin based prodrugs as thioredoxin 
reductase 1 (TrxR1), another important antioxidant enzyme in the thioredoxin (Trx) 
system, was also targeted by using these prodrugs. Influencing both the glutathione and 
the Trx system, these prodrugs and the concurrent effects caused by them provide us 
with a promising approach of targeting chemoresistant tumors.   
In the different studies described within this thesis, we observed that modulation of 
mitochondrial function and mitochondrial proteins can contribute to alterations of 
treatment responses. This provides us with new insights in the involvement of 
mitochondrial function and mitochondrial proteins in cancer therapy. However, 
as tumor tissues are very heterogeneous and adaptive towards their environment, 
patient stratification is essential to see which subpopulations of patients would by 
susceptible for such treatment modulation.  
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Kanker is tegenwoordig een van de meest dodelijke ziektes. Effectieve behandeling van 
solide tumoren is afhankelijk van het toelaatbare effect op het normale weefsel. De 
behandeling dient echter ook effectief genoeg te zijn om de kwaadaardige cellen te 
bestrijden. Momenteel is het noodzakelijk om de kankerbehandeling effectiever te 
maken, waarbij therapie resistentie van de tumoren wordt aangepakt, maar waarbij ook 
de normale weefsels gespaard worden. In het verleden zijn er verschillende 
eigenschappen van tumoren beschreven die de vorming van tumoren en het effect van 
kankerbehandelingen beïnvloeden. Een van deze eigenschappen is het ontregelen van 
het metabolisme van een cel. Onder normale fysiologische omstandigheden spelen 
mitochondriën vaak een belangrijke rol in het regelen van het metabolisme van een cel. 
Vanwege deze rol worden ze vaak beschreven als de energiefabrieken van een cel. Tot 
op heden zijn verschillende verbanden gevonden tussen de veranderingen in de functie 
van deze mitochondriën, de vorming van tumoren en kankerbehandeling. Naast de 
nucleaire genen zijn er ook 37 genen, aanwezig in het eigen DNA van de mitochondriën 
(mtDNA), betrokken bij het regelen van de mitochondriële functie en oxidatieve 
fosforylatie (OXPHOS). Mitochondriën en mtDNA zijn heterogeen en dynamisch van 
aard op verschillende niveaus. Mutaties in mtDNA kunnen bijvoorbeeld alleen aanwezig 
zijn in een subpopulatie van de mtDNA moleculen en aangezien elk individueel 
mitochondrion meerdere kopieën van het mtDNA kan bevatten, kan dit leiden tot een 
verschillende distributie van mutaties in weefsels. Tevens spelen mitochondriën een 
dynamische rol in meerdere processen, omdat ze in staat zijn om ‘fusion en fission’ 
(versmelting en deling) toe te passen om hun functionaliteit te behouden als cellen 
metabolische en/of andere vormen van stress ervaren. De rol van de mitochondriën en 
de interactie met het metabolisme gedurende de behandeling zijn een fascinerend 
onderzoeksveld. 
Het doel van deze studie was het onderzoeken van de rol en bijdrage van de 
mitochondriële functie, reactieve zuurstofverbindingen (ROS) en hypoxie veranderingen 
in tumoren en hoe deze toe te passen in een persoonlijk behandelingsplan van een 
patiënt. Moleculair biologische experimenten werden uitgevoerd om de relatie tussen 
de mitochondriële functie en het effect van energetische stress en/of veroorzakers van 
stress (zoals hypoxie en bestraling) te onderzoeken (hoofdstuk 3 en 4). Als eerste 
evalueerden we het effect van volledige verwijdering van het mtDNA (depletie) op 
bestraling. mtDNA depletie wordt vaak gebruikt als een extreem model om de invloed 
van de mitochondriële dysfunctie te onderzoeken. In hoofdstuk 3 observeerden we dat 
verschillende cellijnen ontdaan van hun mtDNA andere effecten hebben na bestraling, 
een observatie die eerder ook door anderen werd gedaan. De antioxidant capaciteit van 
cellen, hier weergegeven door een afname in de ratio van GSH:GSSG en mitochondriële 
superoxide dismutase (SOD2), kan dit mogelijk beïnvloeden en verklaren waarom een 
verminderd effect na bestraling plaatsvindt in bepaalde celmodellen. Voor effectieve 
radiotherapie is hypoxie een bekende beperkende factor die gerelateerd is aan een 
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verminderde prognose voor patiënten. Normaal gezien maken cellen onder hypoxische 
condities een verandering van hun metabolisme door en stappen ze over op glycolyse, 
het zo genoemde “crab-tree effect”, waarbij meer verzuring buiten de cel optreedt. 
Koolzuur anhydrase 9 (CAIX) is een enzym dat gereguleerd wordt door hypoxie en 
betrokken is bij het onderhouden van de balans tussen een fysiologische zuurtegraad 
binnen en verzuring buiten de cel. In hoofdstuk 4 onderzochten we op 3 verschillende 
manieren het effect van mitochondriële dysfunctie op CAIX. Het veroorzaken van een 
mitochondriële dysfunctie door het verwijderen van het mtDNA, het introduceren van 
een punt mutatie in het mtDNA (hetgeen “mitochondrial encephalomyopathy, lactic 
acidosis, en stroke-like (=beroerteachtige) episodes” (MELAS) veroorzaakt) en 
farmacologische inhibitie van complex I van de OXPHOS leiden tot een verminderde 
CAIX-expressie (op zowel eiwit- als mRNA niveau) onder hypoxische condities. Ook een 
ander eiwit dat wordt beïnvloed door HIF-1α, VEGF, vertoonde een verlaagde expressie. 
Over het algemeen waren ook de HIF-1α eiwitniveaus verlaagd na de inductie van de 
mitochondriële dysfunctie. Dit suggereert dat verlaging van HIF-1α eiwitniveaus wellicht 
kunnen worden veroorzaakt door een verminderde OXPHOS-functie. Echter het exacte 
mechanisme moet nog verder onderzocht worden.  
Tevens werden in deze thesis verschillende manieren van innovatieve 
medicatietoepassingen onderzocht (dual-targeting CAIX fenformine, een ander gebruik 
dan de huidige toepassing van nitroglycerine, en prodrugs zoals 4-acetyl-2-nitro-
benzenesulfonyl doxorubicine (ANS-DOX) op effectiviteit in het beïnvloeden van 
verschillende parameters die een nadelige invloed hebben op kankerbehandelingen 
zoals toxiciteit, hypoxie en resistentie tegen de medicatie (hoofdstuk 5, 6 en 7). CAIX-
expressie is verhoogd in verschillende tumoren en deze verhoogde expressie houdt 
verband met een slechtere prognose voor patiënten. Door deze eigenschappen is CAIX 
een interessant doelwit zodat bepaalde medicatie specifiek gericht tegen CAIX naar de 
tumor gebracht kan worden. Hierdoor kunnen mogelijke bijwerkingen van de medicatie 
worden verminderd. In hoofdstuk 5 gebruikten we deze aanpak om tegelijkertijd de 
activiteit van CAIX en complex I van de OXPHOS te remmen. Hiervoor gebruikten we 
een compound die afgeleid is van metformine, namelijk fenformine. Ondanks dat 
fenformine een krachtigere werking heeft dan metformine, heeft het ook een minder 
goed toxiciteitsprofiel. Dit maakt fenformine echter een interessant molecule voor onze 
strategie gebaseerd op ‘dual-targeting’. Het fenformine CAIXi geconjugeerde derivaat 
18 liet een goede bindingsaffiniteit zien met CAIX en CAXII, echter de functionaliteit van 
het molecule met betrekking tot het remmen van OXPHOS was afwezig in onze 
experimenten. In de literatuur is beschreven dat OXPHOS-remming kan zorgen voor een 
betere zuurstofstatus van de tumor, omdat het zuurstofverbruik is verminderd. Het 
verbeteren van de perfusie van de tumor zou mogelijk een andere manier zijn om de 
zuurstofstatus van de tumor te beïnvloeden. Nitroglycerine, een medicijn dat normaal 
wordt gebruikt voor de behandeling van angina pectoris, geeft stikstofmonoxide af en 
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zorgt voor vaatverwijding (vasodilatatie). Na gebruik van een nitroglycerine pleister 
observeerden we een afname in de hypoxische fractie enkel van de hypoxische tumoren 
(hoofdstuk 6). Hypoxie is een van de belangrijke limiterende factoren voor de 
behandeling van tumoren. In hypoxische tumoren is na het gebruik van een 
nitroglycerine pleister een omgekeerd verband tussen de opname van de hypoxie 
merker HX4, welke bedoeld is om de hoeveelheid hypoxie binnen een tumor te 
bepalen, en perfusie. Door middel van in vitro experimenten konden we uitsluiten dat 
het metabolisme van 2-nitromidazoles, waar HX4 er een van is, niet beïnvloed werd 
door nitroglycerine zelf. Tevens konden we uitsluiten dat de mitochondriële respiratie 
werd verminderd door de blootstelling van nitroglycerine aan een concentratie 
gevonden in het plasma van patiënten. De toevoeging van nitroglycerine aan de 
behandeling van hypoxische tumoren lijkt daarom veelbelovend, echter verder 
onderzoek is nog nodig. 
Naast het gebruik van een dual-targeting benadering (hoofdstuk 5) en het innovatieve 
herbestemming van medicijnen (hoofdstuk 6) werd ook het gebruik van een 
activeerbaar medicijn (prodrug) getest. In deze thesis werd deze benadering gebruikt 
om te onderzoeken of het mogelijk was om resistentie tegen bepaalde medicatie te 
ondervangen. Helaas hebben vele kankerpatiënten last van resistentie tegen 
chemotherapie waardoor hun behandeling minder effectief is, met alle gevolgen van 
dien. Mechanismen welke betrokken zijn bij het glutathion metabolisme zijn vaak 
gerelateerd aan resistentie tegen medicatie en zijn een fenomeen dat niet exclusief 
aanwezig is bij hypoxische tumoren. Glutathion transferases (GSTs) zijn een klasse van 
enzymen betrokken bij de detoxificatie van stoffen en komen vaak tot overexpressie in 
tumoren. In verschillende type tumoren zijn GSTs gelinkt aan de resistentie tegen 
medicatie bij kankerpatiënten. Mogelijk kan door het gebruik van prodrugs de GST 
gemedieerde medicijnresistentie overwonnen worden. In hoofdstuk 7 gebruikten we 
prodrugs gebaseerd op 2 vaak gebruikte chemotherapieën, namelijk etoposide en 
doxorubicine, om GST gemedieerde resistentie te overwinnen. Bij cellen die 
microsomale glutathion transferase 1 (MGST1, aanwezig in de buitenste membraan van 
het mitochondrion en in het membraan van het endoplasmatisch reticulum) tot 
overexpressie brengen, zagen we voor ANS-etoposide een MGST1 afhankelijke toename 
van de therapeutische doeltreffendheid. Echter deze toename was enkel beperkt 
afhankelijk van de toegevoegde concentratie en leidde tot een mindere efficiëntie 
vergeleken met de oorspronkelijke niet-gemodificeerde medicatie. Dit suggereert dat 
de modificatie leidde tot verminderde opname en/of tot verminderde activatie. 
Overexpressie van GSTA1-1, een andere subklasse van GSTs, liet een resistent fenotype 
tegenover etoposide zien die teruggebracht kon worden door het gebruik van ANS-
etoposide. Dit suggereert dat GSTA1-1 afhankelijke activatie van de prodrug aanwezig 
was. Voor doxorubicine, een medicijn dat bekend staat voor het veroorzaken van 
cardiotoxiciteit bij patiënten, lieten we zien dat verschillende sulfonamide restgroepen 
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kunnen zorgen voor een optimaal GST afhankelijk venster. De verschillende vormen van 
de prodrugs kunnen optimaal geactiveerd worden door verschillende subklasses van 
GSTs en selectief werken op de cellen met een GST overexpressie. Hierdoor kunnen 
bijwerkingen op normaal weefsel verminderd worden. In deze studie observeerden we 
echter dat niet alleen GSTs een interactie aangingen met de prodrugs, maar dat ook een 
ander belangrijk antioxidant enzym (thioredoxine reductase; TrxR1) in het thioredoxine 
systeem werd beïnvloed door de prodrugs. Het beïnvloeden van zowel het glutathion 
als het Trx systeem zorgt voor een verhoogd effect en is daardoor een veelbelovende 
aanpak voor de behandeling van chemoresistente tumoren.  
In de verschillende studies beschreven in deze thesis observeerden we dat het 
beïnvloeden van de mitochondriële functie en mitochondriële eiwitten kan bijdragen 
tot de verandering van het effect van de behandeling. Dit zorgt voor nieuwe inzichten in 
de betrokkenheid van mitochondriële functie en mitochondriële eiwitten in 
kankertherapie. Omdat echter tumorweefsels erg divers zijn en zich makkelijk kunnen 
aanpassen aan veranderende omstandigheden en omgeving, is de selectie van 
patiënten die baat hebben bij de aangepaste behandelingsmethoden echter van groot 
belang.  
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In this thesis, the scientific relevance of modulation of mitochondrial DNA and the role 
of mitochondria in the context of cancer treatment has been demonstrated. Scientific 
knowledge and findings should eventually benefit the society in one or another way. 
Worldwide, cancer is now-a-days one of the leading causes of death. In 2015, 104988 
new patients were diagnosed with cancer in the Netherlands [1]. Next to the emotional 
burden of such a disease also the financial aspect plays an important role for patients 
and society. In the Netherlands, cancer treatment costs were already 4,8 billion euro in 
2011 [2] and are rising every year. Currently, in our society a debate is ongoing on 
health and insurance policy in order to control the costs of cancer treatments combined 
with an improvement of survival rates and quality of life [3]. As not every patient is the 
same and there is not yet a perfect cancer therapy, stratification of patients is an 
important tool to select only the patients who will benefit the most from a certain 
(combination) treatment in order to reduce costs.  
Clinical relevance and improvement for health care 
As tumors are highly dynamic and heterogeneous in their appearance, treatment 
should be tailored to the specific needs of a patient; the so-called personalized 
treatment approach. Currently cancer researchers try to find better biomarkers to 
predict the patients’ outcome to a specific treatment or to use as target for treatment. 
Mitochondrial function (chapter 2, 3 and 4), CAIX (chapter 4 and chapter 5), hypoxia 
(chapter 5 and 6) and GST expression (chapter 8) could serve as such biomarkers. 
Complementary to the use of specific drugs to eliminate cancer, possible normal tissue 
toxicity plays an important role in defining the optimal treatment approach. In lung 
cancer patients for example, the healthy tissue tolerance defines the radiation dose 
delivered to the tumor. Therefore, it is important to develop methods that can identify 
patients at risk for e.g. radiation-induced lung toxicity (RILT). Radiation therapy (RT) and 
mitochondria have common molecular processes. Where mitochondria are important 
for energy (ATP) and reactive oxygen species (ROS) production, regulation of apoptosis 
and cellular calcium homeostasis, RT induces the formation of ROS and can lead to cell 
death. Recently, it has been shown that ionizing radiation can elevate mitochondrial 
content and function. Furthermore, mitochondrial DNA (mtDNA) mutations have 
previously been reported to affect mitochondrial function (decreased ATP production, 
increased ROS production). As described in chapter 2 and 3, evaluation of the 
mitochondrial status and their functionality could result in a biomarker that helps us to 
identify new therapeutic targets, potentially limiting normal tissue toxicity or increasing 
tumor specific efficacy and provide us with better working therapies at the same time 
although further progress is necessary. Potentially this could not only work for 
radiotherapy as treatment modality, but could also be expanded to other treatments 
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like immunotherapy or chemotherapy and thereby contribute to a more optimal 
treatment of patients. 
CAIX has been found to influence disease progression and is associated with a higher 
risk to develop metastasis. As CAIX is seen as an endogenous hypoxia marker since its 
expression is often HIF-1α regulated, identification of hypoxic areas could be beneficial 
on several distinctive levels. Different approaches could be pursued to increase the 
effectiveness of treatments by manipulating the tumoral hypoxic fraction. Drugs such as 
nitroglycerin, metformin or phenformin are suggested to reduce the hypoxic fraction 
within tumors. The CAIX inhibitors described in chapter 5 were shown not to be 
effective as single agents or didn’t result in an enhanced efficiency compared to their 
parental compounds and to standard treatment modalities. Therefore, additional 
studies were not pursued. The combination of another biguanide metformin with 
radiotherapy is currently tested in clinical trials and recently mitochondrial targeted 
derivatives of metformin have been developed. Targeting a biguanide to mitochondria 
and making it more effective and consequently reduce side effects remains an 
interesting research area. These newly designed compounds are believed to be more 
effective than metformin itself and could therefore contribute to a beneficial therapy. 
Although these types of compounds require further extensive preclinical and clinical 
testing, the first results are promising. However, until they are proven more effective 
and equally safe as the parental drug, metformin would currently be the way to go 
forward.  
In chapter 6, we indeed observed a decreased hypoxic fraction upon nitroglycerin 
administration in patients harboring hypoxic tumors. Since hypoxia causes resistance to 
radiotherapy, reducing the hypoxic fraction in these treated patients is of great 
importance. As metformin and nitroglycerin are FDA approved drugs, we know the 
possible side effects when patients are treated with these drugs. Therefore, these 
agents could be used relatively safe for repurposing. Of course, the effect on the tumor 
and its microenvironment still need to be carefully elucidated in patients when 
combined with conventional treatment modalities; so adverse tumor effects could be 
prevented. Since nitroglycerin reduced the hypoxic fraction only in patients with 
hypoxic tumors, assessing if a tumor is hypoxic is essential. Multiple hypoxia tracers and 
imaging modalities are currently available; however, it is important to validate these 
tracers in the same model systems to acquire advantages and limitations of each 
imaging modality. During our nitroglycerin study, we observed that performing several 
scans using different imaging modalities (HX4 (hypoxia PET/CT), DCE-CT (perfusion CT), 
FDG PET/CT) increased the burden on patients and physicians excessively resulting in 
premature termination of the study. Furthermore, we observed that it is utmost 
important to stratify patients to increase the chance of an effective non-small cell lung 
cancer (NSCLC) treatment after application of nitroglycerin. 
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Gain for society 
The observations made in this thesis could potentially benefit cancer patients and the 
society in general. Although at first sight the introduction of a personalized medicine 
approach sounds like an expensive one. But unfortunately, from the economic point of 
view, a “one size fits all” strategy in cancer treatment does not lead to a favorable 
treatment outcome for the majority of patients. Therefore, an improvement in 
treatment response with low developmental costs can be considered as a good strategy. 
Repurposing of already FDA approved drugs or even the targeted re-use of drugs with-
drawn from the market in the past due to toxicity problems in other diseases, could be 
interesting approaches. Also, implementing drugs in cancer treatment strategies with a 
known toxicity profile from other diseases would be an interesting approach. In this 
thesis, we have demonstrated that, with a correct patient stratification, previously 
developed drugs such as nitroglycerin (chapter 6) could reduce treatment limiting 
aspects, like for instance hypoxia. Derivatives of drugs such as phenformin or doxorubicin 
(chapter 5 and 7) in order to target specific areas of a tumor or to modulate their toxicity 
profile would help us to reduce the costs for society. Using this approach, investigating 
new potential targets and developing specific therapeutic agents for these targets with 
unknown toxicity profiles can be prevented. This would reduce the development costs of 
new treatments and eventually reduce the costs of a certain treatment. Repurposing of 
drugs is an approach that also gained the interest of the scientific community as it 
creates opportunities for new research. Gaining more knowledge on the biological 
processes involved in certain types of treatment as well as their functional consequences 
benefits not only researchers but also physicians and thereby patients in the long run. 
Patients however should be more often made aware of the fundamental and 
translational research essential to improve the treatment of their diseases.  
Road to the market 
Although it is still a long road, the studies performed in this thesis do have the potential 
to be implemented in daily practice and additional studies to prove the efficiency and 
safety are the next steps to be performed. The dual-targeting agents described in this 
thesis remain to be further developed with respect to efficacy and safety, as the ones 
described in this thesis were found not to be effective enough. On the other hand, CAIX 
expression levels themselves are also interesting for further research. Prior to 
developing a dual-targeting agent, used for homing a drug to the tumor, CAIX 
expression levels itself could be used as a biomarker for malignant and invasive tumors 
and thereby for predicting treatment outcome. Further preclinical and clinical research 
however is necessary before introducing such a biomarker, imaging agents and/or CAIX 
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targeting agents into clinical practice. Similarly, also the GST prodrugs investigated in 
the thesis need further evaluation and validation regarding efficacy, efficiency and 
safety for their use as a treatment for chemoresistant tumors. Previous developed GST 
activated prodrugs such as TLK-286 (Telcyta, canfosfamide) enrolled already into clinical 
trials, thereby demonstrating the potency of this approach. 
For drugs already preclinically used in a safe manner, window-of-opportunity clinical 
trials can elucidate efficacy in patients in a cost-effective manner. Using this approach, 
non-effective adjuvant drugs will be filtered out in an earlier development phase 
instead of going through conventional clinical trials and therefore costs will be reduced. 
Adjuvant drugs will be evaluated for their specific therapeutic effects as monotherapy 
(e.g. reducing hypoxia after application), before combining them with standard therapy. 
When a drug is found to be effective and potentially interesting to continue, clinical 
trials should be performed. Nitroglycerin has been evaluated already in clinical trials as 
adjuvant NSCLC treatment, but didn’t live up to the expectations, explained by the lack 
of patient stratification. In our study (chapter 6) we showed that there is an opportunity 
for the use of nitroglycerin in a subset of patients, namely those patients with hypoxic 
tumors. Since nitroglycerin targets tumor hypoxia, we believe that patient stratification 
based on hypoxia imaging is crucial for these types of drugs. Hypoxia imaging is already 
used in clinical settings and can be exploited for specific targeting of these hypoxic 
areas in tumors or for guiding proper patient stratification. Taking along better and less 
invasive patient stratification methods during drug development, will reduce toxicity 
and increase efficacy for the patient and will eventually lead to a significant cost 
reduction for the society.  
In the future, treatments will become more tailor-made and more specific based on the 
patients’ needs, although the financial pressure on our health system keeps on 
increasing. Improvement of patient stratification can eliminate unnecessary and 
unsuccessful treatments and will thereby reduce treatment costs and therapy burden 
for patients. Investing in modalities to improve stratification is therefore essential. 
Additionally, drug repurposing whether or not in combination with drug modifications 
for potential new treatment approaches could be a valid approach to reduce drug 
development costs and hopefully reduces the burden on our health system.   
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